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Anaemia frequently accompanies chronic inflammatory diseases like 
rheumatoid arthritis and cancer. It is postulated to result 
primarily from the suppression of erythropoiesis by inflammatory 
cytokines. A contributing factor could be the inhibition of 
erythropoietin synthesis which may also be mediated by cytokines. 
Erythropoietin is the hormone which regulates erythropoiesis. 
The aims of this project were to investigate whether cytokines 
can indeed suppress erythropoietin production, and to determine 
whether the erythropoietin response in experimental models of 
acute and chronic inflammation was appropriate for the associated 
anaemia . 
Macrophage-conditioned medium, interleukin-lB, interleukin-6, 
tumour necrosis factor-a, and neopterin were assayed for 
inhibition of erythropoietin synthesis by HepG2 cells in culture. 
All, except neopterin, effected dose-dependent reductions in the 
secretion of the hormone. Interleukin-lB and tumour necrosis 
factor-a down-regulated erythropoietin gene transcription, 
whereas interleukin-6 inhibited a post-transcriptional process. 
Rats with acute inflammation developed a mild anaemia which 
evoked an increase in their serum levels of erythropoietin. The 
serum erythropoietin levels were optimal, since rats with acute 
inflammation and severe phenylhydrazine-induced anaemia did not 
have lower levels of the hormone than controls with a similar 
degree of anaemia, but without acute inflammation. 
Erythropoietin is, therefore, not an acute phase reactant. 
Mice with cancer developed a progressive anaemia which was not 
due to bone marrow invasion by tumour cells. During the first 
fourteen days after inoculating them with cancer cells, the mice 














phenylhydrazine-induced anaemia. Erythropoietin levels measured 
in mice with tumours older than fourteen days were significantly 
l ower than those of control mice with the same degree of 
experimental anaemia. These animals were very cachectic, 
suggesting that a blunted erythropoietin response may depend on 
disease activity. 
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AND CLINICAL APPLICATION. 
1.1 INTRODUCTION 
PHYSIOLOGY, 
In the middle of the last century, Dennis Jourdanet observed 
that Mexicans living at high altitudes had an increased number 
of red blood cells in their circulation. He and a friend, Paul 
Bert, realised that such an increase could provide survival 
advantages for people living at a low oxygen tension (quoted in 
Erslev, 1990). In 1906, Carnot and DeFlandre suggested that 
this response was mediated by a humoral factor (quoted in 
Sherwood, 1984) . Def ini ti ve evidence that erythropoiesis is 
controlled by a circulating factor, acting directly on the 
marrow, was provided by Reismann ( 1950) and Stahlman et al. 
(1 954). Reismann (1950) observed, using parabiosed rats, that 
lowering the blood oxygen saturation to 63 % in one of the rats 
was followed by increased erythropoiesis in both the hypoxic rat 
and the partner, which was breathing room air and had a blood 
oxygen saturation of 97 %. Stahlman and co-workers (1954) 
studied a patient with a patent ductus arteriosus and normal 
oxygen saturation above the diaphragm, but with decreased oxygen 
saturation below the diaphragm. Erythroid hyperplasia was 
observed in the sternal marrow, despite a normal marrow oxygen 
saturation, suggesting that a humoral factor produced below the 
diaphragm, 
Subsequent 
in response to hypoxia, regulated erythropoiesis. 
studies revealed that the factor is produced in 
response to all kinds of hypoxia and it was named erythropoietin 
(Epo) in recognition of its role as the hormone involved 
1 
exclusively with red cell production (Sherwood, 1984). 
1.2 CHEMISTRY AND MOLECULAR BIOLOGY OF ERYTHROPOIETIN 
The purification of Epo from human urine was fully accomplished 
(Miyake et al., 1977). It was found to be a glycoprotein with 
a molecular mass of 34 000 daltons and containing approximately 
30% carbohydrate of which 11 % was sialic acid, 11% total hexose, 
and 8 % N-acetylglucosamine. The protein sequence consisted of 
166 amino acid residues with a calculated molecular mass of 18 
398 daltons (Wang et al., 1985; Lai et al.,1986). 
The elucidation of the primary amino acid sequence of Epo 
enabled the construction of oligonucleotide probes for the 
isolation of human (Jacobs et al., 1985; Lin et al., 1985), 
monkey (Lin et al., 1986), and murine (McDonald et al., 1986; 
Shoemaker and Mitsock, 1986) Epo genes. In all three species, 
the Epo gene exists as a single copy and is highly conserved, 
with the monkey and murine DNA coding sequence having a 94 % (Lin 
et al., 1986) and 80 % (Shoemaker and Mitsock, 1986) homology, 
respectively, with the human gene. The human Epo gene is 
located on chromosome 7 (Law et al., 1986; Powell et al., 1986) 
and, more specifically by in situ hybridisation, has been 
localized to region qll-q22 (Law et al., 1986). It is contained 
in a 5.4 kilobase fragment of the genomic DNA and consists of 
four intrans and five exons for a 193 amino acid peptide. The 
product of the gene includes a 27 amino acid signal peptide, 
which is cleaved during secretion to release the 166 amino acid 
hormonal peptide(Lin et al., 1985). 
Glycosylation of the hormonal peptide seems to be absolutely 
necessary for its in vivo activity (Takeuchi et al., 1989). 
Hormonal activity was abolished after sialic acid residues were 
removed. The asialoerythropoietin had, however, full activity 
2 
when assayed in vitro (Goldwasser et al., 1974). The apparent 
loss of activity of the asialoerythropoietin in vivo can be 
explained by its rapid clearance from the circulation. When 
terminal sialic residues are removed from the oligosaccharides, 
galactose residues become the new terminal sugars. These 
galactose-terminated glycoproteins may then be recognised by 
receptors present in hepatocytes and are internalized by 
endocytosis, followed by digestion with lysosomes (Morell et 
al., 1968; Nielsen et al., 1989). Thus, it is apparent that Epo 
should be fully glycosylated, in particular sialylated, to 
accomplish in vivo hormonal activity. 
1.3 SITE OF ERYTHROPOIETIN PRODUCTION 
Jacobson et al. (1957), demonstrated that the kidney was the 
major organ responsible for increased serum Epo levels. Rats 
with bilateral nephrectomies no longer increased Epo production 
in response to anaemia. Subsequent studies have provided ample 
support for this proposal. It was shown that the normal 
isolated kidney will synthesize Epo when perfused with a serum-
free medium (Erslev, 1974) and that this synthesis is augmented 
when perfused at low p02 (Fisher and Langston, 1968). Serum Epo 
levels were also found to be extremely low in patients with end-
stage renal failure and severe anaemia, but after successful 
renal transplantation these levels reverted to normal (Besarab 
etal., 1987). 
Although the kidney is now widely accepted as the source of Epo 
in the adult mammal, it is by no means the only organ involved 
in Epo biogenesis. Anephric rodents have been found to retain 
10 % of their capacity to produce Epo (Jacobson et al., 1959) and 
anephric patients also had some Epo in their plasma (Mirand et 
al., 1968; Naets and Wittek, 1968). Since hepatectomy abolished 
the residual Epo production of anephric rats (Fried, 1972), the 
3 
liver appears to be the primary site of extrarenal Epo 
production. Extrarenal Epo synthesis in response to anaemia was 
also found to correlate with liver regeneration after partial 
hepatectomy (Naughton et al., 1977). In addition, the liver 
appears to be the major site of Epo production during foetal 
life (Zanjani et al., 1977; Koury et al., 1988). 
The development of genetic probes for Epo mRNA has provided 
additional means for localizing Epo production. Initial studies 
established the anaemic mouse or rat as good models for studying 
Epo production (Bondurant and Koury, 1986). RNA, isolated from 
the . kidney and liver of normal and anaemic mice, was hybridized 
wi th a radioactive Epo mRNA-specific probe. Trace amounts of 
Epo mRNA were detected in normal kidneys when polyadenylated RNA 
was analysed. After anaemia was induced, an increase in Epo 
mRNA was noted by 1.5 h with a rise of more than 200 fold by 4 
h . Small amounts of Epo mRNA were also detected in the anaemic 
liver (Bondurant and Koury, 198 6) . Similar findings were 
reported by Schuster et al. (1987), who studied Epo mRNA 
expression in anaemic rats. Chorh et al. (1991), using the more 
sensitive RNase protection assay, detected Epo mRNA in the 
kidney, liver, and even the lung of uraemic rats. Kidney and 
p l asma Epo levels measured by radioimmunoassay paralleled the 
c hanges in Epo mRNA levels, suggesting that Epo production in 
response to hypoxia represents de novo synthesis. When hypoxia 
was discontinued, rat kidney Epo mRNA decreased to undetectable 
l evels by 3 h, indicating a fairly short half-life (Schuster et 
al , 1987). 
When nuclei of anaemic kidneys and Hep3B cells, which secrete 
Epo, were isolated and examined, both were found to have a 
h i gher level of transcribed Epo mRNA after hypoxia (Schuster et 
al., 1989; Costa-Giomi et al., 1990). Cycloheximide 
administration before hypoxia prevented the increase in mRNA, 
suggesting that protein synthesis was necessary (Goldberg et 
4 
al., 198 8; Caro et al., 198 9) . These nuclear run-off 
experiments indicate that the increase in Epo rnRNA can, at least 
partially, be attributed to an increased rate of transcription 
of the Epo gene. 
1.4 IDENTIFICATION OF EPO-PRODUCING CELLS 
The availability of labelled RNA or DNA probes for 1.n situ 
hybridisation of Epo mRNA has provided a method for identifying 
the individual cells that make Epo. Two groups (Koury et al., 
1988; Lacombe et al., 1988), have demonstrated that a 
per i tubular interstitial cell, outside the tubular basement 
membrane, was the renal cell that produced Epo rnRNA during 
hypoxia . These cells were found in the cortex or outer medulla. 
The cells had an endothelial-like morphology (Koury et al., 
1988), and they contained factor VIII-related antigen (Lacombe 
et al., 1988). Hence, peritubular capillary endothelial cells 
have been considered the most likely candidates for expressing 
Epo mRNA in the hypoxic kidney. Nevertheless, the evidence for 
the peritubular production site is not accepted by all authors. 
Maxwell et al. ( 1990) , using a 32P-labelled DNA probe 
corresponding to part of exon IV of the murine Epo gene, 
reported that Epo mRNA was localized in tubular cells of the 
hypoxic mouse kidney. 
for this discrepancy, 
Although there is no apparent explanation 
it clearly demonstrates that in situ 
hybridisation findings require cautious interpretation. 
When the number of interstitial cells with Epo rnRNA was measured 
in relation to increasing anaemia, it was found that these cells 
increased in an exponential manner in parallel with the 
exponential increase in total Epo rnRNA and serum Epo (Koury et 
al., 1989) . It was, therefore, proposed that when anaemia 
becomes more severe, additional cells are recruited that 
synthesize Epo, with the individual cells responding maximally 
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once activated (Koury et al., 1989). It has been estimated that 20% 
to 30% of the total interstitial population of the inner cortex, but 
less than 10% of the interstitial cells in the subcapsular cortex, 
p r oduced Epo (Koury et al., 1989) . Thus, Epo-producing cells may 
represent a specialised cell type within the cortical interstitium, 
rather than a generalised cell type (Krantz, 1991). Bachmann et al. 
(1993), using an in situ hybridisation technique, has localised Epo 
production to peritubular fibroblasts in the kidneys of anaemic mice. 
This was recently confirmed by Maxwell et al. (1994) who studied the 
expression of the Epo gene in transgenic mice. 
In summary, conflicting opinions still exist with respect to the site 
of the synthesis of Epo in the kidney. Most authors favour a 
peritubular origin, which could either be endothelial cells or 
f i broblasts, but evidence for a tubular origin is also available. 
Epo production in the liver has been found to occur in hepatocytes 
(Koury et al., 1991; Maxwell et al., 1994) as well as in 
nonparenchymal cells, known as Ito cells (Maxwell et al., 1994) . 
Macrophages, particularly those found in the bone marrow, have also 
been reported to manufacture Epo (Rich and Kubanek, 1982). 
1.5 REGULATION OF ERYTHROPOIETIN SYNTHESIS 
It is an established fact that various forms of hypoxia, eg., 
hypobaric hypoxia, anaemia, or carbon monoxide poisoning, lead to an 
i ncrease in Epo secretion from the kidney. In addition, it has been 
shown that certain forms of hypoxia, i.e., anaemia, lead to a 
s i gnificant increase in Epo mRNA (Bondurant and Koury, 1986; Schooley 
and Mahlman, 1972). This shows that the hypoxia-induced increase in 
Epo formation is transcriptionally regulated (Schuster et al., 1989; 
Bauer, 1986). The exact mechanism by which hypoxia triggers the 
i ncreased production of Epo is, however, still unknown. 
The existence of possible 
r egulatory pathway remains 
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) raised cAMP and Epo concentrations in isolated perfused 
dog kidneys (Rodgers et al, 1975); and PGE2 increased Epo levels 
and erythropoiesis in mice (Gross et al., 1976) . Adenosine, 
when perfused through isolated dog kidneys, was also found to 
increase Epo production (Paul et al., 1988). Renal artery 
constriction caused increases in PGE and Epo blood levels in 
dogs; and indomethacin, which inhibits PGE formation, prevented 
increased Epo production after hypoxia (Muj ovic and Fisher, 
197 5) . On the basis of these scattered experiments, many of 
which were done in vivo with multiple variables, it has been 
proposed that renal hypoxia may result in the release of PGE, 
which in turn could increase renal cAMP and, thereby, the 
synthesis of Epo. Cyclic adenosine monophosphate could act 
through a reduction in the intracellular concentration of Ca2+ 
because cobalt, which stimulates Epo production (Goldwasser et 
al., 1958), is a general inhibitor of calcium channels. 
Verapamil and diltiazem, which block calcium entry, have also 
been shown to enhance Epo production (McGonigle et al., 1987). 
Recently, Faquin et al. (1993) showed that activators of protein 
kinase C (PKC), such as phorbol myristate acetate (PMA), 
inhibited Epo production in Hep3B cells and suggested that 
hypoxia-induced Epo secretion may be negatively regulated by 
activators of a PKC-mediated pathway. 
It is clear that much more work needs to be done before the 
mechanism that leads to increased renal Epo production is fully 
understood. 
1.5.1 INITIATION OF EPO mRNA TRANSCRIPTION BY HYPOXIA 
The chemical transducer for hypoxia is difficult to study in 
primary renal or hepatic cells because of the small percentage 
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of Epo-producing cells in these organs and the lack of 
techniques for purification of these cells. However, cell lines 
have been screened for Epo production in response to hypoxia and 
several have been found (Goldberg et al., 1988; Lacombe et al., 
1987 ) . The HepG2 and Hep3B cell lines constitutively produce 
Ep o (Goldberg et al., 1988). Hep3B cells, in particular, have 
one of the largest responses to hypoxia, CoC1 2 , NiC1 2 and MnC1 2 
(Goldberg et al., 1988, 1989). Barely detectable mRNA for Epo 
a t room air oxygen levels is greatly increased by exposure to 2 % 
ox ygen or 50 to 100 µmol/1 CoC1 2 • Because cobalt, nickel, or 
manganese can be substituted for iron in haem and, in the case 
of haemoglobin, lock the protein into a deoxy conformation like 
that of the f errohaem protein with low oxygen, it has been 
p r oposed that a haem protein may regulate Epo production by 
a c ting as an oxygen sensor (Goldberg et al., 1988; Porter and 
Goldberg, 1993). Figure 1. 1 depicts the currently proposed 
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oxygen sensor. This 
model also suggests a mechanism by which cobalt may 
mimic the deoxy state and thereby stimulate Epo 
production. (Adapted from Porter and Goldberg, 1993). 
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The current conceptual framework of the function of the oxygen sensor 
that governs Epo formation is characterized by three major features: 
1 ) The oxygen sensor is thought to be mainly located in the kidney 
itself (Bauer, 1987). However, the extent to which extrarenal 
humoral or neural factors modulate its function has yet to be 
quantified. 
2) The parameter perceived by the sensor is the venous p02 , because 
this variable changes when the oxygen transport capacity of 
the blood increases or decreases (Kurtz et al.,1988). 
3) The function of the oxygen sensor is probably related to proximal 
tubular function, since experimental inhibition of sodium 
reabsorption at the proximal tubular site results in a decreased 
sensitivity of the oxygen sensor in terms of Epo production 
(Eckardt et al., 1989). 
It is not known by which _mechanism the proximal tubule exerts its 
influence on the adjacent Epo-producing cells. The main question is 
whether the Epo-producing cells possess an oxygen sensor of their own 
or if the adjacent tubuli generate biochemical signals upon hypoxia 
that are transferred to the Epo-producing cells. The trans- or 
intracellular biochemical events that lead to an oxygen-dependent 
production of Epo in the kidney are not fully understood and many 
questions remain to be resolved (Bauer and Kurtz, 1989; Eckardt and 
Bauer, 1989). It should be noted,however, that HepG2 cells, which are 
used in this investigation, are capable of regulated Epo expression 
(Goldberg et al., 1987) and, thus, must possess an oxygen sensor. 
Given this fact, it seems likely that the kidney Epo-producing cells 
may also have their own oxygen sensor. 
1.5.2 TRANSCRIPTIONAL REGULATION OF THE ERYTHROPOIETIN GENE 











1986) and mouse 
increased the 
understanding of the mechanism that regulates Epo production. One 
approach to studying Epo transcription has been to put a genomic 
segment containing the entire human Epo gene with 0.4 or 6 kb of 5'-
flanking sequence and O. 7 kb of 3' -flanking sequence into mouse 
zygotes to generate transgenic mice (Semenza et al., 1989). These 
mice had regulated hepatic Epo transgene expression with increased 
hepatic expression after hypoxia or CoC1 2 , but did not have a similar 
renal transgene Epo response. Thus, sequences responsible for liver 
expression map within 0.4 kb of 5 1 -flanking sequences and 0.7 kb of 
3 1 -flanking sequences, and DNA sequences that control inducible kidney 
expression have not been found within 6 kb 5' or O. 7 kb 3' . In 
addition, the smaller transgene had expression in diverse other 
tissues - something which was not generally seen with the larger gene-
suggesting that the Epo gene might contain a negative regulatory 
element between 0.4 and 6 kb 5' to the coding region that restricted 
expression to the liver and kidney. In a subsequent study, Semenza 
et al. (1991) identified a 256 bp region of the 3' flanking sequence 
which could bind four or mor~.different nuclear factors or proteins. 
At least two of these factors could be induced by anaemia in both 
liver and kidney. This region was later narrowed down to a 50 
nucleotide sequence which functioned as a hypoxia-inducible enhancer 
and to which only a hypoxia-inducible factor (HIF-1) could bind 
(Semenza et al., 1992). These studies indicate that control of Epo 
expression is complex with oxygen-sensitive, tissue-specific, and 
negative regulatory sequences (Krantz, 1991). 
Another approach has been to make plasmid constructs, containing 
selected potential transcription control sequences 5' and 3' to a 
reporter gene, and to examine the transcription efficiency of the 
reporter gene in expression assays after transfection of the plasmid 
constructs into appropriate mammalian cells. Goldberg et al. (1989) 
have used growth hormone (GH) as the reporter gene. Their construct 
contained a 1192 bp HindIII-XbaI fragment that extended from 378 bp 
5' to the cap site of the Epo gene, through the first intron attached 
5 ' to the GH coding sequence. In addition, a 255 bp AccI-Bg1II 
fragment, that extended 67 bp upstream from the Epo termination codon 
and covered most of the 3'noncoding region of homology, was added 3'to 
the GH sequence. The plasmid DNAs were transfected by electroporation 
into Hep3B cells, which were then exposed to CoC1 2 or 1% oxygen. 
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Measurement of GH in the cell medium indicated stimulated GH 
expression, which was reduced in the presence of carbon 
monoxide, as is the case with endogenous Epo synthesis by Hep3B 
cells. These results show oxygen regulatory sequences within 
the above regions of the human Epo gene. 
Costa-Giomi et al. (1990) and Caro et al. (1989) have taken yet 
another approach and prepared nuclear extracts from hypoxic 
Hep3B cells to determine if they enhance the transcription of 
the Epo gene. These extracts were added to an in vitro 
transcription system using a DNA template construct consisting 
of a HindIII-EcoRI fragment, extending from 380 bp 5' to 600 bp 
3' of the Epo gene, in a pUC8 vector. This fragment was 
transcribed to a greater extent in the presence of extracts from 
hypoxic nuclei compared to extracts from normal nuclei. The 
nuclear extracts from hypoxic Hep3B cells appeared to contain 
functional transacting factors that specifically stimulated 
transcription of the Epo gene and these factors appeared to 
interact with sequences in the above genomic fragment that 
conferred responsiveness to hypoxia in Hep3B cells. 
Beru et al. (1990) used a double-stranded deoxyoligonucleotide, 
corresponding to region -61 to -45 relative to the start site of 
transcription of the mouse Epo gene, in DNA mobility shift 
assays. In kidney extracts they found one protein and at least 
one ribonucleoprotein that bound to this oligonucleotide. Four 
RNA species also showed specific binding to the oligonucleotide, 
suggesting that recognition of the oligonucleotide by 
ribonucleoprotein was mediated by the RNA component. In nuclear 
extracts of kidneys from stimulated animals, the amount of the 
two largest RNA species was reduced relative to control. This 
suggested that the ribonucleoprotein, which contained the down-
regulated RNA species, may have been a negative transcriptional 
factor and that activation of the Epo gene by cobalt salts may 
involve decreased binding of this factor, thus allowing 
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transcription to proceed. 
Finally, Rondon et al. (1991) reported that hypoxia up-regulates 
the activity of a novel erythropoietin mRNA binding protein, 
suggesting that mechanisms exist for the post-transcriptional 
regulation of the Epo gene. In order to determine if Epo mRNA 
specific binding proteins existed, they probed cytosolic lysates 
from Hep3B cells and mouse tissues with radiolabelled Epo RNA. 
A cytosolic protein that binds specifically to Epo RNA was 
identified in the Epo-producing, hepatoblastoma Hep3B cell line 
by gel mobility shift assays. This protein was identified in 
both normoxic and hypoxic cells and found to be bound 
specifically to a 120 bp fragment of the 3'-untranslated region 
of Epo mRNA. Ultraviolet light cross-linked Epo RNA-protein 
complexes, migrated as two bands of 70 and 135-140 kD on sodium 
dodecyl sulfate-polyacrylamide gels. Binding activity was 
markedly increased in brain and spleen lysates from mice 
subjected to 24 h of hypoxia. They concluded that the post-
transcriptional regulation of Epo expression in response to 
hypoxia may, in part, be due to the interaction of Epo RNA with 
its specific binding protein. 
All these methodologies should provide a means for 
characterization of the controlling sequences, as well as the 
transacting elements necessary for Epo synthesis, but much more 
work is still required for precise determination. 
1.6 SITE OF ACTION OF ERYTHROPOIETIN 
The pluripotential haematopoietic stem cell gives rise to 
specific erythroid progenitor cells that respond to Epo. These 
have been termed the colony-forming unit-erythroid (CFU-E) and 
the burst-forming uni t-erythroid (BFU-E) ( Stephenson et al., 
1971; Tepperman et al., 1974; Gregory et al., 1978; Eaves and 
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Eaves, 1984). The CFU-E is a rapidly dividing cell which is 
highly responsive to small concentrations of Epo (Gregory et 
al., 1978; Ogawa et al., 1977) and gives rise to erythroblast 
colonies (Stephenson et al., 1971; Tepperman et al., 1974). The 
BFU-E is a much more immature cell that divides less frequently 
(Gregory et al., 1978). This cell requires another growth 
factor such as IL-3 or granulocyte-macrophage colony stimulating 
factor (GM-CSF) plus Epo (Emerson et al., 1985, 1988). These 
cells are part of a continuum of development from the earliest 
BFU-E to the latest CFU-E, with intermediate cells termed mature 
BFU-E. Figure 1.2 is a schematic outline of erythropoiesis. 
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Figure 1.2 Schematic representation of erythropoiesis. 
(Adapted from Erslev, 1990) 
The predominant measurable effects of Epo on early erythroid 
progenitor cells (BFU-E) are primarily proliferative (Dessypris 
and Krantz, 1984). As these cells mature and reach the stage of 
the CFU-E to proerythroblast, differentiation events become much 
more prominent and, at the orthochromatic erythroblast stage, 
proliferation ceases. Studies on the effect of Epo on mouse 
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bone marrow cells infected with the Friend virus that produces 
anaemia (FVA) (Koury et al., 1982), or thiamphenicol and 
phenylhyrazine-treated animals (Nijhof et al., 1987), have 
demonstrated that Epo induces an increase in the synthesis of mRNA 
and this is closely followed by the induction of alpha- and beta-
globin gene transcription. Previous studies have shown that 
induction of RNA synthesis constitutes one of the earlier 
biochemical events, following exposure of erythroid cells to Epo, 
and that stimulation of RNA synthesis is independent of DNA 
synthesis (Gross and Goldwasser, 1970). Other Epo-induced 
differentiation events include increased iron uptake, haemoglobin 
synthesis, and the appearance of erythrocyte membrane proteins 
(Koury et al., 1982; Gross and Goldwasser, 1970; Hanspal et al., 
1991). Thus, Epo exerts profound effects on erythroid cell 
development and on their terminal differentiation. 
The mode of action of the hormone could 
programmed cell death (apoptosis), since in 
also be to prevent 
the absence of Epo, 
erythroid progenitor cells were found to accumulate DNA cleavage 
fragments characteristic of those found in apoptosis (Koury and 
Bondurant, 1990). 
Besides the erythroid cells, the only other haematopoietic cells 
that were found to be stimulated by Epo were the megakaryocytes 
(MK) and their progenitors (Tsukuda et al., 1992) . In murine 
marrow, megakaryocyte colony formation could be induced by Epo, but 
required the presence of an unknown serum factor. Neutrophil 
production in newborn rats was reported to be diminished following 
the administration of high doses of Epo (Christensen et al., 1991). 
1.7 ERYTHROPOIETIN RECEPTOR 
The availability of purified recombinant erythropoietin and the 
development of techniques for obtaining almost pure populations 
of Epo-responsive cells (Nijhof and Wierenga, 1987) allowed 
studies on the mechanism of attachment of Epo to specific 
membrane molecules, the Epo receptors. Epo receptors were 
i ni tially detected on murine erythroid cells infected by FVA 
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(Krantz and Goldwasser, 1984). FVA-infected splenic erythroid 
cells were found to have approximately 800 to 1000 receptors per 
cell of which 300 had a high affinity for Epo (kd 0.09 nM), while 
the remainder had a lower affinity (kd 0 . 57 nM) (Sawyer et al., 
1987). Purified human erythroid cells that were generated in 
vitro from circulating immature erythroid progenitors were also 
found to express two classes of high- and low-affinity Epo 
receptors on their membranes, with an overall density of 1050 
receptors per cell (Fukamachi et al., 1987; Sawada et al., 
1989). 
Following binding of Epo to its receptor, the hormone is rapidly 
endocytosed and degraded (Sawyer et al., 1987) . The 
physiological significance of high- versus low-affinity Epo 
receptors is not fully understood. It is likely that only the 
high affinity form is responsible for the biologic effect of Epo, 
as few low-affinity receptors are expected to be occupied at 
physiological concentrations (Landschulz et al., 1989; Sawyer et 
al., 1987). 
The density of Epo receptors on normal human erythroid progenitor 
cells appears to correlate with their responsiveness to, and 
dependence on, this hormone. Erythroid cells at the stage of 
the CFU-E to the proerythroblast seem to have the highest density 
of receptors on their membranes. As the cell matures, the number 
of Epo receptors decreases and eventually they disappear at the 
stage of the orthochromatic erythroblast (Sawyer and Koury, 1987; 
Landschulz et al., 1989). In erythroid cells earlier than the 
CFU-E, such as the erythroid burst forming unit (BFU-E), 
preliminary studies indicate that the number of Epo receptors is 
very small and increases to the density found at the CFU-E stage 
within the first 4 days of culture (Mufson and Gesner, 1987). 
Studies on the structure of Epo receptors have demonstrated two 
bands of 100 and 85 kD by SDS-polyacrylamide gel electrophoresis 
15 
(Sawyer et al., 1987). Peptide mapping of proteolytic fragments 
of these two peptides showed a very similar, if not identical, 
pattern (Sawyer, 1989). Both human (Jones et al., 1990) and 
murine (D'Andrea et al., 1989) Epo receptor genes have recently 
been cloned. The human gene encodes a 508 amino acid molecule, 
including a 24 residue signal peptide, a 226 amino acid external 
domain, a transmembrane spanning region of 22 amino acids, and a 
cytoplasmic domain of 236 amino acids. There is an 80% overall 
homology between the human and murine erythropoietin receptor 
sequences (Ehrenman and St John, 1991). This single gene can 
generate both high- and low-affinity binding sites on transfected 
cells (D'Andrea et al., 1989). 
1.8 SIGNAL TRANSDUCTION 
Once the Epo-receptor-complex is endocytosed, signals must be 
transduced to the nucleus which will initiate proliferation and 
differentiation of the target cell. Despite the availability of 
the cloned receptor, the biochemical nature of the growth-
regulating signals has remained poorly understood. Before 
cloning of the receptor cDNA, it was shown that Epo induces a 
rapid ca2 + influx in erythroid cells infected with the Friend 
virus (Sawyer and Krantz, 1984) and in immature erythroblasts 
(Miller et al., 1988). By contrast, mouse CFU-Es did not show a 
similar increase in intracellular ca2+ (Imagawa et al., 1989). In 
addition, neither cAMP (Tsuda et al., 1989), nor cyclic guanosine 
monophosphate (White and George, 1981), seem to act as second 
messengers. Lipoxygenase products of arachidonic acid metabolism 
have been considered essential for differentiation of 
erythrocytic progenitors (Beckman et al., 1987; Mason-Garcia and 
Beckman, 1991) . However, clear proof that eicosanoids are 
mediators of the effect of Epo is lacking. 
The Epo receptor which lacks intrinsic kinase activity, couples 
ligand binding to phosphorylation by association with the 
cytoplasmic protein tyrosine kinase Janus kinase 2 (Jak2) 
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(D'Andrea et al., 1989; Witthuhn 
cytoplasmic proteins termed STATs 
et al., 
(signal 
1993) . Latent 
transducers and 
activators of transcription) also become activated, presumably by 
the Jaks, through phosphorylation of tyrosine residues. The 
activated STAT proteins are translocated to the nucleus where 
they bind to specific sequences (response elements) and stimulate 
transcription (Darnell et al., 1994). Tyrosine kinase activity 
of cellular proteins is, thus, involved in a signalling pathway 
triggered by Epo. Some of the intracellular proteins include an 
85 kD regulatory subunit of phosphatidylinositol 3-kinase (Darnen 
et al., 1993), the c-fps/fes proto-oncogene product (p92c-fos), 
nonreceptor tyrosine kinase (Hanazono et al . , 1993), and the c-
raf proto-oncogene product, Raf-1 (Carroll et al., 1991). 
Exposure of UT-7 Epo responsive megakaryoblastic cells to Epo, 
also induced tyrosine phosphorylation of several proteins 
(Komatsu et al., 1992). In fact, the Epo receptor itself becomes 
phosphorylated upon binding to its ligand (Linnekin et al., 
1992) . 
The cumulative data suggest that the Epo receptor undergoes 
phosphorylation in response to Epo, which in turn induces 
phosphorylation of other cytoplasmic or membrane proteins. The 
precise sequence of events that eventually culminate in a growth 
signal, as well as the counter-signals that turn the signal off, 
remain to be elucidated. 
1.9 ASSAYS FOR ERYTHROPOIETIN 
The concentration of Epo in plasma or serum can be measured by four 
general techniques: in vivo bioassay, in vitro bioassay, 
radioimmunoassay (RIA) and enzyme-linked immunosorbent assay (ELISA). 
The in vivo bioassay measures the biologic activity of Epo in the 
intact animal and it is considered the reference assay against which 
the other assays are compared. Epo measurements are usually expressed 
in units or milliunits of the reference Standard B prepared under the 
auspices of, and distributed by, the World Health Organisation. The 
Standard B was prepared from urine of anaemic patients and has a 
specific activity of about 5 units/mg (Caro and Erslev, 1988). A unit 
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was originally defined as the erythropoietic activity elicited 
in rats after the injection of 5 µM of C0Cl 2 .6H20. 
The in vivo bioassay utilizes polycythemic mice by either 
hypertransfusion or pre-exposure to hypoxia for a period of two 
weeks (Alippi et al., 1983a,b; Dunn and Lange, 1980; Caro and 
Erslev, 1988). These polycythemic animals have a very low 
endogenous level of Epo and can be utilized for the measurement 
of exogenously injected Epo. The effect of Epo on red cell 
production is measured by the incorporation of 59 Fe into 
circulating erythrocytes. The lowest limit of sensitivity with 
this assay is about 50 mU and it will not detect the 
erythropoietic activity found in normal plasma. 
Numerous in vitro bioassays have been designed and shown to be 
of use in measuring Epo titres. These assays are based on 
short-term cultures of erythroid tissue derived from bone-
marrow, spleen or foetal livers (Sakat et al., 1987; Caro and 
Erslev, 1988). The erythropoietic effect is measured by the 
incorporation of 59 Fe into newly formed haem, the uptake of 3H-
thymidine as a measure of cellular proliferation, or the 
stimulation of CFU-E formation in semisolid media. The main 
problem with in vitro techniques is the presence of some poorly 
defined inhibitors in human sera and the nonspecific stimulatory 
effect of other growth factors in these in vitro systems. 
The successful purification of human Epo has allowed the 
development of sensitive and specific radioimmunoassays. 
Recombinant human Epo (rhu-Epo) eventually replaced pure native 
Epo in the RIA (Lertora et al., 1975; Nielsen, 1988). These 
assays utilize radiolabelled pure Epo and antibodies developed 
against either pure or impure Epo, Epo oligopeptides, or fusion 
proteins. Radioimmunoassays have the potential of measuring 
nonbiologically active asialo-Epo. However, there have been no 
confirmed reports on significant discordance between bioassays 
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and radioimmunoassays. The lower limit of sensitivity of the 
RIA is about 2 to 4 mU/ml and it is quantitative. The primary 
d i sadvantage of the RIA is the use of radioactively labelled Epo 
(Caro and Erslev, 1988). 
The combined availability of recombinant human Epo and 
monoclonal antibodies has recently led to the development of 
en zyme-linked immunosorbent assays. One assay, described by Noe 
et al. ( 1992 ) , utilizes a monospecif ic polyclonal antibody 
raised in rabbi ts against rhu-Epo. The procedure involves 
coating the wells of a microtitre plate with anti-Epo, adding 
the Epo standards and samples and then leaving them to bind to 
the catchi ng antibody. This is followed by the addition of the 
same antibody that has been biotinylated. Finally, anti-biotin 
conjugated to alkaline phosphatase is added and the enzyme 
reaction developed and read spectrophotometrically at 405 nm. 
The assay is rapid, reproducible and, above all, quantitative, 
specific, and sensitive with a minimum detectable concentration 
of 1.2 to 2 mU/ml of serum. 
The clinical utility of Epo assays has not yet been proved. 
Measurement of Epo levels may be helpful in distinguishing 
primary from secondary polycythemia and may be able to identify 
cases of anaemia with a poor Epo response, as in patients with 
chronic renal disease. 
1.10 PATHOPHYSIOLOGY OF ERYTHROPOIETIN 
Ex cessive production of Epo leads to secondary erythrocytosis. 
It may be induced by hypoxia or arise autonomously. In 
contrast, polycythemia vera is caused by erythropoietin-
independent growth of erythrocytic progenitors from abnormal 
s t em cell clones (Cashman et al., 1983; Dai et al., 1991) 
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Wi th peripheral oxygen delivery being the main regulatory 
parameter, the production of erythropoietin increases at lowered 
arterial oxygen tension. Both natives and visitors at high 
a l titude, exhibit erythrocytic hyperplasia of their bone marrow, 
erythrocytosis, and increased blood haemoglobin concentration 
(Lenfant and Sullivan, 1971). Even though the action of Epo is 
p r otective against anaemia, its benefits in terms of improved 
oxygen transport are outweighed by rheological and haemodynamic 
d i sadvantages in hypoxaemia (Editorial, 1989). Peripheral 
resistance and work load of the heart are increased. In 
p a rticular, blood flow is obstructed in the lungs where 
hypoxaemia causes vasoconstriction. Erythrocytosis, congestive 
heart failure, and dyspnoea are the most serious manifestations 
of chronic mountain sickness. 
In contrast with altitude hypoxaemia, 
fail ure at sea level seldom leads to 
chronic respiratory 
severe erythrocytosis 
(Fried et al., 1970). The percentage of patients reported with 
e l evated plasma Epo, has varied between 21 and 85 % (Guidet et 
al ., 1987; Mi ller et al., 1981). Intermittent nocturnal hypoxia 
in patients with obstructive sleep apnoea is not accompanied by 
e l evated serum erythropoietin or erythrocytosis (McKean et al., 
19 90) . 
Hypoxia-induced erythrocytosis occurs as an inherited disorder, 
in association with mutant haemoglobins or red blood cell 2,3-
bi sphosphoglycerate deficiency, causing high blood oxygen 
a f finity (Adamson and Finch, 1975). Inherited erythrocytosis 
was also recently documented in a family with a truncated Epo 
receptor due to a single mutation in their receptor gene 
sequence (De La Chapelle et al., 1993). Elevated plasma Epo 
wi thout manifest erythrocytosis was observed in subjects with 
c ongestive heart failure, and this elevation was abolished by 
t reatment wi th the angiotensin-converting enzyme-inhibiting 
d rug, enalapril (Fyhrquist et al., 1989). 
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Certain tumours cause erythrocytosis secondary to the production 
of Epo by the neoplastic cells. Thorling (1972) measured 
increased plasma Epo bioactivity in 19 of 25 patients with renal 
carcinoma-associated erythrocytosis. Da Silva et al. ( 1990) 
measured high serum .levels of Epo by RIA in three patients who 
also presented with renal adenocarcinoma and polycythemia. 
Patients with liver carcinoma (Kew and Fisher, 1986), 
haemangioblastoma (Trimble et al., 1991) and meningioma (Bruneval 
et al., 1993) associated with erythrocytosis, also had elevated 
serum levels of Epo. In some cases, plasma Epo, haematocrit, and 
blood haemoglobin concentration normalised after the tumour-
bearing kidney was removed and later increased again, heralding 
tumour recurrence (Murphy et al., 1976, Bruneval et al., 1993). 
Erythropoietin deficiency is the primary cause of the anaemia in 
chronic renal failure (Eschbach, 1984) . The hypoproliferati ve 
anaemia associated with uraemia is usually normochromic and 
normocytic (Eschbach et al., 1980, 1984). Its severity increases 
with the impairment of r~nal function regardless of the underlying 
disease (Zappacosta et al., 1982). Switching from haemodialysis 
to continuous ambulatory peritoneal dialysis occasionally improves 
the anaemia (Zappacosta et al., 1982). Still, almost all of the 
patients in the later stages of renal failure were anaemic until 
recombinant human Epo became available for therapy (Winearls et 
al., 1986; Casati et al . , 1987; Adamson and Eschbach 1989). 
Acute (Chandra et al., 1988) or chronic (Muto et al., 1987) 
hypoxic stress may result in greatly increased plasma Epo activity 
in patients with chronic renal failure. This finding indicates 
that the capacity to produce Epo is not necessarily abolished in 
uraemia. Instead the mechanisms that control the synthesis of Epo 
may operate at a lower set point in some of the patients with 
chronic renal failure (Chandra et al., 1988). 
Mild anaemia frequently develops in patients with chronic 
infections, autoimmune diseases, or malignancies (Hansen, 1983; 
Cartwright and Lee, 197l). The factors which characterized this 
so-called anaemia of chronic disorders include insufficient iron 
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availability, decreased total iron-binding capacity of the 
plasma, reduced saturation of transferrin with iron, decreased 
bone marrow sideroblasts, normal or increased 
reticuloendothelial iron, inhibition of the proliferation of 
erythrocytic progenitors by inflammatory cytokines, increased 
haemolysis, and bleeding (Cartwright and Lee, 1971; Cash and 
Sears, 1989; Birgegard, 1989). In addition, plasma Epo levels 
may also be inappropriately low for the degree of anaemia (Baer 
et al., 1987; Spivak et al., 1989; Miller et al., 1990) . 
The immune system may have a modulating role on the production 
of Epo. Infectious and inflammatory processes induce the 
production of immunomodulatory peptides by leucocytes, tissue 
macrophages, fibroblasts, and endothelial cells. In turn, these 
peptides or cytokines are involved in the control of the immune 
reactions and of haemopoiesis (Hausen et al., 1991; Fribbe and 
Wl lemze, 1991; Arai et al., 1990). Regarded as important 
mediators of the anaemia of chronic disorders, interleukin-1 
(Johnson et al., 1989) and tumour necrosis factor-alpha (Johnson 
et al., 1990; Broxmeyer et al., 1986), have been shown to lower 
red blood cell production in vivo. The influence of 
immunomodulatory peptides on the production of Epo remains to be 
clarified and is the primary aim of this investigation. 
1.11 CLINICAL APPLICATIONS 
The successful cloning and expression of the human Epo gene has 
made recombinant human Epo (rhu-Epo) available, not only for 
biological investigation, but also for therapeutic application. 
The therapeutic efficacy of rhu-Epo was first evaluated in 
patients with end-stage renal disease with severe anaemia. The 
results of the initial phase I and II clinical trials with rhu-
Epo were reported by Eschbach and co-workers (1987). A dose-
and time-related increase of reticulocytes and haematocrit was 
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recorded, and correction of anaemia and disappearance of blood 
transfusion requirements was achieved in the majority of 
patients receiving effective dosages. Elimination of 
transfusion requirements represents a major improvement for such 
patients, who thus avoid the risk of iron overload, exposure to 
infectious agents, and alloirnrnuni zation ( Foa, 1991) . These 
encouraging results have been confirmed by other studies which 
all showed the efficacy of the recombinant hormone in this type 
of anaemia (Casati et al., 1987; Winearls et al., 1986). 
Recombinant human Epo is today approved in more than fifty 
countries, including South Africa, for the treatment of the 
anaemia associated with chronic renal failure. In addition, it 
has also been evaluated in other types of anaemia. Patients 
with the anaemia of rheumatoid arthritis showed excellent 
haematologic responses to recombinant Epo (Pincus et al., 1990). 
So did patients with the anaemia of cancer (Abels, 1992) and 
infants with the anaemia of prematurity (Halperin et al., 1990; 
Phibbs et al., 1992). AIDS patients, with anaemia associated 
with HIV infection or zidovudine therapy, have also benefitted 
from treatment with rhu-Epo (Fischl, 1990). 
Development or worsening of hypertension is generally considered 
the most serious adverse effect of the treatment with rhu-Epo 
(Raine, 1988). Its frequency appears to be higher in patients 













infectious and immunological hazards of donor blood (Foa, 1991). 
Despite the development of anaemia, the level of endogenous Epo 
increases only slightly in response to repeated phlebotomy in 
autologous blood donors (Kickler and Spivak, 1988). A 
multicentre study in humans confirmed the ability of Epo 
treatment to facilitate autologous blood donation (Goodnough et 
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al., 1989). Aside from the possibility of improving autologous 
blood donation, the severity and the duration of postoperative 
anaemia might be lessened by the application of recombinant 
human Epo some days before surgery (Abels and Rudnick, 1991). 
1.12 HYPOTHESIS AND OBJECTIVES 
Chronic inflammatory diseases are frequently accompanied by a 
persistent anaemia, which is now widely believed to be due to 
the suppression of bone marrow erythropoiesis by inflammatory 
cytokines (Means and Krantz, 1992). Several investigators have 
also postulated that a compromised erythropoietin response may 
contribute to the protracted anaemia (Miller et al., 1990; 
Spivak et al., 1989; Baer et al., 1987). This inappropriate or 
blunted Epo response is purportedly also mediated by cytokines. 
The cytokines, interleukin-1 (IL-1) and tumour necrosis factor-
alpha (TNFO'.), were found to inhibit Epo secretion by Epo-
producing hepatoma cell lines in culture (Jelkmann et al., 1990; 
Faquin et al., 1992). No in vivo studies have yet been carried 
out to confirm these findings. 
Both IL-1 and TNFa, together with interleukin-6, are mediators 
of the hepatic protein response during acute inflammation in 
mammals (Andus et al., 198 8; Mortensin et al., 198 8) . Since 
acute inflammation is often accompanied by a mild anaemia 
(Schreiber et al., 1989), the accompanying Epo response may also 
be compromised. 
It is hypothesized, therefore, that Epo synthesis is antagonised 
by cytokines elaborated during acute and chronic inflammation. 
This results in a persistence of the cytokine-induced anaemia, 
which will only resolve once the underlying inflammatory 
reaction has subsided. 
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Verification of this hypothesis would require: 
1 . Determining whether inflammatory cytokines do indeed 
inhibit Epo synthesis in vitro and, if so, elucidating 
the mechanism of such inhibition. 
2 . Studying the synthesis of Epo in animal models of acute and 
chronic inflammation and comparing it to that in normal 




CYTOKINE-MEDIATED INHIBITION OF IN VITRO 
ERYTHROPOIETIN SYNTHESIS 
2.1 INTRODUCTION 
The pathogenesis of the anaemia of chronic disorders (ACD) is 
now widely accepted to be due to cytokines secreted by activated 
monocytes and macrophages during inflammation (Means and Krantz, 
1 992; Hausen et al., 1991). Interleukin-1 and tumour necrosis 
factor-alpha are the two main cytokines implicated in a reduced 
erythropoiesis. The growth in culture of human erythroid 
precursor cells, known as burst forming units-erythroid (BFU-E) 
and colony forming units-erythroid (CFU-E), was significantly 
i nhibited by low doses of TNFa (Broxmeyer et al., 1986; Roodman 
et al., 1987). Chronic administration of TNFa also suppressed 
erythropoiesis in mice (Johnson et al., 1989, 1990) and rats 
(Moldawer et al., 1989). Interleukin-1 was found to antagonize 
the proliferative effect of Epo on mouse erythroid precursor 
cells in culture (Clibon et al., 1990). 
Recently it was proposed that cytokines may also reduce the 
increased Epo biosynthesis that occurs in response to anaemia. 
A decreased Epo response was reported in patients with the 
anaemia of cancer (Miller et al., 1990) and in anaemic patients 
i nfected with the human immunodeficiency virus (Spivak et al., 
1989). These findings appear to support the contention that Epo 
synthesis may be compromised during chronic disease. Cytokines 
u sually contribute positively to the host's defenses against 
pathogenic agents that precipitate inflammatory responses (Arai 
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et al., 1990; Offner et al., 1990). However, a sustained and 
prolonged stimulation of inflammatory cells (eg. macrophages), 
as would be the case during chronic inflammation, frequently 
leads to overproduction of these substances which can result in 
tissue and/or systemic pathology (Dinarello and Wolff, 1993; de 
Benedetti et al., 1991; Vassalli, 1992). Failure of the anaemia 
to become resolved in patients with chronic disease may, 
therefore, be due in part to a cytokine-mediated inhibition of 
Epo biosynthesis. This hypothesis was tested by studying the 
effects of macrophage-conditioned medium (MCM), as well as 
selected purified products of macrophages, on the in vitro 
production of Epo by a hepatoma cell line that constitutively 
expresses the hormone. Before reporting on the findings, a 
summary of the characteristics of each macrophage factor 
investigated for suppression of Epo synthesis, is given. 
2.1.1 INTERLEUKIN-1 
Interleukin-1 (IL-1) is a cytokine that is responsible for 
mediating a variety of processes in host defence, inflammation, 
and response to injury (Arai et al., 1990; Dinarello et al., 
1991). Although initially described as a product of activated 
macrophages and monocytes, IL-1 is now known to be produced by 
a variety of cells in response to infection and injury. These 
include fibroblasts, keratinocytes of the skin, T and B 
lymphocytes, as well as brain astrocytes and microglial cells 
(Dinarello et al., 1991). IL-1 consists of two distinct but 
related molecules: IL-la and IL-1.B. Both have a similar 
molecular size, 17 kD; however, IL-la is acidic with an 
isoelectric point (pl) of 5. 3, while IL-1.B has a pl of 7. 2 
(Dinarello et al., 1974). Although there is only a 26 % amino 
acid sequence homology and a 45% nucleotide homology between the 
two forms of IL-1, they have essentially identical biological 
properties and share the same receptor (Dinarello, 1991). 
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IL-1 appears to be a primary molecule in inflammatory reactions 
through its induction of other inflammatory metabolites. It 
i nduces production of prostaglandin E2 , collagenase, and 
phospholipase A2 (Dejana et al., 1987). In addition to 
attracting leucocytes into inflamed tissues, IL-1 also causes 
degranulation of basophils and eosinophils, stimulates 
t hromboxane synthesis in macrophages and neutrophils, and 
potentiates the activation of neutrophils by chemoattractant 
peptides (Dinarello, 1988). In contrast to its catabolic 
activities, IL-1 participates in the reparative process by 
increasing fibroblast proliferation as well as the synthesis of 
c ollagens and glucosaminoglycans (Dinarello, 1988). IL-1 also 
has the properties of an hepatocyte-activating factor and 
mediates the induction of acute-phase proteins by the liver 
(Mortensin et al., 1988; Andus et al., 1988). 
I L-1 has also been implicated as a mediator of disease. 
Fibrosis and deposition of abnormal proteins in tissues appear 
to be, in part, mediated by IL-1: In rheumatoid joint disease, 
t his contributes to thickening of scar tissue which results in 
t he restriction of joint movement (Dinarello, 1988). The 
mechanism of IL-1-induced shock appears to be the ability of IL-
1 to increase the plasma concentrations of platelet-activating 
f actor, prostaglandin, and nitric oxide. These substances are 
potent vasodilators and induce shock (Dinarello and Wolff, 1993; 
Okusawa et al., 1988). Other diseases in which a role for IL-1 
h as been identified include inflammatory bowel disease 
(Dinarello and Wolff, 1993), insulin-dependent diabetes mellitus 
( Dinarello and Wolff, 1993; Corbett et al., 1993) , acute and 
c hronic myelogenous leukaemia (Peled et al., 1992), and 
atherosclerosis (Ross, 1993). IL-1 may also induce anaemia by 
an tagonizing the action of Epo on erythroid precursors (Schooley 
e t al., 1987 ) . 
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2.1.2 INTERLEUKIN-6 
Interleukin-6 (IL-6), along with IL-1, is perhaps the best 
example of a cytokine that mediates different host responses. 
It is not only produced by a number of cells including T cells, 
macrophages, and fibroblasts, but is also involved in the 
regulation of a number of cell types, including 
nonhaematopoietic cells (Arai et al., 1990). 
On haematopoietic cells and stem cells, IL-6 can stimulate the 
growth of haematopoietic colonies composed of granulocytes and 
macrophages (Wong et al., 1988). In addition, IL-6 appears to 
stimulate the ability of stem cells to respond to IL-3. When 
I L-6 is combined with other recombinant haematopoietic factors, 
i t can augment responses to these factors or even modify them 
(Rennick et al., 1989). IL-6 is also a potent inducer of 
differentiation when added to certain myeloid leukaemia cell 
l ines (Chiu and Lee, 1989). IL-6 also appears to function as a 
growth factor for certain transformed B cells (Tosato et al., 
1 988 ) , and as a stimulatory factor for T cells at different 
stages of differentiation (Hodgkin et al., 1988). IL-6 also 
mediates the acute phase response by liver cells (Andus et al., 
1988; Castell et al., 1989). 
Elevated serum levels of IL-6 have been detected in patients 
wi th rheumatoid arthritis (Wood et al., 1992; de Benedetti et 
al ., 1991) and in animals with experimental chronic inflarn,mation 
(Shacter et al., 1992; Utsunomiya et al., 1991). 
2.1.3 TUMOUR NECROSIS FACTOR-alpha 
Tumour necrosis factor-alpha (TNFO'.) caused the necrosis of 
certain tumours when injected into tumour-bearing animals and 
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was found to be cytotoxic to a number of transformed cell lines 
in vitro (Carswell et al., 1975; Helson et al., 1975; Philip and 
Epstein, 1986). The exaggerated production of TNFa in vivo can 
cause profound systemic alterations with potentially life-
threatening consequences. Its involvement in septic shock is 
supported by several lines of evidence. For example, the 
infusion of TNFa into experimental animals resulted in a 
syndrome similar to the effects of lipopolysaccharide (LPS) 
infusion and septic shock (Tracey et al., 1986). In addition, 
in patients with meningococcal septicaemia, plasma levels of 
TNFa were predictive of the outcome of the illness; TNFa was 
detectable in the plasma of 10 of 11 patients who died (Waage et 
al ., 1987), but in only 6 of 68 survivors. Perhaps the most 
convincing evidence for the role of TNFa in septicaemia is 
derived from studies in which anti-TNFa antibodies were 
administered to mice before a lethal dose of LPS (Beutler et 
al., 1985). The group receiving the TNFa antibodies showed a 
significantly reduced mortality rate compared with the control 
group. TNFa, as discussed earlier, has also been shown to 
induce anaemia in vivo (Johnson et al., 1989; Moldawer et al., 
1989) probably by inhibiting the proliferation of erythroid 
precursor cells (Broxmeyer et al., 1986; Roodman et al., 1987). 
2.1.4 NEOPTERIN 
Neopterin is a pyrazino-pyrimidine compound derived from 
guanosine triphosphate. It represents an intermediate in the 
synthetic pathway of biopterin (Smith and Nichol, 1986). 
Biopterin, itself , is known to serve as an essential cofactor in 
neurotransmitter synthesis (Kaufmann et al., 1978). Immune 
responses in vitro and in vivo are accompanied by increased 
neopterin levels. In vitro release of neopterin from human 
peripheral blood mononuclear cells was induced by stimulation 
with alloantigens, virally or chemically modified autologous 
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cells, or with mitogenic lectins (Huber et al., 1983). In vivo, 
increased neopterin excretion was demonstrated in patients 
suffering from infections with viruses and intracellular 
bacterial or protozoal pathogens (Huber et al., 1984), from 
rheumatoid arthritis (Reibnegger et al., 1986), and from acute 
cellular graft rejection or graft-vs-host disease (Huber et al., 
1983) . Elevated neopterin levels were also seen in patients 
with acquired immunodeficiency syndrome (Fuchs et al., 1984) and 
in those with certain tumour states (Reibnegger et al., 1986). 
In these diseases, an increase of neopterin excretion usually 
precedes the clinical manifestation, and is correlated with the 
activity of the underlying disease. 
It is clear from the discussion above, that high concentrations 
of IL-1, IL-6, TNFa, and neopterin predominate in the serum of 
patients with chronic disease. At such high concentrations, 
agents like IL-1 and TNFa have been shown to cause pathological 
effects on normal metabolism. Down-regulation of Epo expression 
during chronic inflammation may, thus, also be a consequence of 
their action, thereby contributing to the development of ACD. 
This hypothesis was tested by investigating the effects of these 
agents, together with MCM, on the in vitro biosynthesis of Epo 
by HepG2 cells, a cell line capable of regulated production of 
the hormone. 
2.2 MATERIALS AND METHODS 
2 . 2 . 1 REAGENTS 
Human recombinant IL-lB was provided by the Biological Resources 
Branch of the Biological Response Modifiers Program, Division of 
Cancer Treatment/NCI, Frederick, Maryland, USA. It had a 
specific activity of 1.81 units/mg protein with an endotoxin 
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content of 2.5 Eu/mg protein. Its purity was greater than 99 % 
as determined by SDS-PAGE, isoelectric focusing, and reverse-
phase HPLC analysis. Recombinant human IL-6 (specific activity 
of approximately 2x10 8 U/mg protein) and TNFa (specific activity 
greater than lxl0 8 U/mg protein), were purchased from Boehringer 
Mannheim (S.A.). Foetal calf serum was obtained from Highveld 
Bi ological, and trypsin, thioglycollate broth, phosphate 
buffered saline (PBS), Hepes buffer, and alpha-minimal essential 
medium (a-MEM) from Gibco. Dexamethasone, neopterin, 
lipopolysaccharide (LPS), 3-[4,5-dimethyl-thiazol-2-yl]-2,5-
d i phenyltetrazolium bromide (MTT), and dimethyl sulfoxide (DMSO) 
were purchased from Sigma. Sac-eel (donkey anti-rabbit antibody 
c oated cellulose suspension) was obtained from IDS (England). 
I odinated 125I-erythropoietin ( 370 kBq, 10 µg/0. 5 ml") was 
pu rchased from Amersham (England). 
2.2.2 CELLS AND CELL CULTURE 
HepG2 cells, a human hepatoma cell line capable of both 
cons ti tuti ve and regulated Epo expression ( Goldberg et al., 
1987; Ueno et al., 1989), were a gift from Dr B B Knowles 
(Wistar Institute, Pennsylvania, 19104). The cells were 
c u ltured in a-MEM, supplemented with 10 % FCS (not heat-
inactivated ) , in a humidified atmosphere containing 5 % CO2 at 
37 °C. Near confluent cultures were passaged once per week by 
treatment with O. 25 % trypsin and O. 02 % EDTA, in Ca2+- and Mg2+-_ 
fr ee PBS. 
2.2.3 PREPARATION OF CONDITIONED MEDIUM 
Inflammatory macrophages were induced in five adult male Balb/c 
mice (±20 g ) by an intraperitoneal injection of 2 ml of 3 % (w/v) 
thioglycollate broth. Three days later the macrophages were 
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collected by peritoneal lavage using PBS containing 2 % heat-
inactivated FCS. The cells were pooled and centrifuged at 200g 
for 10 min at 4°C. The cells were washed once with a-MEM 
containing 5 % FCS and gentamicin (20 µg/ml). Adherent 
macrophages were obtained by plating the cells in Falcon plastic 
75 cm2 flasks (Becton Dickinson) for 2 hat 37°C in 5 % C0 2/95 % 
air, followed by removal of nonadherent cells by suction. Half 
of the cultures were incubated with a-MEM, supplemented with 10 % 
FCS and 10 µg/ml LPS, while the other half were incubated with 
the same medium containing, in addition, 1 µM dexamethasone. 
The cells were cultured for 18 h under standard conditions at a 
density of 10 6 cells/ml. 
2.2.4 CELL VIABILITY ASSAYS 
Since TNFa can lyse sensitive tumour cells (Philip and Epstein, 
1986; Helson et al., 1975), cytotoxicity assays were carried out 
to define a dose range for each compound in which it would be 
nontoxic to HepG2 cells. 
A colorimetric assay, based on the selective ability of living 
cells to reduce the yellow salt, MTT, to formazan (dark blue 
product), was used to determine cell viability (van de 
Loosdrecht et al., 1993). Briefly, HepG2 cells were seeded at 
lxl0 4 cells/well in 96-well plates and incubated overnight under 
standard conditions to permit adherence. The next morning the 
culture medium was replaced with 200 µl of fresh medium per 
well, with or without macrophage-conditioned medium (dose range: 
0 to 50 % of culture volume), recombinant cytokines (0 to 1000 
U/ml), or neopterin (0 to 1000 nM). Plates were returned to the 
incubator for 44 h, whereafter 50 µl MTT (2 mg/ml) was added to 
each well, followed by a final incubation at 37°c for 4 h. The 
culture medium was aspirated from the wells, after which the 
formazan crystals were dissolved in 200 µl DMSO. The absorbance 
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was recorded directly on 
( Cambridge Technology Inc) 
a microplate spectrophotometer 
at a wavelength of 540 nm. The 
spectrophotometer was calibrated using wells that contained only 
DMSO. _ Doses for each test agent were assayed in replicates of 
eight and each experiment was repeated thrice. The results of 
one experiment are presented which were representative of all 
three. Cell viability was assessed by comparing the absorbance 
of the formazan product obtained with controls with that of 
treated cells. 
2.2.5 GROWTH CURVES 
Growth curves for HepG2 cells in the presence and absence of a 
fixed concentration of each test agent were carried out. For 
neopterin the concentration was 1000 nM, and for IL-1B, IL-6, 
and TNFa the dose was 1000 U/ml. (These were the maximum doses 
used for determining the dose-response effect of each agent on 
HepG2 Epo synthesis). Cells were plated in 60 mm petri dishes 
at a density of 2x10 5 cells/dish in 4 ml of standard medium 
containing the test substance. Viable cells in three cultures 
were counted with a haemocytometer every alternate day after 
trypsinization. 
2.2.6 DOSE-RESPONSE CURVES 
HepG2 cells were plated at 5x10 5 cells/well in 24-well Falcon 
culture plates. Following adherence, after overnight 
incubation, spent medium was replaced by 1 ml of standard 
culture medium containing a specific dose of test substance. 
Cells were cultured in this medium for 24 h, after which the 
medium was transferred to Eppendorf tubes (Lasec), and stored at 
-40°C for Epo analysis. Cell monolayers were washed with PBS 
and the cells lysed with 0.5 ml of NP-40 lysis buffer 
(Appendix) . Protein analysis was carried out on a 1 in 10 
dilution (with PBS) of the cell lysates using the Bio-Rad 
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micro-assay kit (Bio-Rad Laboratories, UK). This was done in 
order to express the concentration of Epo in terms of mass of 
cellular protein, thereby, compensating for any effects of the 
test substances on cell growth. Each agent was assayed over a 
range of concentrations (0 to 1000 U/ml for cytokines, 0 to 40 % 
for MCM, and Oto 1000 nM for neopterin) in quadruplicate, and 
each experiment was repeated three times. 
2.2.7 CYTOKINE COMBINATION ASSAYS 
Synergism amongst macrophage-derived cytokines, especially in 
the induction of acute phase protein synthesis, has been 
reported (Andus et al., 1988; Helle et al., 1988). To determine 
whether synergism also occurs amongst the test agents on Epo 
synthesis, HepG2 cells (5x10 5 cells/well) were incubated for 24 
h with single doses (100 U/ml) of each cytokine in the following 
combinations: IL-lB and IL-6, IL-lB and TNFa, IL-6 and TNFa, 
and finally, IL-lB, IL-6, and TNFa. Combinations of each 
cytokine with neopterin (100 nM) and MCM (10 %) were also 
investigated for synergistic effects on HepG2 Epo production. 
Each combination was assayed in quadruplicate and · each 
experiment was repeated thrice. 
2.2.8 ERYTHROPOIETIN ASSAY 
An in-house RIA method for Epo, developed in the Haematology 
Department at UCT, was used. The method is similar to that of 
Garcia et al. (1982) with minor modifications. To 100 µl of 
sample or standard in 5 ml plastic tubes was added 200 µl of 
rabbit anti-human Epo antiserum. This was allowed to react for 
72 hat 4°C. To this was added 200 µl of radioactively labelled 
125 I-Epo equivalent to 10 000 cpm. This was incubated for a 
further 24 hat 4°C. The next step was to add 100 µl of Sac-eel 
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(donkey anti-rabbit antibody coated cellulose suspension). The 
mixture was allowed to stand at room temperature for 30 min 
after which 1 ml of distilled water was added. The tubes were 
centrifuged for 10 min at 1500g and 4°C. Supernatants were 
decanted and the radioactivity in the pellets was counted with 
a Crystal I I mul tidetector RIA system ( Packard Instruments, 
USA). Using the logistic fit of the instrument, a standard 
curve was drawn from which the results were automatically 
calculated. The dose range of the standard curve was from Oto 
50 0 mU/ml. The intra-assay coefficient of variation (% CV) was 
found to be 10.4 % and the interassay CV, 9.8 %. 
2.2.9 STATISTICAL ANALYSIS 
Data are expressed as means± standard error of the means (SEM). 
One-way analysis of variance was used to analyse the dose-
response curves. Differences between doses were compared using 
multiple range analysis. Comparisons of the effects of single 
doses of test substances alone and in combination were carried 
out using Dunnet's t-test. A probability (p) value less than, 
or equal to, 0.05 was considered significant. 
2.3 RESULTS 
2.3.1 CELL VIABILITY 
Figure 2. 1 represents the effects of the macrophage-derived 
factors on the viability of HepG2 cells in culture. None of the 
factors, including macrophage-conditioned medium, had any 
deleterious effects on HepG2 cell viability over their tested 
concentration range. Tumour necrosis factor-alpha, a known 
cytotoxin for certain tumour cell lines (Cairns et al., 1991; 
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Helson et al., 1975), did not induce necrosis in cells over the 
48 h time course of the experiment (Figure 2.lc). Neither did 
MCM ( Figure 2. la) , IL-1.B ( Figure 2. lb) , or neopterin ( Figure 
2. ld) . Interleukin-6 was not tested for cytotoxicity. Studies 
on IL-6 as a modulator of acute phase protein synthesis by HepG2 
cells and in which the concentration range used was the same as 
in this investigation have been reported (Castell et al., 1989). 
Viability of the cells in these studies was not affected. 
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Figure 2.1. The effect of a) MCM, b) IL-1~, c) TNFa, 
and d) neopterin on the viability of HepG2 cells in 
culture. Viability of the cultures was determined by 
assessing their ability to reduce MTT to its formazan 
product after a 44 h incubation with different doses of 
the test agents. Data are representative of three 
independent experiments. 
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2.3.2 CELL GROWTH 
Proliferation of HepG2 cells was generally not affected when 
cultured with the four macrophage-derived factors. 
average growth rates of the cells exposed to 
2.2a ) , IL-6 (Figure 2.2b), TNFc:x (Figure 2.2c), 
Although the 
IL-1.B ( Figure 
and neopter in 
(Figure 2 .2d) were lower than for the controls, the differences, 
especially over the first five days, were not statistically 
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Figure 2.2. The effect of a) IL-1~, b) IL-6, c) TNFa, 
and d) neopterin on the growth of HepG2 cells in 
culture. Growth rates were determined by incubating 
HepG2 cultures with (• ) or without (0) a fixed dose of 








Conditioned medium obtained from LPS-stimulated macrophages 
caused a dose-dependent decrease in Epo secretion by HepG2 cells 
(p !> 0 . 05). In contrast to this, the decrease observed with 
conditioned medium from LPS-stimulated macrophages that were 
treated with dexamethasone, was substantially less and differed 
significantly (p !, 0. 05) from that of untreated macrophages 
cultures (Figure 2.3a). IL-lB (Figure 2.3b), IL-6 (Figure 2.3c) 
and TNFa .(Figure 2. 3d) also resulted in statistically 
significant (p !, 0.05) dose-dependent reductions in Epo 
synthesis. Interleukin-lE was the most potent cytokine with a 
half-maximal inhibitory concentration of 5 U/ml compared with 
70 U/ml for TNFa. IL-6 was the least potent inhibitor of Epo 
production. A half-maximal inhibitory concentration for this 
cytokine could not be obtained from the graph, since the highest 
dose (1000 U/ml) ·only induced a 44% inhibition in Epo secretion. 
Neopterin had no effect on Epo synthesis (Figure 2.3e). 
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Figure 2.3. Dose-response effects of a) MCM, b) IL-10, 
c) IL-6, d) TNFa, and e) neopterin on Epo production by 
HepG2 cells in culture. All, except neopterin, 
inhibited the secretion of the hormone by the cells. 
The inhibitory effect of MCM (0) was partially 
abrogated by dexarnethasone Data are 
representative of three independent experiments. 
2.3.4 CYTOKINE COMBINATION EFFECTS 
1 
Interleukin-lB and TNFa enhanced each other's effects on Epo 
production by HepG2 cells (Figure 2.4). The inhibition in Epo 
synthesis obtained with a combination of the two cytokines was 
significantly more (p ~ 0.05) than the reduction observed with 
each cytokine alone. IL-6 did not augment the inhibitory 
effects of either IL-lB or TNFa. The reduction in Epo secretion 
observed when all three cytokines were simultaneously incubated 
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with HepG2 cells, was significantly greater (p ~ 0.05) than that 
achieved with IL-6 and TNFa alone (p ~ 0.05), but not greater 
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Figure 2.4. Additive effects of IL-1~, IL-6, and TNFa 
on Epo production by HepG2 cells. Potentiation occurred 
between IL-1~ and TNFa, but not between IL-6 and the 
other two cytokines. Data are representative of three 
independent experiments. 
Neopterin did not augment the reduction in Epo synthesis obtained 
with IL-lB, TNFa, or with all three cytokines · used together 
(Figure 2.5). However, it did effect a significant potentiation 
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Figure 2.5. The effect of neopterin on IL-1~-, IL-6-, 
and TNFQ-rnediated suppression of Epo biosynthesis. 
Neopterin potentiated the effect of IL-6 only. 
Al l three cytokines, IL-1B, IL-6, and TNFa, caused a significant 
enhancement in the inhibition of Epo secretion achieved with 
conditioned medium from LPS-stimulated macrophages (p ~ 0.05). 
The magnitude of the additive effect on MCM-mediated Epo 
inhibition was similar for all three cytokines (Figure 2.6). An 
even greater inhibition of Epo production was observed when the 
HepG2 cultures were incubated with a mixture of the three 
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Figure 2.6. The effect of IL-1~, IL-6, and TNFa on the 
MCM-mediated inhibition of Epo synthesis by HepG2 cells. 
The response to MCM was enhanced by each cytokine. 
Greater enhancement was observed when MCM was combined 
with a mixture of the three cytokines. Data are 
representative of three independent experiments. 
2.4 DISCUSSION 
In this study, mediators of the inflammatory response were 
investigated for suppressive effects on in vitro erythropoietin 
production by cells of the hepatoma cell line, HepG2. HepG2 
cells express the Epo gene in a constitutive and regulated manner 
(Goldberg et al., 1987; Ueno et al., 1989). When these cells are 
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cultured in a hypoxic atmosphere ( 1 % 0 2 ) , they increase their 
output of Epo. Under normoxic culture conditions (21 % 02), the 
amount of Epo that they secrete is substantially less. Since the 
secretion of the hormone by Epo-producing cells in the body is 
similarly regulated by oxygen tension in the blood, HepG2 cells 
can serve as an appropriate model for studying Epo synthesis. 
None of the test agents, in the concentration ranges used, were 
found to be toxic to HepG2 cells. Macrophage-conditioned medium 
( Leu et al., 1991; Van de Loosdrecht et al., 1993) and TNFO'. 
( Cairns et al., 1992; Helson et al., 197 5) reportedly induce 
cell-death in certain tumour cell lines. HepG2 cells, derived 
from a primary hepatoblastoma in a child (Knowles et al., 1980) 
was, however, insensitive to the toxic effects of either TNFO'. or 
MCM. 
The growth rate of HepG2 cells was also not significantly 
affected when cultured in the presence of the test compounds. 
Al though the growth rates were slightly lower, there was no 
statistical difference between the mean growth rate of control 
and test cultures. Epo concentration is nevertheless expressed 
in terms of units per mass of cellular protein (mg), as opposed 
to units per volume of culture medium (ml), to adjust for this 
s l ight variation. A reported decrease in Epo concentration is, 
therefore, specific and not the result of a cytokine-mediated 
generalized decrease in protein synthesis (which would manifest 
as reduced cell growth). 
Macrophage-conditioned medium (MCM), obtained from LPS-stimulated 
mouse peritoneal macrophages, caused a significant (p ~ 0.05) and 
dose-dependent reduction in the amount of Epo secreted by HepG2 
cells in culture. This decrease was significantly (p ~ 0.05) 
less in the case of conditioned medium obtained from 
dexamethasone-treated, 
Gl ucocorticoids, such as 
LPS-stimulated, macrophages. 
dexamethasone, down-regulate the 
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expression of such cytokine genes as IL-1 (Lew et al., 1988), 
IL-6 ( Tobler et al., 1992) , and TNFO'. (Beutler et al., 198 6) . 
Inhibition of Epo synthesis by MCM could, therefore, have been 
mediated by these three cytokines. 
IL-lB, IL-6, and TNFO'. all effected dose-dependent decreases in 
Epo production. The most potent inhibitor was IL-lB with a half-
maximal inhibitory concentration (IC50 ) of 5 U/ml, followed by 
TNFO'. with an IC 50 of 7 0 U/ml. An IC50 for IL-6 could not be 
determined from its dose-response curve since the highest dose 
(1000 U/ml) only induced a 44 % reduction in Epo output. A 25 % 
inhibition in Epo secretion was induced with an IL-6 
concentration of 45 U/ml ( IC25 ) • For IL-lB, the IC25 was O. 4 U/ml 
and for TNFO'. it was 12 U/ml. Interleukin-6 is, therefore, a weak 
inhibitor of Epo synthesis. Neopterin, unlike the other test 
compounds, had no effect on Epo secretion. 
The cytokines, IL-lB, IL-6, and TNFO'. reportedly act 
synergistically in modulating acute phase protein gene expression 
(Andus et al., 1988; Helle et al., 1988). IL-lB and TNFO'. were 
found to enhanced each other's effects on Epo synthesis. Their 
combined effect was significantly greater (p ~ O. 05) than the 
inhibition observed with either cytokine alone. No synergism 
was, however, observed between IL-6 and the other two cytokines. 
It has been reported, that IL-6 may counteract the inhibitory 
effects of IL-lB and TNFO'. on Epo production (Faquin et al, 1992). 
In our study, this was found not to be the case. The inhibition 
obtained with IL-6 and IL-lB or IL-6 and TNFO'. was neither 
greater, nor less, than that achieved with either IL-lB or TNFO'. 
alone. 
Neopterin, a macrophage product with no effect on Epo production 
by HepG2 cells, did not contribute to the Epo inhibitory effects 
of IL-lB or TNFO'.. It did, however, cause a slight, but 
nevertheless significant (p ~ 0.05), potentiation in the 
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inhibition mediated by IL-6 on Epo synthesis. 
Each of the three cytokines, IL-lB, TNFa, and IL-6 enhanced the 
inhibition of Epo synthesis obtained with MCM. Greater synergism 
was seen when all three cytokines were combined with MCM (p ~ 
O. 05). An interesting observation was that the degree of 
potentiation in the effect of MCM obtained with IL-6 was not less 
than that achieved with either IL-lB or TNFa. As mentioned 
earlier, IL-6 failed to enhance the Epo inhibition obtained with 
IL-lB or TNFa. It, therefore, appears that MCM, apart from 
containing IL-lB and TNFa, may also contain another factor which 
can synergize with IL-6 to induce significant inhibition in Epo 
synthesis. It is unlikely that this unknown factor is neopterin 
since the degree of synergism observed between neopterin and IL-6 
was not as great as that seen with IL-6 and MCM. 
This study demonstrates that macrophages, cells prevalent during 
inflammatory episodes in the body, secrete factors which are 
potent inhibitors of erythropoietin synthesis. The expression 
and, hence, secretion of these factors can be modulated by 
dexamethasone, a glucocorticoid, which almost completely 
abrogated the Epo inhibitory effect of MCM. The results also 
suggest that the macrophage factors, which mediate this 
inhibition, could include IL-lB, TNFa, and IL-6. IL-lB and TNFa 
acted synergistically in exerting inhibition in Epo synthesis. 
It is likely that another factor, or factors, are secreted by 
macrophages which can interact with IL-6 to induce substantial 
reduction in Epo secretion by HepG2 cells in culture. 
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CHAPTER THREE 
MECHANISMS OF CYTOKINE-INDUCED INHIBITION 
OF ERYTHROPOIETIN SYNTHESIS 
3.1 I NTRODUCTION 
Interleukin-1B, IL-6, and TNFa, each effected a dose-dependent 
suppression in the secretion of Epo by HepG2 cells in culture 
(Chapter 2). These cytokines are known to exert their 
bioactivities by binding to complementary receptors on the 
surface of target cells (Sims et al., 1988; Yamasaki et al., 
1988; Schall et al., 1990). The receptors are transmembrane cell 
surface polypeptides that consist of an intracellular domain, 
concerned with transducing signals to the nucleus, and an 
extracellular cytokine-binding portion. The association of 
cytokine with the binding domain of the receptor regulates the 
activity of the cytoplasmic portion of the receptor molecule , 
thus delivering a signal which is imparted to the nucleus (Arai 
et al., 1990; Mixajima et al., 1992). The biochemical nature of 
the intracellular signalling pathway is virtually unknown . It 
has, however, been established that protein tyrosine 
phosphorylation occurs which ultimately leads to modulation of 
gene transcription via transcription factors (Mixajima et al. , 
1992). Transcription factors are nuclear proteins that recognize 
and bind specific regulatory DNA sequences and stimulate or 
repress transcription (Latchman , 1993) . 
The inhibited Epo synthesis induced by IL-1B, IL-6, and TNFa 
could, therefore, be a transcriptional event in which case there 
would be a reduction in the concentration of transcribed Epo 
47 
mRNA. Alternatively, the inhibition could occur at a post-
transcriptional level. Mechanisms exist in cells which regulate 
the rate of mRNA translation of certain proteins, thereby 
controlling their average rate of synthesis (Darnell et al., 
1990) . Translation control is usually effected by substances 
that can regulate the efficiency of translational initiation. If 
the translation of Epo mRNA is subject to such a regulatory 
mechanism, the decreased secretion of the hormone by HepG2 cells 
may be a consequence of a reduced rate of translation mediated by 
the three cytokines. In such a case, the level of transcribed 
Epo mRNA would not be altered. 
In order to elucidate the mechanism by which IL-lB, IL-6, and 
TNFa inhibited the synthesis of Epo by HepG2 cells, the level of 
Epo mRNA expression in cells cultured in the presence and absence 
of an inhibitory concentration of each cytokine was determined. 
3.2 MATERIALS AND METHODS 
3 . 2 . 1 REAGENTS 
Human recombinant IL-lB was a gift from the Biological Response 
Modifiers Program (Frederick, MD). Interleukin-6, TNFa, EcoRI, 
PstI , lambda and pox DNA markers were purchased from Boehringer-
Mannheim (SA) . Foetal calf serum was obtained from Highveld 
Biological (Sandton, SA) and trypsin, phosphate-buffered saline 
(PBS), and alpha-minimum essential medium (a-MEM) were from Gibco 
(Grand Island, NY) . Agar, Bacto-tryptone and Bacto-yeast 
extract were from Difeo (Detroit, MI). Bovine serum albumin 
(BSA), transcription buffer (5X), dithiothreitol (DTT), DNase I, 
RNase ONE and SP6 polymerase were obtained from Promega (Madison, 
WI). Agarose, ethidium bromide (EtBr), formamide, MOPS (3-[N-
morpholino]propanesulphonic acid), sodium acetate, sodium lauryl 
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sulphate ( SLS) and tris (hydroxymethyl) aminomethane (Tris) were 
bought from Sigma (St Louis, MO). Acrylamide, ammonium 
persulphate, bisacrylamide (NN'-methylene-bis-acrylamide), TEMED 
(N, N, N', N' -tetramethylethylenediamine) and urea were obtained 
from BDH (Poole, England). Sephadex G50 was purchased from 
Pharmacia (Uppsala, Sweden). 
3.2.2 CELLS AND CELL CULTURE 
HepG2 cells were obtained from Dr BB Knowles (Wistar Institute, 
Pennsylvania). The cells were cultured in a-MEM supplemented 
with 10% FCS (not heat-inactivated) in a humidified atmosphere of 
5% CO2 and 95% air at 37°c. (This cell line cannot proliferate 
in medium that has been fortified with heat-inactivated FCS). 
Cells were passaged once per week by trypsinization. IW32 cells, 
a mouse erythroleukemic cell line that constitutively expresses 
Epo, were a gift from Dr C Lacombe (Inserm, France). The cells 
were maintained in a-MEM with 5% heat-inactivated (56°C for 30 
min) FCS. Cells were passaged twice per week by diluting the 
culture 1:10 with medium. 
3.2.3 PROBES 
The rat Epo probe was generously provided by Dr P J Ratcliffe 
(John Radcliffe Hospital, Oxford). The probe was obtained by 
amplification of rat genomic DNA using the polymerase chain 
reaction (PCR) . Oligonucleotides complementary to conserved 
regions in exons IV and V of the published mouse sequence were 
used as primers. From the amplification products, a PstI/SacI 
fragment, containing 132 base pairs (bp) of exon V and 
approximately 300 bp of the adjoining intron, was constructed and 
inserted into pSP64 (Ratcliffe et al., 1990). 
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The human Epo cDNA probe, inserted at the EcoRI site of the 
polylinker in pSG5, was received from Dr MA Goldberg (Harvard 
Medical School, Boston, MA). 
Upon receipt of the plasmids (pSG5 and pSP4), they were amplified 
by introducing them into competent E. coli bacteria as described 
below. This generated a large supply of probe DNA. 
3.2.3.1 PREPARATION OF COMPETENT E. coli BACTERIA 
The method employed was adopted from Sambrook et al. (1989) . The 
DK 1.1 strain of E. coli was used. To 50 ml of LB medium 
(Appendix) was added 0.5 ml of an overnight culture of E. coli. 
This was incubated at 37°C in a shaking water bath until the 
optical density at 600 nm was 0.4. The culture was chilled on 
ice for 10 min . This was followed by transferring 20 ml of the 
cell suspension to a 50 ml sterile screw-cap tube (Falcon) and 
centrifuging it at 3 000 rpm for 10 min at 4°C. The supernatant 
was discarded and the cell pellet resuspended in 10 ml ice-cold 
50 rnM CaC1 2 • This was placed on ice for 60 min. The suspension 
was re-centrifuged as before, supernatant discarded, and the 
cells, which were now competent, resuspended in 1 ml ice-cold 50 
rnM CaC1 2 • To 200 µl of cell suspension in a sterile Eppendorf 
tube, was added approximately 50 ng of plasmid DNA. After 
mixing, the preparation was stored on ice for 30 min. The next 
step was to heat-shock the cells by transferring them to a water 
bath at 42°C for 2 min. LB medium (1 ml) was added to each tube, 
and the cells incubated at 37°C for 60 min. Different volumes 
(50 , 100, and 150 µl) of the transformation mixture and blank 
were plated on sterile agar plates containing ampicillin ( 50 
µg/ml) . A sterile bent-end glass rod was used to spread the 
cells evenly over the surface of the plates. Plates were 
incubated inverted at 37°C overnight, and inspected for colony 
growth the next day. 
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3.2.3.2 ISOLATION AND PURIFICATION OF PLASMID DNA. 
The method followed is a modification of one in Davis et 
al. (1986). A transformed colony was picked from the agar plate 
prepared above, inoculated into 5 ml of LB medium containing 
ampicillin (50 µg/ml) and incubated overnight at 37°C in a 
shaking water bath. The next day 100 ml of LB medium containing 
the antibiotic was inoculated with 1 ml overnight culture. The 
culture was incubated at 37°c with vigorous shaking until the 
optical density at 600 nm was 0.4. To this was added 0.5 ml of 
stock chloramphenicol solution (34 mg/ml in ethanol) so that the 
final concentration of chloramphenicol in the culture was 170 
µg/ml. Incubation was continued overnight with vigorous shaking. 
Bacterial cells were harvested the next day by centrifugation at 
2500g for 10 min at room temperature. The supernatant was 
discarded and the pellet suspended in 2. 5 ml glucose buffer 
(Appendix). To this was added 750 µl freshly prepared lysozyme 
solution (8 mg/ml in glucose buffer). The mixture was allowed to 
stand at room temperature for 5 min and then transferred to a 
sterile 30 ml corex tube. Addition of 6 ml of freshly prepared 
0.2 M NaOH solution containing 1% SDS followed. It was mixed and 
p l aced on ice for 5 min. To this was added 4. 5 ml ice-cold 
potassium acetate solution (Appendix) followed again by mixing 
with a vortex, and placing it back on ice for a further 10 min. 
The mixture was centrifuged at 12 OOOg for 10 min at 4°C. The 
supernatant was carefully transferred to another corex tube, 
mixed with 0.6 volumes of isopropanol, and placed in a -20°C 
freezer for 15 min to precipitate the DNA. The DNA was recovered 
by centrifugation at 12 OOOg for 15 min at 4°C. The supernatant 
was discarded, the DNA dissolved in 400 µl TE buffer (Appendix), 
and transferred to an Eppendorf tube. The DNA solution was 
further purified by extracting it first with one volume of a 
mixture of phenol and chloroform (1:1) and then with one volume 
of chloroform alone. After the two phases had separated, the 
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upper aqueous phase was transferred to a new Eppendorf tube, and 
mi xed with a tenth volume of 3M sodium acetate solution (pH 7.4) 
and two and a half volumes of absolute ethanol. The mixture was 
p l aced at -20°c for 1 h, centrifuged at 12 OOOg for 10 min at 4°C, 
a n d the supernatant discarded. The pellet was washed with 70 % 
e t hanol, dried in a vacuum chamber, and redissolved in 200 µl TE 
bu ffer. The concentration of the DNA was determined by measuring 
the absorbance at 260 nm of a 1:500 diluted solution, and the 
purity assessed by calculating the ratio of the absorbance values 
a t 260 and 280 nm. 
3.2.3.3 PROBE ISOLATION 
The rat Epo probe was isolated by digesting the pSP64 plasmid 
wi th the restr i ction enzymes PstI and EcoRI. The pSG5 plasmid 
p r eparation was digested with EcoRI to yield the human Epo cDNA 
p r obe. All enzyme reactions were carried out in appropriately 
b u ffered solutions in a 37°C water bath for 2 h. The digests 
we re subjected to electrophoresis at 80 volts through 1 % agarose 
g e ls with lX TBE (Appendix) as running buffer. After 
e l ectrophoresis, the gels were stained in dilute ethidium bromide 
(0 .5 µg/ml ) solution. 
Pr obe bands were cut out with a sharp razor blade. The DNA was 
e l uted from the gel pieces by placing them on a bed of sterile 
g l ass wool inside a small Eppendorf tube (0.5 ml) with a hole 
p unctured through the bottom. The gel pieces were frozen in 
l i quid nitrogen, the tube fitted inside a bigger Eppendorf tube 
(1 .5 ml), and spun at 13 000 rpm for 20 min at room temperature. 
Th e supernatants carrying the probes flowed through the hole in 
t h e bottom of the small tube into the larger one. 
The DNA solutions were extracted once with one volume of a 
mixture of equal parts of phenol and chloroform and then with one 
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volume of chloroform alone. Probes were precipitated with 0.3 M 
sodium acetate and 2.5 volumes of absolute ethanol, and placed at 
-20°c for 1 h. The pellets were spun down at 13 000 rpm for 15 
mi n at 4°C, washed in 70 % ethanol, vacuum-dried, and then 
redissolved in TE to give 50 to 150 ng/µl solutions in which they 
were stored at -20°C. 
3.2.3.4 RADIOACTIVE LABELLING OF PROBE 
Labelling of probes was performed with the Multiprime DNA 
labelling system (Amersham, RPN 1600Y) . Probes were labelled 
wi th [cx- 32 P]dCTP (Amersham) to give lxl0 6 cpm per ml of 
hybridisation solution. Labelling proceeded as follows: 50 ng 
of probe DNA in 5 µl TE was denatured in a 95°C water bath for 5 
mi n and then transferred directly onto ice. To this was added 10 
µl of concentrated buffer solution containing hexanucleotides of 
random sequence which bind to the denatured probe DNA, plus dATP, 
d TTP, and dGTP. This was followed by the addition of 5 µl of 
s o lution which contained the Klenow fragment of E. coli DNA 
po lymerase I, and 5 µl of [cx- 32P] dCTP. The reaction mixture was 
made up to 50 µl with sterile distilled water, mixed with a 
vortex and left overnight at room temperature. 
the reaction was stopped by adding 1 µl 
The next morning, 
10 % SDS and 20 µg 
denatured salmon sperm (ss) DNA. Labelled probe was separated 
from unincorporated nucleotides by size exclusion chromatography 
on a Sephadex G50 (fine) column using TE as elution buffer. The 
radioactivity was measured by counting 10 µl of the 1 ml eluate 
containing the labelled probe in 5 ml toluene scintillant with a 
scintillation counter (Packard Tri-carb 4530) . The labelled 
probe was denatured again by boiling for 5 min and immediately 
transferred to ice. It was then ready for hybridisation. 
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3.2.4 RNA EXTRACTION 
Glassware was washed in chromic acid solution (Appendix), rinsed 
several times with distilled water and dried in an oven (100°C). 
The clean glassware was then siliconized by dipping it in a 1 % 
dichloromethylsilane solution and baking it at 120°C for 1 h. 
After baking, the glassware was rinsed with distilled water and 
treated with O. 01 % diethylpyrocarbonate (DEPC) . All aqueous 
solutions, except those containing Tris, were also treated with 
O. 01 % DEPC. DEPC inactivates ribonucleases. These enzymes, 
which degrade RNA, are very stable and found everywhere (glass 
surfaces, bench tops, hands, etc.). After DEPC treatment (which 
was carried out at room temperature for 3 to 5 h), solutions and 
glassware were autoclaved for 20 min at 121 °C to remove the 
volatile DEPC and for sterilization. Electrophoresis tanks were 
cleaned with detergent solution, rinsed in water, and then filled 
wi th a solution of 10 % H20 2 • After 10 min at room temperature, 
the tanks were rinsed in DEPC-treated distilled water and left 
upside down on clean absorbent paper to dry. 
throughout all experimental procedures. 
3.2.4.1 EXTRACTION OF TOTAL RNA 
Gloves were worn 
IW32 cells, which grow in suspension, were collected by 
centrifugation at 2 000 rpm for 5 min at room temperature, and 
washed three times by resuspension in ice-cold PBS ~acking 
calcium and magnesium ions. HepG2 cells, which grow in 
monolayers, were trypsinized first, then centrifuged and washed 
as above. After estimating the volume of packed cells, the 
cells were resuspended in 10 volumes of RNA extraction buffer 
(Appendix) . The cell suspensions were mixed on a vortex, placed 
on ice for 5 min, mixed again and transferred to sterile 
Eppendorf tubes. The preparations were centrifuge in a Biofuge 
A (Heraeus) at 13 000 rpm for 2 min and supernatants transferred 
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to 15 ml sterile corex tubes. To these were added one volume of 
p r ote i nase digestion buffer (Appendix). After mixing on a 
vortex, proteinase K was added to a final concentration of 50 
µg/ml. The solutions were mixed again and then incubated for 30 
mi n in a 37°C water bath. Proteins were removed by extracting 
twice with an equal volume of phenol (containing 0.1 % 
hydroxyquinoline), then once with a 1:1 mixture of phenol and 
ch loroform/amyl alcohol solution (25:1) and then finally once 
wi th chloroform/ amyl alcohol alone. The aqueous layer was 
transferred to a sterile plastic tube to which was added 0.3 M 
sodium acetate, pH 7.5, and 2.5 volumes absolute ethanol. Total 
RNA was allowed to precipitate at -20°C overnight. The 
precipitated RNA was centrifuged at 12 000 rpm for 10 min at 4°C. 
Th e supernatant was discarded, the pellet washed with 70 % 
e t hanol, and then vacuum-dried. The pellet of RNA was 
redissolved in 200 µl TE (pH 7. 6) and its concentration 
determined spectrophotometrically at 260 nm (Shimadzu, uv-120-
02) . The concentration was calculated based on an OD260 reading 
o f 1 for a RNA solution of 40 µg/ml. The RNA solution was stored 
a t -2 0 °C after addition of 500 µ l absolute ethanol. 
3.2.4.2 ISOLATION OF POLY(A)+ RNA 
Messenger RNA was isolated from other forms of RNA (tRNAs and 
rRNAs) by affinity chromatography on an oligo (dT) -cellulose 
co l umn. A slurry of the oligo(dT)-cellulose was prepared in 0.1 
N NaOH, and the column packed in a sterile, siliconized pasteur 
p i pette plugged with sterile, DEPC-treated glass wool. The 
column was washed with 3 column volumes of sterile, DEPC-treated 
water, and then with sterile lX column loading buffer (Appendix) 
un til the pH of the effluent was less than 8. The total RNA 
sample, dissolved in sterile water, was heated to 65°C for 5 min, 
rapidly cooled to room temperature, mixed with 2X column loading 
b u ffer (Appendix), and applied to the column. Once all the RNA 
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solution had entered the column, one column volume of lX column 
loading buffer was added. Eluate was collected continuously in 
a sterile tube. When all the solution eluted from the column, 
the eluate was heated to 65°C for 5 min and reapplied to the 
column. 
The column was washed with 5 to 10 column volumes of lX column 
loading buffer while collecting 1 ml fractions in sterile 
Eppendorf tubes. The absorbance of each fraction was measured at 
260 nm. When the fractions showed no absorbance, indicating the 
absence of nonpolyadenylated RNA, poly (A) + RNA was eluted from 
the oligo(dT)- cellulose with 2 to 3 column volumes of sterile, 
RNase-free elution buffer (Appendix) . The absorbance of the 
e l uate, collected in fractions, was measured at 260 nm, followed 
by pooling of those fractions which contained RNA. To the pooled 
fractions were added sodium acetate (pH 5.2), to a final 
concentration of O. 3 M, and 2. 5 volumes of ice-cold absolute 
ethanol. After mixing on a vortex, the preparation was stored at 
-20°C overnight. The next day, the poly(A) + RNA was recovered by 
centrifugation at 10 OOOg for 15 min at 4°C. The supernatant was 
d i scarded, the pellet washed with 70 % ethanol, and then vacuum-
dried. Finally, the RNA was redissolved in a 100 µl sterile, 
DEPC-treated water and its concentration determined 
spectrophotometrically. 
3.2.5 RNA ANALYSIS 
3.2.5.1 FORMALDEHYDE GEL ELECTROPHORESIS OF RNA 
RNA was electrophoresed on a 1.1 % agarose gel containing 2.2 M 
formaldehyde. The gel was prepared by mixing 170 mg agarose with 
1.5 ml lOX MOPS buffer (Appendix) and 12.75 ml sterile DEPC-
treated deionized water. After heating to dissolve the agarose, 
the mixture was cooled to 40°C under running tap water. 
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Formaldehyde (0.75 ml) was then added and the mixture poured onto 
a 5 x 7.5 cm perspex plate on which was positioned a perspex comb 
about 1 cm from the narrow top edge. The gel was allowed to 
solidify at room temperature after which the comb was gently 
removed. RNA samples in sterile, DEPC treated water, were mixed 
wi th the same volume of RNA loading dye mixture (Appendix) and 
l oaded into the wells created by the perspex comb. The samples 
were electrophoresed at 60 volts for 2 h using lX MOPS as gel 
running buffer. Standards, consisting of E. coli rRNA, were also 
included. After electrophoresis, the gel was transferred to a 
di lute solution of ethidium bromide in lX MOPS. The gel was left 
in this solution for 5 to 7 min to allow the EtBr to stain the 
RNA. After staining, the gel was inspected on a transilluminator 
(Spectroline, model TS-302) and photographed. 
3.2.5.2 NORTHERN TRANSFER 
After electrophoresis, the formaldehyde gel was washed in 0.1 N 
NaOH for 20 min to ensure complete denaturation of RNA. This was 
fo llowed by washing the gel in DEPC-treated water for 20 min and 
then equi l ibrating it twice in lOX SSC (Appendix), also for 20 
min. The gel was mounted on a filter paper wick which dipped 
into a reservoir of lOX SSC (transfer buffer). The Hybond-N 
nylon hybridisation membrane (Amersham), cut to the same size as 
the gel, was sandwiched between the gel and three pieces of 
fil ter paper (Whatman) of the same size. The filter p~per in 
contact with the nylon membrane was first soaked in 2X SSC. On 
t op of this was stacked paper towels (5 to 8 cm high) which 
served to draw the transfer buffer through the gel by capillary 
a c tion. The whole assembly was compressed by a 500 g weight. 
Blotting was carried out overnight (8 to 12 h). The paper towels 
a nd filter paper were discarded and the membrane inspected with 
the transilluminator. The positions of the E. coli ribosomal RNA 
(1 6S and 23S), which were still stained with EtBr, were marked by 
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making holes in the membrane with a sharp needle. The nylon 
membrane was placed between two sheets of Whatman filter paper 
and baked for 2 hat 80°C. Gels were also inspected to check the 
efficiency of transfer. 
3.2.5.3 HYBRIDISATION 
The baked membrane was prewetted in 6X SSC, placed on top of a 
nylon mesh which prevented the membrane from overlapping, and 
both mesh and membrane were then rolled into a spiral and placed 
inside a leak-proof hybridisation bottle. Prehybridisation 
solution (Appendix), containing denatured ssDNA, was added to the 
bottle which was then sealed and fitted in the rotisserie unit of 
the hybridisation oven (Hybaid). The membrane was prehybridised 
at 42°C for 3 to 4 h. Denatured labelled probe was added 
directly to the prehybridisation solution to give a final 
concentration of lx10 6 cpm/ml. Hybridisation was then carried 
out at 42°c overnight. 
After hybridisation, the Northern blots were washed as follows: 
2X SSC, 0.5% SDS for 10 min at room temperature, 
2X SSC, 0.1 % SDS for 15 min at room temperature, and 
0.lX SSC, 0.1 % SDS for 30 min at 65°C. 
3.2.5.4 AUTORADIOGRAPHY 
After the final wash, the blot was wrapped in Saran Wrap and 
taken to a darkroom where it was placed on a X-ray film (Cronex-
4) between two intensifying screens in a light-proof cassette. 
Exposure was done at -70°C for 7 to 10 days. The film was 
developed in the darkroom as follows: 5 min in X-ray developer 
followed by 1 min in a water bath, 5 min in fixer solution and, 
58 
finally, 15 min in running water. All the solutions were at 
room temperature. The film was eventually air dried and visually 
inspected for radioactive signals. 
3.2.5.5 STRIPPING OF BLOTS 
Northern blots were stripped for rehybridisation using a method 
of Davis et al. (1986). Stripping was accomplished by placing the 
blots in a 1 % glycerol solution for 2 min at 80°C, followed by 
4 to 5 washes in DEPC-treated water at room temperature. The 
blots were then exposed for 5 days to assess the efficiency of 
the stripping procedure. 
3.2.5.6 RIBONUCLEASE PROTECTION ASSAY 
Ribonuclease (RNase) protection is an extremely sensitive 
technique for quantification of specific mRNAs in solution 
(Sambrook et al., 1989). It is 20 times more sensitive than 
Northern blots and is, therefore, particularly useful for the 
detection of low abundance mRNA species. To perform protection 
assays, high specific activity 32P-labelled RNA probes 
(riboprobes) complementary to the mRNAs of interest, are used in 
solution hybridisations. Unhybridised material is removed by 
digestion with RNase. The protected fragment is analyzed by 
denaturing polyacrylamide gel electrophoresis followed by 
autoradiography. 
The riboprobe was synthesized at room temperature by adding the 




[ cx- 32P) UTP ( 3 000 Ci/mmol, 10 Ci/ml) 
SX transcription buffer (Appendix) 
100 mM dithiothreitol (DTT) 
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0.5 µl RNasin 
1 µl GTP (10 mM) 
1 µl CTP (10 mM) 
1 µl ATP (10 mM) 
0.5 µl UTP (0.4 mM) 
2 µl BSA (1 mg/ml) 
2 µl (1 µg) EcoRI-linearized pSP64 plasmid DNA with Epo 
probe. 
1 µl DNA-dependent Sp6 RNA polymerase 
Th e reagents were mixed by gently tapping the tube and the 
mi xture was incubated in a 40°C water bath for 2 h. To this was 
added O. 5 µl RNasin and 1 µl of RNase-free DNase I ( 1 mg/ml) . 
Af ter further incubation for 15 min at 37°C, 30 µl of column 
buffer (Appendix) was added and the mixture chromatographed 
through a Sephadex G50 column. The front peak of radioactivity 
wa s collected and the eluate divided into 400 µl aliquots. To 
each was added 40 µl of 3M sodium acetate, 10 µg tRNA and 2.5 
v o lumes of ice-cold absolute ethanol. After mixing, the 
r i boprobe solution was placed inside a lead container and stored 
in a freezer at -20°C overnight. 
The riboprobe was collected by centrifugation at 12 OOOg for 15 
min at 4°C, washed with 70 % ethanol and resuspended in 100 µl 
DEPC-treated water. The radioactivity was quantified by 
d i ssolving 2 µl of riboprobe solution in 10 ml toluene 
sci ntillant and measuring it with a B-counter. 
The hybridisation reactions were started by coprecipi ta ting 
individual RNA samples and riboprobe (200 000 cpm) with 0.3 M 
sodium acetate and 2. 5 volumes absolute ethanol in 1. 5 ml 
Eppendorf tubes. After centrifugation at 12 OOOg for 15 min at 
4° C, the pellets were rinsed with ice-cold 70 % ethanol, spun 
bri efly in a microcentrifuge, and dried in a vacuum chamber. The 
pellets were resuspended in 30 µl hybridisation buffer 
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(Appendix). Samples were heated at 85°C for 5 min to denature 
the RNA and then incubated at 47°C for 12 to 16 h to allow 
hybridisation to occur. Two aliquots of 50 µg tRNA were included 
as controls; one was treated with RNase and the other was left 
untreated. 
After overnight incubation, 300 µl of RNase digestion buffer 
(Appendix) and 10 uni ts of RNase ONE were added. A further 
incubation at 37°C for 60 min followed. Digestion was stopped by 
adding, to each sample (except tRNA control without RNase), 3.3 
µl of 10 % SDS and 20 µg carrier tRNA. After mixing with a 
vortex, 700 µl of ice-cold absolute ethanol was added and the 
samples chilled at -70°C for 15 min. RNA samples were pelleted 
by centrifugation at 12 OOOg for 15 min, washed with 0.2 ml 70 % 
ethanol, and vacuum-dried . Pellets were dissolved in 2 µl DEPC-
treated water and 4 µl formamide loading dye (Appendix). After 
heating at 95°C for 5 min, the samples were resolved by 
electrophoresis at a 1000 volts on a 6% polyacrylamide/7 M urea 
gel (Appendix) . The protected fragments were detected by 
autoradiography and quantified with a densitometer (Hoefer GS 
300). 
3.3 RESULTS 
3.3.1 PROBE ISOLATION 
The 432 bp rat genomic Epo probe was isolated from the pSP64 
vector by digestion with the restriction endonucleases, EcoRI and 
PstI. A diagnostic gel with the digests was run showing the 
plasmid vector and excised probe fragment (Figure 3.la). The 
EcoRI linearized plasmid containing the probe is also shown. A 
bulk isolation of the fragment of interest was then carried out 
(Figure 3.lb). A thin section of gel containing the probe was 
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Fi gure 3 . 1. Isolation of the 450 bp rat Epo probe. 
a) Lane 1 contains A/Hind III DNA markers. Lane 3 shows 
the probe fragment after digestion of pSP64 vector with 
EcoRI and PstI . Lane 4 contains the pSP64 vector with 
the 450 bp Epo insert after linearization with EcoRI. 
b) Bulk isolation of the probe (-+) after large-scale 
digestion of pSP64 with EcoRI and PstI. 
Figure 3 . 2a shows the human Epo cDNA probe isolated from the pSGS 
vector after digestion with EcoRI. A bulk digestion and 
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Figure 3 . 2 . Isolation of the human cDNA probe. a) Lane 
1 contains the pox/EcoRI DNA marker. Lane 3 shows the 
probe (-+) after digestion of the pSG5 vector, which 
contained the probe, with EcoRI. b) Mass isolation of 
the Epo cONA probe after bulk digestion of the vector 
with EcoRI . The gel containing the fragment of interest 
was carefully excised and the probe isolated by spin 
elution . 
3.3.2 RNA ISOLATION AND EVALUATION 
Total cellular RNA was isolated from IW32 and HepG2 cells by the 
phenol-chloroform method (Sambrook et al ., 1989) , and evaluated 
on a formaldehyde-agarose gel. Figure 3 . 3a shows the RNA 
isolated from three separate cultures of IW32 cells. Both 18S 
and 28S ribosomal RNA (rRNA) bands are distinct , indicating 
successful extraction . RNA was also successfully extracted from 
HepG2 cell cultures (Figure 3.3b). The prominent 18S and 28S 
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Figure 3.3. Formaldehyde-agarose gels of RNA. a) IW32 
RNA after phenol-chloroform extraction (lanes 3 to 5). 
The 18S and 28S rRNA bands are distinct indicating that 
the RNA did not degrade during isolation. Lane 1 
contains E. coli RNA as markers. b) HepG2 RNA in lanes 
2 to 9 showing clear rRNA bands. 
3.3.3 NORTHERN BLOTS 
a) HYBRIDISATION WITH THE RAT EPO PROBE 
-28S 
-18S 
Northern blot analysis of RNA, extracted from IW32 and HepG2 
cells and probed with the PstI/SacI fragment of the rat genomic 
Epo probe, demonstrated an Epo mRNA species only in the IW32 RNA 
sample. The size of Epo mRNA is about 1.8 kb (Lacombe et al., 
1987) which is also the approximate size of mammalian 18S rRNA. 
The two will, therefore, run together on an agarose gel. The 
autoradiograph in Figure 3.4a shows an intense band at the 18S 
position of Lane 1 and a less intense band at the 28S position. 
In lane 2, which contains the HepG2 RNA sample, the 28S band is 
more intense than the 18S band. In the photograph of the EtBr-
stained gel taken prior to hybridisation (Figure 3.4b) the bands 
at the 28S position of bath lane 1 (IW32) and lane 2 (HepG2) 
were more prominent than the 18S bands. If the hybridised 
signals in lanes 1 and 2 of the autoradiograph represented only 
64 
nonspecific binding of the probe to rRNA, then the signals at 
the 28S position in both lanes should have been more intense 
than the signals at the 18S position . The higher intensiti of 
the 18S signal in lane 1 , compared to the 28S signal , suggests 
that in addition to nonspecific binding to 18S rRNA the probe 
also hybridised to a specific Epo transcript . The low intensity 
signal at the 18S position in lane 2 (HepG2 RNA) of the 
autoradiograph seems to suggest that the probe is either too 
specific for rat Epo mRNA and , hence , cannot hybridise to human 
Epo rnRNA or that HepG2 cellular RNA contains much less Epo mRNA 
than the same amount of IW32 cellular RNA. Attempts at reducing 
nonspecific binding by increasing the stringency of the washing 
step resulted in the loss of the hybridised signal . 









Figure 3 . 4. Northern blot analysis of IW32 and HepG2 
cellular RNA with the rat Epo probe . a) Autoradiograph 
of IW32 RNA (lane 1) and HepG2 RNA (lane 2). The signal 
at the 18S position is more intense than the one at 28S 
in lane 1 . In lane 2 the 28S signal is more intense . 
Epo rnRNA migrates with 18S rRNA. The dense signal at 
18S in lane 1 could represent nonspecific binding of 
probe to rRNA and specific hybridisation to Epo rnRNA. 
b) EtBr-stained gel of IW32 (lanes 1 and 4) and HepG2 
(lanes 2 and 6) RNA prior to hybridisation . Note how 






b} HYBRIDISATION WITH HUMAN EPO cDNA PROBE 
Northern analysis of HepG2 RNA (lane 1) and IW32 RNA (lane 2) 
with the human Epo cDNA probe showed hybridisation of the probe 
to mRNA species in the IW32 sample, but not in the HepG2 sample 
(Figure 3.5). IW32 cells possess two alleles of the Epo gene. 
The one allele is normal whereas the other is rearranged and 
amplified (Goldwasser et al., 1987; Lacombe et al., 1987). The 
two signals in lane 2 may represent hybridisation to transcripts 
of both alleles, one of which is much shorter than the other. 
Alternatively, the smaller signal at the bottom could represent 
hybridisation of the probe to degraded mRNA. What is important 
to note, however, is that the human Epo cDNA probe failed to 
hybridise to Epo mRNA in the RNA sample isolated from the human 




Figure 3.5. Northern analysis of HepG2 and IW32 RNA 
with the human Epo cDNA probe. Lane 1 represents probe 
hybridisation to HepG2 RNA. A definite signal is 
lacking. Lane 2 represents hybridisation to the IW32 
RNA sample. Two distinct hybridisation signals are 
present. This may indicate annealing to two transcripts 
or the bottom signal may be due to hybridisation to 
degraded Epo mRNA. 
Figure 3.6 is an autoradiograph of a Northern blot of cellular 
RNA of IW32 and HepG2 cells as well as of poly(A)+ RNA isolated 
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from total RNA of the two cell lines. The blot was probed with 
labelled human Epo cDNA. Hybridisation occurred to Epo mRNA in 
lane 4 which contained IW32 cellular RNA. Lane 3, which 
contained IW32 poly(A)+RNA, had no definite signal. Lane 2 which 
was loaded with HepG2 cellular RNA had two hybridisation signals 
which were located at the 18S and 28S positions. These signals 
probably represent nonspecific hybridisation to the two rRNA 
species. Lane 1 was loaded with 20 µg poly(A)+-enriched HepG2 
RNA. Hybridisation of. a probe to poly (A) +RNA sometimes appear 
as a smear down the lane. The signal may, therefore, represent 
hybridisation to Epo mRNA. The reason why no clear signal was 
detected in the IW32 poly(A)+RNA sample could be due to 
degradation of the sample. 
I. 
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Figure 3.6. Northern blot analysis of total and poly(A)• 
RNA isolated from IW32 and HepG2 cultures. 
Hybridisation occurred to the total IW32 RNA sample 
(lane 4) but not to the poly (A)+ RNA sample (lane 3), 
probably because of sample degradation. Lane 2 
contained total HepG2 RNA. The two signals in this lane 
represent nonspecific hybridisation to 18S and 28S rRNA. 
Lane 1 contained 20 µg of poly(A)• HepG2 RNA. A smear is 
usually indicative of hybridisation to a specific rnRNA 
species in a large amount of enriched poly(A)• RNA. 
67 
3.3.4 RNase PROTECTION 
Ribonuclease protection analysis of 10-fold different amounts of 
IW32 cellular RNA was carried out using the 32 P-labelled 
riboprobe synthesised from the Pstl/Sacl fragment of the rat 
genomic Epo gene. A protected fragment of 132 bp was observed 
only with the 50 µg RNA sample (Figure 3.7, lane 8). 
Hybridisation reactions, in which lower amounts of RNA were 
used , did not yield a protected fragment (lanes 4 to 7). 
12345678 
Figure 3. 7. Autoradiograph of a protection assay of 
varying amounts of IW32 RNA probed with the 132 bp rat 
Epo riboprobe. Only the 50 µg sample (lane 8) yielded 
a signal indicative of the protected fragment. Lane 1: 
markers, Lane 2: tRNA with RNase, Lane 3: tRNA without 
RNase, Lane 4: 0.005 µg IW32 RNA, Lane 5: 0.05 µg, Lane 
6: 0.5 µg, Lane 7: 5 µg and Lane 8: 50 µg RNA. 
Protection assays with HepG2 RNA also yielded protected 
fragments of approximately 132 bp in size (see arrow in Figure 
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3.8a). Densitometric analysis of these fragments showed that 
the RNA samples isolated from cells treated with IL-1B and TNFa 
contained a lower concentration of Epo mRNA than the control 
sample obtained from untreated cells (Figure 3.8b). The density 
of the hybridisation signal generated by the RNA sample, 
extracted from cells treated with IL-6, was not different from 
that of the control sample. This suggest that IL-6, unlike IL-
1B and TNFa, did not affect Epo mRNA transcription. 
1 
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Figure 3.8. Protection analysis of HepG2 RNA isolated 
from cells exposed to cytokines. a) Autoradiograph 
showing a protected fragment (4) for the control (lane 
1), IL-1~ (lane 2), IL-6 (lane 3), and TNFa (lane 4) 
treated samples. b) The density of the signals of 
samples treated with IL-1~ and TNFa was lower than for 
the control, suggesting down-regulation of Epo 
expression by these cytokines. There was no difference 
in the density of the control and IL-6-treated sample. 
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3.4 DISCUSSION 
Interleukin-lB, IL-6, and TNFa were found to inhibit Epo 
synthesis by HepG2 cells in culture (Chapter 2). This finding 
led to the investigation into the mechanism underlying this 
inhibition. Protein synthesis can be altered by extracellular 
modulators either during transcription of the gene into mRNA or 
it can be a post-translational event (Klausner and Harford, 1989; 
Darnell et al., 1990) . A common method of assessing whether 
transcription of a gene is affected is to determine its mRNA 
concentration. Northern blot analysis is the most frequently 
employed technique to quantify mRNA. The procedure typically 
involves electrophoresis of RNA through a 1% agarose/formaldehyde 
gel, followed by blotting onto nylon or nitrocellulose membranes 
which are then probed with a complementary DNA sequence that has 
been radioactively labelled. The blot is eventually 
autoradiographed after extensive washing to remove background 
radioactivity (Sambrook et al., 1989). 
Northern blots of cellular RNA extracted from HepG2 cells were 
first analyzed with a probe synthesised from highly conserved 
regions in exons IV and V of the published mouse sequence. As 
control, RNA isolated from the murine erythroleukemic cell line, 
IW32, was also included on the blots. The labelled probe was 
capable of hybridising to Epo transcripts in IW32 but not in 
HepG2 RNA samples (Figure 3.4a). This suggested that the probe 
could either not cross-hybridise with human Epo mRNA, or that the 
level of expression of the Epo gene in HepG2 cells was too low 
for its transcripts to be detected by Northern blotting. 
When the human Epo cDNA was eventually obtained and used to probe 
Northern blots, it hybridised only to IW32 Epo transcripts 
(Figure 3.5). This proved conclusively that Epo mRNA in HepG2 
cells was rare. The Epo mRNA was eventually detected in a sample 
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of enriched poly(A) + HepG2 RNA. Enriching numerous RNA samples 
is time-consuming and expensive. Large quantities (800 to 1000 
µg) of total RNA is usually required to obtain a few micrograms 
(5 to 20 µg) of poly(A) + RNA. The amount of RNA that can be 
extracted from cell cultures is also extremely variable. As 
little as 30 µg is sometimes obtained from 107 cells (Sambrook et 
al., 1989). Special precautions need to be taken when isolating 
poly(A) + RNA to prevent its degradation by ribonucleases. These 
inherent difficulties of Northern blot analysis prompted the 
search for an alternative technique. 
Ribonuclease (RNase) protection assays are 20 times more 
sensitive than Northern blotting (Sambrook et al.,). They can 
detect as little as 0.1 pg of an mRNA species. Poly(A) + RNA is 
also not required. In this technique an RNA molecule, 
complementary to the target sequence, is used as probe and 
hybridisation is carried out in solution. Normal mRNA, also 
referred to as sense RNA, is transcribed from the 3' to 5' strand 
of a double stranded DNA molecule. The RNA probe, or riboprobe, 
used in protection assays is synthesised from the 5' to 3' strand 
of DNA. It is thus complementary to normal or sense RNA and can 
hybridise to it. RNA transcribed from the 5' to 3' DNA strand is 
also referred to as antisense RNA. 
The antisense probe was transcribed from the PstI/SacI fragment 
of the rat Epo genomic DNA and labelled with a 32 P-UTP (Amersham). 
The size of the probe was 132 bp which corresponded to the size 
of the exonic sequence of the DNA fragment. Ten-fold different 
amounts of IW32 cellular RNA were first probed with the antisense 
RNA. Autoradiography after three days exposure at -70°C showed 
a 132 bp protected fragment only for the 50 µg RNA sample (Figure 
3. 7) . Lower amounts of RNA failed to yield a hybridisation 
signal. Samples of 50 µg cellular RNA were, therefore, used in 
the assays for Epo mRNA concentrations in control and cytokine-
treated cultures of HepG2 cells. Figure 3.8a is a representative 
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autoradiograph of the results of such a protection analysis after 
17 days exposure at -70°C. A protected fragment of approximately 
132 bp in size was obtained for each sample. The density of the 
hybridisation signals obtained for the RNA samples extracted from 
cultures treated with IL-lB and TNFa was lower than for the 
control signal. This suggests that these two cytokines suppress 
Epo synthesis by inhibiting transcription of the Epo gene. A 
s i milar finding was reported by Faquin et al., ( 1992) who studied 
the effects of cytokines on hypoxia-induced Epo synthesis by 
Hep3B cells. There was no difference in the density of the 
c ontrol signal and the one generated by the RNA sample isolated 
from cells treated with IL-6. The decrease in the biosynthesis 
of Epo induced by IL-6 was, therefore, a post-transcriptional 
event. 
In conclusion, these results support the idea that IL-lB and TNFa 
can induce a blunted erythropoietin response by interfering with 
the transcriptional process of the Epo gene. Interleukin-6, a 
weak inhibitor of Epo production, appears to exert its activity 
e i ther during translation or at a post-translational level. 
3.5 COMMENTARY 
The figures which appear in this chapter represent the best of 
e i ght to fifteen results. Numerous Northern blots were run in 
order to define appropriate stringency conditions, hybridisation 
buffers, hybridisation temperatures, probe concentrations, sample 
RNA concentrations, and exposure times. Probes were initially 
labelled using nick translation. The specific activity of these 
probes, however, proved to be too low and even failed to detect 
Epo mRNA of IW32 cell cultures. For protection assays, 35S-
labelled probes were also used but without success. The decay 
energy of 35S was probably too low since an adequate signal could 
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/ 
not be obtained, even after exposing the autoradiographs for two 
months. This was originally done to contain costs since 35S has 
a longer half-life than 32 P. Several RNase protection assays 
a l so had to be done in order to define optimum conditions. 
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CHAPTER FOUR 
ERYTHROPOIESIS AND ERYTHROPOIETIN SYNTHESIS 
DURING ACUTE ASEPTIC INFLAMMATION 
4.1 INTRODUCTION 
The response of higher organisms to disturbances of their 
homeostasis due to infection , tissue injury, neoplastic growth, 
or immunologic disorders is called the acute phase response(APR) 
(Kushner, 1982). As schematically shown in Figure 4 .1, it 
consists of an initial local reaction at the site of injury 
followed by a systemic reaction. The local reaction is 
characterized by a number of responses such as aggregation of 
p l atelets and clot formation, dilatation and leakage of blood 
vessels, and an accumulation and activation of granulocytes and 
mononuclear cells. After stimulation, these cells release 
inflammatory cytokines. These act on specific receptors on 
different target cells leading to a systemic reaction, which is 
characterized by fever, leucocytosis, increase in erythrocyte 
sedimentation rate, increases in secretion of 
adrenocorticotrophic hormone (ACTH) and glucocorticoids, 
activation of complement and clotting cascades, and decreases in 
serum levels of iron and zinc. Furthermore, drastic changes in 
the concentration of some plasma proteins occur. These plasma 
proteins, which are synthesized in the liver, are referred to as 
acute phase proteins or reactants (Castell et al.,1989; Kushner, 
1982) . 
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Figure 4.1. The acute phase response 
(Adapted from Castell et al.,1989) 
acute phase reactants fulfil essential functions by 
neutralizing harmful consequences of injury (Pepys and Baltz, 
1983). For example, proteinase inhibitors such as a:i-
anti trypsin, a 1-antichymotrypsin, a 1-macroglobulin, 
macroglobulin, and a 1-inhibitor III antagonize the activity of 
proteinases released from macrophages and granulocytes (Gordon, 
1976; Lonberg-Holm et al., 1987; Pepys and Baltz, 1983). 
Fibrinogen participates in blood clotting and wound healing 
(Furie and Furie, 1988). C-reactive protein (CRP) and serum 
amyloid P (SAP) efficiently bind negatively charged molecules 
such as phosphorylcholine, a component of plasma membranes (Pepys 
and Baltz, 1983). Thus CRP opsonizes bacteria, parasites and 
plasma membranes, facilitating their clearance by phagocytic 
cells. 
The whole spectrum of changes in gene expression of acute phase 
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proteins during inflammation is not caused by the action of a 
s i ngle factor. Among all cytokines secreted by monocytes and 
macrophages, those shown to be involved in the APR are IL-1, 
TNFa, and IL-6 (Ramadori et al., 1985; Perlmutter et al., 1986; 
Darlington et al., 1986; Castell et al., 1988; Morrone et al., 
1988). Together with these factors, glucocorticoids appear to act 
as important cofactors for the induction or repression of APR 
genes both in vivo and in vitro ( Figure 2. 2) (Baumann et al., 
1987 ) . 
f ibroblas t s 
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Figure 4.2 . Regulation of hepatic acute 
phase protein synthesis by inflammatory 
mediators. (Adapted from Castell et al., 1989) 
Recombinant IL-1 induces some acute phase genes such as serum 
amyloid A (SAA), human C3 and factor B, and decreases the 
s ynthesis of albumin, but does not exert any effect on other 
acute phase reactants such as CRP or haptoglobin (Ramadori et 
al., 1985; Perlmutter et al., 1986; Darlington et al., 1986). 
Tumour necrosis factor has an even more restricted spectrum of 
activity. This cytokine has been shown only to induce complement 
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C3 and factor B and to a certain extent 0:1-antichymotrypsin 
(ACH) (Darlington et al., 1986; Perlmutter et al., 1986) . 
Interleukin-6 has been identified as the major modulator of the 
APR (Castell et al., 1989). Recombinant IL-6 is a potent inducer 
of the expression of f ibrinogen, ACH, haptoglobin, factor B, 
haemopexin, SAA, CRP and o:1-acid glycoprotein (Baumann et al., 
1987; Gauldie et al., 1987; Castell et al., 1988; Morrone et al., 
198 8) . 
Recombinant IL-l(Johnson et al., 1989) and TNFo: (Moldawer et al., 
1989; Tracey et al., 1988) reportedly induce anaemia in vivo. 
Acute inflammation may, therefore, be accompanied by an anaemia 
i nduced by these two cytokines. Serum Epo levels would, thus, be 
expected to rise in order to resolve the anaemia. Since IL-10, 
I L-6, and TNFo: have been shown to inhibit in vitro Epo production 
(Chapter 2), the likelihood exists that these modulators of the 
a cute phase response may also compromise the expected increased 
Epo synthesis in vivo. 
l i ke a negative acute 
Erythropoietin could, therefore, behave 
phase reactant. Such a blunted Epo 
response would result in the persistence of the anaemia, as has 
been reported for chronic inflammation (Spivak et al., 1989; 
Mi ller et al., 1990) . 
In order to determine whether Epo 





e r ythropoiesis and erythropoietin synthesis, were studied in an 
in vivo model for acute inflammation. 
4.2 MATERIALS AND METHODS 
4.2.1 ANIMALS 
Adult male Long-Evans rats weighing between 275 to 360 g were 
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used. Animals were kept in a well-ventilated room with a 12 h 
dark/light cycle and a thermostatically controlled temperature of 
23 ± 1°c. The rats were group-housed (3 to 4) in polypropylene 
cages with metal rung tops and had free access to rat chow and 
water. One week prior to the experiment, animals were handled 
daily to reduce the effects of handling stress on the study. 
Sacrificing of animal groups took place in a separate room from 
the one in which the remainder of the animals were kept. 
4.2.2 INDUCTION OF ACUTE INFLAMMATION 
A well-established model for inducing acute inflammation, is by 
the subcutaneous injection of turpentine (Williams and Johnson, 
1976; Schreiber et al., 1982). Turpentine (Alchemist, SA) was 
sterilized with a O. 22 µm filter (Millipore, UK), and 
administered at a dose of 0.5 ml per 100 g body mass. Control 
animals received the same dose of sterile pyrogen-free isotonic 
saline (Sabax, SA). 
At intervals of 0, 8, 12, 16, 24, 36, and 48 h after injection, 
groups of control and treated rats were anaesthetized with ether, 
their thorax surgically opened, and blood collected via cardiac 
puncture with a 26 gauge needle and 10 ml syringe. Between 5 and 
8 ml blood was usually obtained from each animal. Approximately 
2 ml was transferred to sterile 5 ml tubes containing a solution 
of the anticoagulant, EDTA. This was used for haematological 
determinations. The remainder of the blood was transferred to 
additive-free tubes for serum isolation. Groups of three to four 
animals were used per time interval. 
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4.2.3 HAEMATOLOGICAL MEASUREMENTS 
Haemoglobin (Hb), haematocrit (Hct), red cell count (RCC), and 
white cell count (WCC) values were determined with a Coulter 
counter (Coulter Electronics, Model S-Plus). The mean cell volume 
(MCV), mean cell haemoglobin (MCH), and mean cell haemoglobin 
concentration (MCHC) were automatically calculated by the 
i nstrument from the Hb, Hct, and RCC values. Measurements were 
generally performed within 6 h of collecting the blood specimens. 
4.2.4 PREPARATION OF SERUM 
Whole blood was allowed to clot at room temperature for 1 h. The 
c l ot was disrupted with a blunt wooden applicator to release the 
serum and the sample centrifuged (Sigma, Model 3E-1) at 3000 rpm 
fo r 1 0 min. The serum was transferred to 1.5 ml Eppendorf tubes 
and stored at -40°C until required. 
4.2.5 PROTEIN ESTIMATION 
Total serum protein was assayed using the Bio-rad™ dye-binding 
mi croassay kit (Bio-rad, UK) . Briefly, to 5 µl of serum was 
added 200 µl of dye reagent (diluted 1:4 with water) plus 795 µl 
o f distilled water. Four 200 µl aliquots of each sample were 
t r ansferred to a 96-well plate (Sterilin, UK) and . their 
a b sorbances read at 640 nm on an ELISA plate reader (Cambridge 
Technologies, Model 7520). Bovine serum albumin (fraction 
V) [Sigma] was used as standard. 
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4.2.6 ALBUMIN DETERMINATION 
Serum albumin levels were determined using a dye-binding method 
(Grant and Kachmar, 1976) with minor modifications. A bromocresol 
green working solution (Appendix) served as dye reagent. This 
reagent was diluted (1:6) with distilled water prior to use. To 
25 µl of serum was added 5 ml of diluted dye reagent. This was 
mixed on a vortex, allowed to stand for 10 min at room 
temperature, and the absorbance read on a spectrophotometer 
(Beckman, Model DB) at 640 nm against the dye reagent as blank. 
Bovine serum albumin (Sigma) served as reference standard. 
4.2.7 ERYTHROPOIETIN DETERMINATION 
Serum Epo concentrations were determined using a commercially 
available radioimmunoassay (RIA) kit ( Incstar, USA) . The RIA 
procedure is a competitive binding disequilibrium 
radioimmunoassay which utilizes recombinant human Epo for both 
tracer and standards. Samples were incubated with the primary 
goat antibody and allowed to react for two hours before the 
tracer labelled with 1251 was added. Following an overnight 
incubation, the donkey anti-goat secondary antibody was incubated 
with standards or samples, primary antibody and tracer, for 
thirty minutes before the test tubes were centrifuged at 1600g to 
separate the bound from the unbound tracer. The unbound tracer 
was removed by decanting the supernatant from each test tube. The 
bound tracer in the remaining secondary antibody complex pellets 
was counted in a gamma counter (Packard, Model B5412). The 1251 
counts are inversely proportional to the amount of Epo present in 
each sample. Although the primary antibody of the kit was raised 
against human Epo, studies done in our laboratory have shown 
cross-reactivity with rat Epo. 
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4.2.8 TUMOUR NECROSIS FACTOR-alpha DETERMINATION 
Serum TNFa levels were measured with a commercially available 
ELISA kit (Genzyme, USA) . The assay is a solid-phase enzyme 
immunoassay employing the multiple antibody sandwich principle. 
A hamster monoclonal antibody specific for murine TNF was coated 
on microtitre wells in a 96-well plate. Tumour necrosis factor 
present in standard, samples and unknown specimens was captured 
by the solid-phase monoclonal antibody. A goat polyclonal anti-
murine TNF antibody, which binds to multiple epitopes on the TNF 
contained on solid phase, was added. A third antibody, 
horseradish peroxidase-conjugated rabbit anti-goat 
immunoglobulin, was used to bind to anti-murine TNF:murine 
complexes. The peroxidase enzyme reacts with peroxidase 
substrate and OPD (chromagen) to produce colour which was 
proportional in intensity to the amount of TNF present. 
Colour intensity was quantified by measuring absorbance at 492 nm 
using an ELISA reader (Multiskan, MCC 340). A reference curve 
was obtained by plotting the TNF concentration of several 
dilutions of standard versus absorbance. The TNF concentrations 
in experimental samples were read off the reference curve. 
According to the manufacturer the antibodies in the test, in 
spite of being raised against mouse TNFa, can detect rat TNF as 
well . 
4.2.9 HISTOLOGY 
Within 12 to 24 h after turpentine treatment, rats developed a 
solid lump at the site of injection. The lump was surgically 
removed from three such animals at the time of sacrifice, and 
transferred to containers with fixative (Appendix). 
The tissues were dehydrated and processed as follows: 
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i) 2 x 6 h incubations at room temperature in 70 % ethanol. 
This step was repeated. 
ii) 1 x 16 h incubation in 90 % alcohol. 
i ii)3 x 2 h incubations in absolute ethanol. 
The dehydrated tissues were embedded in wax by placing them in 
xylene overnight and transferring them to paraffin wax at 60°C 
for 1 h. The latter step was repeated thrice. Finally, the 
tissues were transferred to fresh wax which was allowed to 
solidify at 4°C overnight. Tissues blocks were sectioned with a 
microtome (Jung AG, Model 29988) and the sections (4 µmin width) 
mounted on a glass slide. The sections were dewaxed by placing 
the slides in xylol for 10 min and then hydrated as follows: 
i) 3 x 1 min changes in absolute alcohol, 
ii ) 2 x 1 min changes in 90 % alcohol, followed by 
ii i ) l x 1 min change in 70 % alcohol and 1 x 1 min change in 
50 % alcohol. 
iv) The sections were rinsed in running tap water for 1 to 
2 min. 
Each section was stained with haematoxylin and eosin by immersing 
t he slides in haematoxylin for 10 min, washing in running tap 
water for 2 to 3 min, followed by differentiation in 1% 
h ydrochloric acid in 7 0% alcohol for a few seconds. This was 
stopped by washing in running tap water for 5 min. The slides 
were then transferred into 1% aqueous eosin for 10 min. Surplus 
s t ain was washed off with water and the sections dehydrated in 
a l cohol and cleared in xylene as above. Finally, they were 
mounted in entellen mountant and examined microscopically. 
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4.2.10 STATISTICS 
Data are represented as means plus standard error of the means 
(SEM). Statistical comparisons between group means at various 
time points within control and treated populations, as well as 
between control and treated means at corresponding time 
intervals , were performed using a two-way analysis of variance 
(ANOVA) (Bartlett's test) A p value less or equal to 0.05 was 
considered significant. 
4.3 RESULTS 
4.3.1 HISTOLOGICAL EXAMINATION 
Figure 4.3 is a typical photograph of a cross section through the 
node which developed in rats after subcutaneous injection with 
turpentine . The lesion is filled with leucocytes, typical of a 
turpentine-induced granuloma (Rocha e Silva and Leme, 1972). 
Figure 4.3. Granulomatous lesion which developed at the site 
of turpentine injection . Note the numerous leucocytes (~). 
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4.3.2 SERUM PROTEIN CONCENTRATIONS 
Protein concentrations in groups of control and treated rats are 
depicted in Figure 4. 4. The average protein level remained 
unchanged in both control and treated animals throughout the 
duration of the experiment. There was also no statistical 
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Figure 4.4. Total serum protein concentrations in 
control(O) and treated (•) rats at different 
time intervals after treatment. 
4.3.3 SERUM ALBUMIN 
The mean serum albumin concentrations in the treated animals were 
re l atively constant over the first 24 h (Figure 4.5). It started 
to decline, thereafter, with the levels in the 36 and 48 h groups 
being significantly less than in the Oh group (p ~ 0.05). No 
fluctuations in serum albumin levels were detected in control 
groups. The concentration of serum albumin in the 36 and 48 h 
treated groups were also significantly less then in the 
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Figure 4.5. Serum albumin concentrations in control(O) 
and treated (• ) rats at different time intervals. 
(The SEM of certain data points are smaller than the symbols) 
4.3.4 HAEMATOLOGICAL PARAMETERS 
Total leucocyte counts dropped sharply over the first 16 h 
following 
differed 
turpentine injection (Figure 





groups (p ~ 0. 05) . Thereafter, the wees gradually increased 
until they reached normal levels by 36 h. 
The red cell counts (Rees) and haematocri ts (Hcts) remained 
relatively constant over the first 24 h in both treated and 
untreated groups (Figures 4.6b and 4.6c). Both parameters 
declined in the turpentine-treated group thereafter, with the 
values at 36 and 48 h differing significantly from the group at 
Oh (p ~ 0.05). The mean Rees and Hcts of the treated groups at 
36 and 48 h were, however, not significantly different from those 
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of the corresponding control groups. 
The average Hb values, as was the case with the RCCs and Hcts, 
did not undergo significant changes over the first 24 h (Figure 
4.6d). A rapid decrease occurred in treated animals thereafter, 
so that the Hb values of the groups at 36 and 48 h were 
significantly different (p ~ 0.01) compared to the one at Oh. 
Unlike the case with the RCCs and Hcts, the Hb values of the 36 
and 48 h treated groups were also significantly less (p ~ 0.05) 
than those of corresponding control groups. 
The MCV, MCH, and MCHC values did not undergo any significant 
changes in treated or untreated groups over the time course of 
the experiment (Figures 4.6e, 4.6f, 4.6g). These parameters also 
did not differ between treated and untreated animals. 
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Figure 4.6. Haematological status of control(O) 
and treated (•) groups. a) White cell count 
(WCC); b) Red cell count (RCC); c) Haematocrit 
(Hct); d) Haemoglobin (Hb); e) Mean cell volume 
(MCV); f) Mean cell haemoglobin (MCH) and g) Mean 
cell haemoglobin concentration (MCHC) . SEM of 










Fluctuation in the serum levels of Epo was observed in both 
treated and control rats over the first 24 h of the experiment 
(Figure 4.7). No statistical difference in the concentration 
of the hormone between control and treated groups was observed 
during this period. Thereafter, the level of serum Epo in the 
treated animals started to increase so that its concentration 
in the groups at 36 and 48 h was significantly higher than in 
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Figure 4.7. Serum erythropoietin levels in control(O) 
and treated (•) rats following treatment with saline 
and turpentine, respectively. 
4.3.6 TUMOUR NECROSIS FACTOR-alpha 
Serum TNFa levels started to rise 24 h after turpentine 
administration and remained elevated until the experiment was 
terminated (Figure 4.8). The concentrations of this cytokine in 
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the 36 and 48 h groups differed significantly from that of the 
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Figure 4.8. Serum TNFa levels in treated groups at 
12 h intervals following turpentine administration. 
4.4 DISCUSSION 
In this investigation, the effect of acute inflammation on 
erythropoiesis, in general, and on erythropoietin synthesis, in 
particular, was assessed. The well-established turpentine model 
of acute inflammation was used (Williams and Johnson, 1976; 
Schreiber et al., 1982). 
Serum albumin concentrations were found to decrease 
significantly (p ~ 0.05) 36 h after turpentine treatment and 
continued to decline, thereafter (Figure 4.5). In contrast, the 
level of this protein in the serum of control animals remained 
relatively unchanged. Albumin is a negative acute phase 
reactant whose concentrations in serum, along with its synthesis 
in the liver, usually decrease during acute inflammation 
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(Northemann et al., 1983; Dowton and Colten, 1988). The reason 
for the delay in the drop in serum albumin concentration was due 
to the indirect action of turpentine. A cascade of reactions, 
including activation of monocytes and macrophages, the 
formation, secretion, and transport of inflammatory mediators 
from the local abscess to the liver, has to proceed before 
changes in acute phase protein responses can occur. This is 
borne out by the observation that significant TNFO'. levels 
appeared in the serum only 36 h after turpentine administration 
(Figure 4.8). Acute phase protein responses usually occur much 
earlier when animals are treated with the inflammatory mediators 
directly (Geiger et al., 1988). The observed reduction in serum 
albumin levels subsequent to turpentine treatment suggests, 
therefore, that an acute phase response was elicited in treated 
animals. 
Total serum protein levels in treated animals did not differ 
significantly from those in controls ( Figure 4. 4) . This was 
expected since the decrease in serum concentrations of negative 
acute phase proteins is compensated by an increase in the levels 
of positive acute phase reactants. The overall change in total 
serum protein levels during acute inflammation, therefore, 
remains negligible (Schreiber et al.,1989). 
An initial drop in wee was observed in treated animals (Figure 
4.6a). This may be due to the migration of white cells from the 
systemic circulation to the site of injection. Histological 
examination of the local abscess which developed in response to 
the turpentine, showed the presence of a large number of small 
white blood cells. A gradual increase in this parameter started 
to occur in the 24 h treated group and by the end of the 
experiment the wee value was the same as that in controls. This 
probably represents enhanced proliferation of white blood cells 
in the bone marrow followed by an increased influx into the 
blood. As was the case with serum albumin, the RCC, Hct, and Hb 
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values showed significant decreases only 36 h after turpentine 
injection. This was about the same time that significant TNFa 
levels were detected in the serum. Tumour necrosis factor-alpha 
and IL-1 have been shown to antagonize bone marrow 
erythropoiesis (Moldawer et al., 1989; Schooley et al., 1987). 
The reduction in the values of these haematological parameters 
could, 
these 
therefore, be a reflection of the inhibitory action of 
cytokines on erythropoiesis during the inflammatory 
process. 
The calculated haematological parameters, MCV, MCH, and MCHC, 
did not undergo any changes in response to turpentine-induced 
acute inflammation. Alterations in these parameters are usually 
observed during anaemia when they are used to classify or 
describe the condition in terms of the size of red blood cells, 
as well as the haemoglobin content of the erythrocyte (Dacie and 
Lewis, 1975) Since no changes were observed in these 
parameters in the treated group and, since the decreases in the 
RCC and Hct values were not significantly different from 
corresponding control animals, the reduced erythropoiesis which 
developed in response to the acute inflammation cannot be 
classified as anaemia. Nevertheless, the reduction in the 
number of circulating red blood cells and, particularly the drop 
in haemoglobin in the 36 and 48 h treated groups, were 
sufficient to effect an increase in the level of serum Epo in 
these animals (Figure 4.7). Prior to the increase, Epo levels 
in treated animals fluctuated in the same manner as in control 
rats, being high in one time-group and then low in the next one. 
Such a pattern is suggestive of a rhythmic synthesis of the 
hormone. In fact, it has been reported that the production of 
Epo is subject to a circadian or diurnal rhythm in man (Miller 
et al., 1981; Wide et al., 1989). It is, therefore, likely that 
such a mode of biosynthesis may also occur in rats. The 
cyclical mode of production was, however, abolished in those 
rats with lowered red cell indices in which a need existed for 
91 
enhanced Epo synthesis to correct the haematological status of 
the animals. 
The findings obtained in this study suggest that erythropoiesis 
is antagonized during acute inflammation. Such antagonism is 
most likely mediated by IL-1 and TNFa. Both these cytokines 
have been shown to antagonize red blood cell production in vivo 
( Schooley et al., 1987; Moldawer et al., 198 9) . It was also 
found that those animals with lowered RCC, Hct, and Hb values 
responded by increasing their levels of serum Epo. It is not 
possible to conclude from the data, however, whether Epo 
synthesis was affected by any of the mediators of the acute 
phase response. All three acute phase mediators (IL-1~, TNFa, 
and IL-6) were shown to inhibit Epo production in vitro (Chapter 
2). The likelihood, therefore, exists that the increased Epo 
levels detected in the serum of rats with a reduced 
erythropoiesis may not be optimal. It was for this reason that 
the study was repeated, but with rats which were stressed 
haematologically to ensure optimal production of the hormone. 
If the inflammatory mediators could inhibit Epo synthesis in 
vivo, then the optimal Epo response in treated animals should be 
less than in anaemic controls. 
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4. 5 THE EFFECT OF ACUTE INFLAMMATION ON 
OPTIMAL ERYTHROPOIETIN PRODUCTION IN 
HAEMATOLOGICALLY STRESSED RATS 
4.5.1 INTRODUCTION 
In the previous study, the erythropoietic response to aseptic 
acute inflanunation in Long-Evans rats was examined. A slight, 
but statistically significant, decrease in certain haemopoietic 
indices (haemoglobin, haematocrit and red cell count) was noted 
which was accompanied by an enhanced serum erythropoietin 
concentration. Unfortunately, it could not be deduced whether 
the Epo response was optimal. It was demonstrated in Chapter 2 
that the mediators of the acute phase response, notably IL-1~, 
IL-6, and TNFO'. can inhibit Epo biosynthesis in vitro. The 
likelihood exists, therefore, that these cytokines may also 
antagonize Epo synthesis during the APR. In order to ascertain 
whether Epo production was appropriate, experimental anaemia was 
induced in rats followed by the induction of acute inflanunation . 
The Epo response in these animals was compared to a control 
group with a similar degree of anaemia, but without acute 
inflanunation. 
4.5.2 MATERIALS AND METHODS 
4.5.2.1 INDUCTION OF ANAEMIA 
Adult male Long-Evans rats weighing between 200 and 270 g were 
used . Haemolytic anaemia was induced by an intraperi tone al 
(i.p .) injection of phenylhydrazine hydrochloride (PZN) [Sigma], 
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at a dose of 60 mg/kg, on two consecutive days (Rencricca et 
al., 1970; Hara and Ogawa, 1976). 
4.5.2.2 INDUCTION OF ACUTE INFLAMMATION 
Two days after PZN injection, rats were divided into two 
batches. One batch was injected with sterile turpentine (0.5 
ml/100 g). The other batch received the same dose of sterile 
isotonic saline and served as control. At intervals of 12 h 
thereafter, groups of 3 to 4 animals from each batch were 
sacrificed and blood collected via cardiac puncture as before. 
4.4.2.3 HAEMATOLOGICAL INVESTIGATION 
The red cell indices, Hct, RCC, Hb, MCV, MCH, and MCHC were 
determined as before ( section 4. 2. 3) . Erythropoietin 
concentrations were measured in serum with the RIA kit described 
in section 4.2.7. 
4.4.2.4 STATISTICAL ANALYSIS 
Data are represented and were analysed in the same manner as in 
the previous study. A p value less or equal to O. 05 was 
considered significant. 
4.5.3 RESULTS 
4.5.3.1 HAEMATOLOGICAL PARAMETERS 
The Hb ( Figure 4. 9a) and Hct ( Figure 4. 9b) of control and 
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treated groups sacrificed immediately after saline or turpentine 
injection, were significantly lower than the normal values (Hb: 
14.1 ± 0.3 g/dl; Hct: 38.68 ± 1.632 %) for Long-Evans (LE) rats 
(p ~ 0.01 for Hb of control rats; p ~ 0.05 for Hb of treated rats 
and Hct of both). These indices remained low in rats of both 
groups sacrificed at 12 and 24 h after injection. Thereafter, 
control groups had Hb and Hct values which were significantly 
elevated above those of earlier groups (p ~ 0. 01) . However, 
treated rats sacrificed at 36 and 48 h after turpentine 
administration had values which remained depressed and which 
were significantly less than corresponding controls (p ~ 0.05). 
Only in the 72 h group did treated rats show an increase in 
their Hb and Hct, although these did not differ significantly 
from the values obtained for earlier groups. 
The RCCs in both control and treated animals were also initially 
lower than the normal RCC (6.158 X 1012 ± 0.308 X 1012 /1) of LE 
rats (p ~ 0.01). However, the RCCs were higher in the 36 h 
control and treated groups, and continued to increase in groups 
sacrificed thereafter (Figure 4.9c). The differences in the RCC 
between treated and corresponding control groups were not 
significant. 
The MCVs (Figure 4.9d) in both control and treated animals were 
initially higher than the normal value (62.76 ± 1.544 fl) for LE 
rats (p ~ 0.01). It started to decrease in subsequent groups, 
and continued to do so, until the experiment was terminated. 
Control and corresponding treated groups did not differ in their 
average MCV values. 
The MCHs (Figure 4.9e) showed the same trend as the MCVs, being 
high in the first control and treated groups and decreasing in 
groups sacrificed thereafter. The MCHs in both control and 
treated animals were also substantially elevated (p ~ 0.05) above 
the normal value (22.88 ± 0.63 pg). Differences in the MCH 
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between control and treated groups at specific time intervals 
were not statistically significant. 
in control and treated groups The MCHCs 
sacrificed 
(Figure 4. 9f) 
immediately after saline and turpentine 
administration (0 h groups) were significantly lower than the 
normal value (36.44 ± 0.971 g/dl) for five LE rats (p ~ 0.05). 
The index gradually increased in both control and treated groups 
sacrificed at subsequent intervals. Values for MCHC in control 
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Figure 4.9. Haematological status of groups of 
control(O) and treated (•) anaemic rats at different 
time intervals following the administration of saline 
or turpentine, respectively. a) Hb; b) Hct; c) RCC; 





Initial Epo levels (Figure 4.10) in control and treated rats 
were significantly elevated (p ~ 0.01) ~bove the normal value 
(33.6 ± 5.8 mU/ml) measured in a group of five LE rats of 
similar mass and housed under identical conditions. The 
concentration of Epo remained high in control and treated 
animals sacrificed 12 and 24 h after treatment, with no 
difference between the corresponding groups. The level was 
lower in the 36 h control group and remained on a plateau in 
subsequent groups. The Epo concentrations measured in these 
animals were within the normal range and differed significantly 
(p ~ 0.01) from those sacrificed at earlier time-points. 
97 
{ 
In spite of the downward trend in the concentration of Epo in 
the 36 to 72 h treated groups, the levels did not differ 
statistically from those measured in groups at earlier 
i ntervals. The mean Epo concentrations of the 36, 48 and 72 h 
control groups were, however, significantly lower than those of 







E 100 ....... 
z 
j::: 80 w 
0 
a.. 
0 60 a:: 
::I: 




0 12 24 36 48 60 72 
TIME (HOURS) 
Figure 4.10. Serum Epo concentrations of anaemic 
control(O) and treated (•) rats at different time 




The objective of this study was to determine whether the 
enhanced erythropoietin synthesis, observed during acute 
inflammation, was appropriate for the associated reduction in 
erythropoiesis. Mediators of the acute inflammatory response, 
no t ably IL-lS, IL-6, and TNFa, have been shown to inhibit Epo 
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production by the hepatoma cell line, HepG2 (Chapter 2). The in 
vivo synthesis of this hormone may, therefore, also be 
compromised during acute inflammation. This was investigated by 
comparing the Epo response, at intervals after inducing anaemia, 
in rats with and without acute inflammation. 
Phenylhydrazine (PZN) produced a severe anaemia as evidenced by 
the low initial Hct, Hb, and RCC values in both control and 
treated rats. There was no difference in the values for these 
indices in control and treated rats sacrificed immediately after 
saline or turpentine administration ( 0 h interval) . The 
initial degree of anaemia was, therefore, similar in both 
groups. The high initial MCVs and low MCHs in control and 
treated rats, describe a macrocytic anaemia which is 
characteristic of excessive erythropoiesis due to haemolysis 
(Jacobs and Bird, 1983; Dacie and Lewis, 1975). 
The anaemia was accompanied by high levels of serum Epo in both 
control and treated animals. Groups, sacrificed at intervals 
over the first 24 h, had very high serum concentrations of the 
hormone with no differences in the levels between control and 
corresponding treated animals (Figure 4.10). Groups of control 
rats sacrificed subsequent to the 24 h interval had elevated 
RCC, Hct, and Hb values, indicating recovery from the anaemia. 
This occurred in response to the high concentrations of Epo 
which stimulated erythropoiesis. Resolution of the anaemia in 
turn lowered Epo production, causing serum levels of the hormone 
to decline in these groups. 
In the case of treated animals, however, rats sacrificed after 
the 24 h interval continued to have low values for the three 
haematopoietic indices (Hb, Hct, and RCC) indicating the 
persistence of the anaemia. As expected, serum Epo levels 
remained elevated in these groups. The continued anaemia was 
most likely due to the suppression of erythropoiesis by the 
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cytokines, IL-1 and TNFO'., elaborated during the APR. 
Interleukin-1 can antagonize the action of Epo on erythroid 
precursors (Schooley et al., 1987), and TNFO'. has been found to 
inhibit erythropoiesis in vivo (Johnson et al., 1989; Moldawer 
et al., 1989; Broxmeyer et al., 1986; Tracey et al., 1988). 
Apart from suppressing the proliferation and differentiation of 
erythroid precursors, the two cytokines, together with IL-6, 
have also been shown to inhibit the biosynthesis of Epo, albeit 
in vitro. It is not possible, however, to determine from the 
data whether the cytokines exerted any effect on the synthesis 
of the hormone. The reason being that inflammatory mediators 
initiated their effects 36 h after turpentine treatment, by 
which time, Epo synthesis had already passed its peak. As 
explained before, turpentine acts indirectly. Its 
administration is followed by a cascade of reactions, leading 
ultimately to the formation, secretion, and transport of acute 
phase cytokines into the circulation. This accounts for the lag 
period of approximately 36 h before their effects manifest. The 
detection of significant TNFO'. levels 36 h after turpentine 
injection (Figure 4.8) adds support to this reasoning. 
Phenylhydrazine, on the other hand, appears to act rapidly in 
inducing anaemia. Maximal Epo synthesis must have occurred 
during the two day period prior to administering turpentine to 
treated rats. By the time the inflammatory cytokines started to 
exert their effects, active Epo synthesis was either terminated 
or down-regulated. Erythropoietin levels in control rats at 
this stage (36 h interval) were already within the normal range. 
The higher Epo levels in the treated groups sacrificed after the 
24 h interval were most probably due to stimulated Epo synthesis 
in response to the cytokine-mediated reduction in 
erythropoiesis. Whether the Epo output was appropriate for the 
degree of anaemia, cannot be deduced, since Epo levels for 
corresponding control groups with the same degree of anaemia, 
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are lacking. It is interesting to note, however, that anaemia 
due to a chemical insult, unrelated to acute inflammation, can 
be prolonged by mediators of the acute phase response. 
The two day treatment-free period, following PZN 
administration, was to allow the haemoglobin released from 
lysed erythrocytes to be excreted. The Coulter counter 
measures total haemoglobin concentrations only. By ensuring 
the excretion of free haemoglobin molecules, accurate Hb values 
for each animal could be obtained. This precaution, 
unfortunately, precluded any observation of possible cytokine 
effects on maximal Epo synthesis. The experiment was, 
therefore, repeated with the influx of cytokines into the 
systemic circulation of treated animals being synchronized with 








HAEMATOLOGICALLY STRESSED RATS 
4.6.1 INTRODUCTION 
The objective of this investigation was to determine whether the 
mediators of the acute phase response (APR) could antagonize the 
synthesis of Epo in anaemic rats. The experiments carried out 
thus far have revealed that aseptic acute inflammation induces 
a lowering in the values of the three basic haemopoietic indices 
(Hct, RCC, and Hb), with a concomitant increase in serum Epo 
concentrations. It was also found that acute inflammation can 
prolong existing anaemia in haematologically stressed animals. 
However, it has not been possible to conclude from the data 
whether optimum Epo synthesis in response to phenylhydrazine-
induced anaemia, was affected by mediators of the APR. 
The following experiment was designed to ensure that 
inflammatory mediators are present in the circulation of rats 
when active synthesis of Epo, in response to experimentally-
induced anaemia, is occurring. This was achieved by inducing 
anaemia 36 h after turpentine administration. The effect of 
cytokines, which would appear in the circulation after the 36 h 
lag period, on maximal Epo synthesis could then be assessed and 
compared with Epo levels in rats having the same degree of 
haemolytic anaemia, but without acute inflammation. 
Phenylhydrazine effects anaemia within 12 to 24 h of 
administration (Rencricca et al., 1970; Hara and Ogawa, 1976). 
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4.6.2 MATERIALS AND METHODS 
4.6.2.1 INDUCTION OF ACUTE INFLAMMATION 
Adult male Long-Evans rats, weighing between 225 and 375 g, were 
used. The animals were treated and housed under the same 
conditions as described in section 4.2.3. The rats were divided 
into two batches. One batch was injected subcutaneously with 
sterile turpentine (0.5 ml/100 g), and the other, which served 
as control, with the same dose of sterile apyrogenic isotonic 
saline. Blood was withdrawn, via cardiac puncture, from groups 
of three to four animals from each batch, at 12 h intervals. 
The animals were kept under ether anaesthesia during the 
procedure. 
4.6.2.2 INDUCTION OF ANAEMIA 
Thirty six hours after the initial treatment, all rats received 
a single i.p. injection of sterile PZN in isotonic saline (60 
mg/kg). Groups of control and turpentine-treated rats continued 
to be sacrificed and their blood collected at intervals of 12 h 
until 72 h after the initial injection. The last group from 
each batch was sacrificed 24 h after the previous group, i.e., 
96 h after the start of the experiment. 
4.6.2.3 HAEMATOLOGICAL DETERMINATIONS 
Haematocrits and RCCs were determined with a Coulter counter, as 
before. Accurate Hb values could not be obtained, since soluble 
haemoglobin from lysed erythrocytes was present in all blood 
specimens. The MCH and MCHC, which are calculated from the Hb 
value were, therefore, also inaccurate. The MCV was 
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automatically generated by the instrument. Erythropoietin 
concentrations were assayed in serum with the commercial RIA 
kit, as described in section 4.2.7. 
4.6.2.4 STATISTICAL ANALYSIS 
Data are represented as means± SEM. Statistical comparisons 
were performed as described in section 4.2.10. As before, a p 
value less or equal to 0.05 was considered significant. 
4.6.3 RESULTS 
4.6.3.1 HAEMATOLOGICAL INDICES 
The values of the Hct were within the normal range (38·7 ± 1·6%) 
for both control and treated groups over the first 36 h 
following saline or turpentine administration (Figure 4.lla). 
Thereafter, they declined and were significantly lower (p ~ 
O. 05) in control and treated groups sacrificed at the 48 h 
interval. The mean Hcts for groups of treated rats, sacrificed 
from the 48 h time interval until the end of the experiment at 
96 h, were also significantly less (p ~ 0.05) than those of the 
corresponding control groups. 
The RCCs of control and treated groups remained within the 
normal range for the first 36 h. In all subsequent groups, a 
highly significant decrease (p ~ 0.01) in RCC was noted for both 
groups (Figure 4. llb). Although the mean RCCs for treated 
groups after PZN injection were lower than those for the 
corresponding controls, the differences were not significant. 
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Figure 4.11. Haematological status of control(O) and 
treated rats made anaemic with PZN after 
administration of saline and turpentine, respectively. 
a) Hct; b) RCC and c) MCV. The SEM of some data points 
are smaller than the circles. 
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4.6.3.2 ERYTHROPOIETIN 
Serum Epo concentrations in both control and treated rats 
sacrificed at 12 h intervals, up to and including the 36 h 
interval, were within the normal range for Long-Evans rats (33·6 
± 5·8 mU/ml) . Following the 36 h interval and after the 
injection of PZN, the Epo levels increased in both control and 
treated groups (Figure 4.12). The concentrations of the 'hormone 
measured in the serum of control and treated animals, sacrificed 
48 h after initial treatment, were significantly higher (p ~ 
O. 01) than in those sacrificed immediately after the first 
injection ( O h groups) . The peak Epo levels in control and 
treated rats were recorded in the groups sampled 60 h after 
saline or turpentine administration, i.e., 24 h after PZN 
injection. Epo levels in groups sacrificed at the end of the 
experiment (96 h groups) still had elevated serum levels of the 
hormone. At none of the intervals during the experiment were 
the Epo levels measured in treated animals significantly 
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Figure 4.12. Serum Epo concentrations in groups of 
rats at different time intervals with (•) and 
without(O) acute inflammation. Anaemia was induced 
with PZN 36 h after initial treatment. 
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4.6.4 DISCUSSION 
In this investigation, optimal Epo production during haemolytic 
anaemia in rats was analysed in the presence of an acute 
inflammatory reaction. The aim was to establish whether the 
mediators of acute inflammation could effect a blunted Epo 
response . Such a blunted reaction is believed to be a 
contributing factor to the persistent anaemia associated with 
chronic inflammation (Spivak et al., 1989; Miller et al., 1990). 
The macrophage-derived cytokines, IL-1 and TNFa, are regarded as 
the prime mediators of this effect (Jelkmann et al., 1992; Faquin 
et al., 1992). It has been demonstrated that these two 
cytokines , together with IL-6 and macrophage-conditioned medium, 
have the ability to down-regulate Epo expression in HepG2 cells 
in vitro (Chapter 2). These cytokines are the primary regulators 
of the acute phase reaction (Mortensin et al., 1988; Andus et 
al., 1988 ; Castell et al., 1989). A blunted Epo response may, 
therefore, also be a feature of acute inflammation. 
It has been established thus far that an increase in serum Epo 
levels , signifying enhanced renal biosynthesis of the hormone, 
occurs during aseptic acute inflammation. This was in response 
to the mild anaemia which had developed. It was also observed 
that acute inflammation can prolong recovery from experimentally 
induced anaemia, even in the presence of raised serum levels of 
Epo. This could have been mediated by the acute phase cytokines. 
Interleukin-1 was shown to inhibit the action of Epo on erythroid 
precursors (Schooley et al., 1987). The data generated in the 
two earlier experiments were, however, not sufficient to 
determine whether in vivo Epo production was affected by acute 
inflammation. The reason for not solving this issue in the 
previous experiment was because stimulated Epo synthesis, in 
response to PZN-induced anaemia, did not coincide with the 
release of cytokines into the systemic circulation. In this 
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experiment the two endogenous responses have been synchronized. 
Haematological indices, including serum Epo levels, measured in 
groups of control and treated rats after saline or turpentine 
administration, but before PZN injection, did not differ 
statistically and were within the normal range for Long-Evans 
rats. However, 12 h after administering PZN, a decrease was 
noted in the Hcts and RCCs of both control and treated groups 
(Figures 4.lla and b). The MCVs in groups of control and 
experimental rats did not change during the course of the 
experiment (Figure 4.llc). Although significant decreases (p ~ 
0.05) occurred in RCCs of all animals after PZN administration, 
the value of this index in control groups did not vary 
statistically from that of corresponding treated rats. The Hct 
levels in treated groups after PZN injection were significantly 
(p ~ 0.05) lower than those in corresponding control rat groups. 
This slight exaggeration of anaemia in treated animals probably 
resulted from the additive effect of acute inflammation on 
erythropoiesis. However, since the RCCs in groups of control and 
treated rats did not differ, and because the difference between 
their Hct values were so slight, the degree of anaemia in control 
and treated groups can be regarded as similar, al though not 
identical. 
Erythropoietin concentrations increased in rats of both control 
and treated groups subsequent to PZN injection (Figure 4.12). In 
both groups, the peak serum levels of the hormone were detected 
24 h after inducing haematological stress. Increased 
transcription of the Epo gene and synthesis of the hormone must 
have occurred over this period. The serum Epo levels gradually 
declined in subsequent groups. Neither the peak levels of the 
hormone, nor the levels measured at any other time interval in 
corresponding control and treated groups were statistically 
different. The mean levels in treated groups were, however, 
slightly, although not significantly, elevated above those of 
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associated controls. Since the degree of anaemia in the two 
groups was similar, the observation that their Epo levels were 
not significantly different, suggests that Epo synthesis was not 
inhibited during acute inflammation. 
therefore, not an acute phase reactant. 
Erythropoietin is, 
How would one explain the inhibition of Epo synthesis by IL-10, 
IL-6, and TNFcx observed in HepG2 cells? It is known that 
cytokines are very potent, exerting their activities at 
concentrations in the nanomolar and picomolar range (Dinarello, 
1 988). Moldawer et al. (1987), evaluated serum levels of IL-1 
and TNFcx in mice with various inflammatory conditions, including 
turpentine-induced abscess in which an acute phase protein 
r esponse was documented. They were unable to detect measurable 
amounts of the cytokines in any of the disorders and concluded 
that an hepatic acute phase response can occur during 
inflammatory states without the appearance of either IL-1 and 
TNFO'. in the circulation. Their assay was probably not sensitive 
e n ough, but the study does demonstrate that an APR may be 
e li c i ted by very low concentrations of these cytokines. 
In flammatory mediators during acute inflammation may, thus, be 
hi gh enough to induce the synthesis of acute phase reactants in 
the liver (which is beneficial), but at a level too low for a 
p a thological effect on Epo production. The APR is, afterall, 
considered to be a host-generated protective mechanism aimed at 
containment or destruction of the inflammatory stimulus, removal 
o f damaged tissue, and repair of the affected organ. Inhibition 
o f Epo synthesis can hardly be considered beneficial to an 
organism, since acute phase responses can be precipitated by 
inj uries in which extensive blood loss may also occur (Kushner, 
1982; Schreiber et al., 1989). 
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CHAPTER FIVE 
ERYTHROPOIESIS AND ERYTHROPOIETIN PRODUCTION 
DURING CHRONIC INFLAMMATION 
5.1 INTRODUCTION 
Chronic inflammatory diseases, such as cancer, rheumatoid 
arthritis (RA), and the acquired immunodeficiency syndrome 
(AIDS), are often accompanied by an anaemia, commonly referred 
to as the anaemia of chronic disorders (ACD) (Cartwright, 1966; 
Cartwright and Lee, 1971; Hansen, 198 3) . It is a mild to 
moderate, normochromic/normocytic anaemia, which is 
characterized by reduced serum iron and total iron-binding 
capacity, with normal or increased iron stores (Cartwright and 
Lee, 1971; Means and Krantz; 1992). Reticulocytes are also not 
increased appropriately for the degree of anaemia, indicating 
that this is principally an "underproduction" anaemia (Means and 
Krantz, 1992). 
Al though frequently diagnosed, the pathogenesis of ACD has 
remained unclear. At least four pathologic processes are 
postulated to be involved (Cartwright, 1966; Pavlovic-Kentera et 
al., 1979; Baer et al., 1987). These are a shortened 
erythrocyte survival, failure of the bone marrow to increase red 
blood cell production to compensate for an increased demand, 
impaired release of iron from the reticuloendothelial system 
(RES) , and insufficient Epo production. 
A shortened red cell life span has been reported in only a 
minority of patients (Lewis and Porter, 1960; Morgan and Jacox, 
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1964). In ten patients with 
inflammatory disease, Cavill et al. 
different types of chronic 
(1977), using a ferrokinetic 
technique, found mean red cell life spans in the range of 43 to 
122 days. Al-Ismail et al. (1979), using the same technique, 
found values of 60 to 154 days in patients with Hodgkins 
disease. These results did not differ significantly from the 
range of 70 to 123 days obtained by this method in normal human 
adults. A shortened red cell survival, therefore, does not seem 
to be an important contributor to ACD. 
The importance of iron metabolism in the anaemia of chronic 
disease has also been controversial (Means and Krantz, 1992; 
Cavill et al., 1977; Douglas and Adamson, 1975). There is 
overwhelming evidence that the sequestration of iron in the 
reticuloendothelial system (RES) is an epiphenomenon unrelated 
to the anaemia (Williams et al., 1982; Lukens et al., 1967; 
Cavill and Bentley, 1982). The diversion of red blood cell iron 
to the RES cannot explain the anaemia in chronic disease, 
because the anaemia does not respond to oral iron (Davidson et 
al., 1984; Ward et al., 1969; Weber et al., 1988). Orally 
administered iron was found to be absorbed normally in the 
anaemia secondary to uraemia (Weber et al., 198 8; Milman and 
Larsen, 1976) and normally, or almost normally, in the anaemia 
secondary to rheumatoid arthritis (RA). In comparison to normal 
controls, it is sometimes slightly decreased (Weber et al., 
1988), sometimes unchanged (Vreugdenhil et al., 1990), and 
sometimes slightly increased (Boddyk and Will, 1969) . Iron 
absorbed from the gastrointestinal tract binds to transferrin 
and transferrin-bound iron is incorporated efficiently into the 
erythron in the ACD ( Finch et al. , 197 0) . Abnormal iron 
metabolism in chronic 
secondary importance in 
anaemia. 
inflammation may, therefore, be of 
the pathogenesis · of the associated 
Another mechanism proposed to explain the anaemia in chronic 
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disease, is the direct cellular or humoral inhibition of 
erythropoiesis resulting in the failure of the bone marrow to 
increase RBC production. Improved understanding of the 
pathogenesis of inflammation has led to the identification of 
cytokines that are involved in this process. Tumour necrosis 
factor-alpha levels have been reported to be increased in 
patients with cancer (Balkwill et al., 1987), RA (Teppo and 
Maury, 1987) , parasitic and bacterial infections ( Teppo and 
Maury 1987; Kern et al., 1989) , as well as patients infected 
with HIV (Ayehunie et al., 1993) . Chronic administration of 
TNFa to animals resulted in the development of anaemia (Moldawer 
et al., 1989; Tracey et al., 1988) which was characterized by 
low serum iron and normal iron stores similar to ACD in humans 
(Alvarez-Hernandez et al., 1989). When recombinant TNFa was 
administered to cancer patients in a phase I trial, those 
patients who completed four weeks of therapy became anaemic 
(Blick et al., 1987) . 
Interleukin-1 is another cytokine whose levels are elevated in 
patients with RA, as well as other ACD associated conditions 
(Fujiwara et al., 1986; Maury et al., 1988), and this elevation 
correlates with markers of disease activity, such as anaemia 
(Maury et al., 1988; Eastgate et al., 1988). Interleukin-1 has 
been shown to inhibit murine erythropoiesis in vitro (Schooley 
et al., 1987) and in vivo (Johnson et al., 1989). In humans, 
decreases in haemoglobin in patients with RA were found to 
correlate directly with the IL-1 level (Eastgate et al., 1988). 
Both cytokines reduce erythropoiesis by inhibiting the 
proliferation of BFU-E and CFU-E cells (Roodman et al., 1987; 
Maury et al., 1988) . These bone marrow cells are also the 
primary targets of Epo (Landschultz et al., 1989; Dessypris et 
al., 1988). The cytokines may, therefore, induce anaemia by 
antagonizing the biological effects of Epo. This may explain 
why exogenously administered Epo can resolve the anaemia in 
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chronic disease (Means et al., 1989) . Failure of the bone 
marrow to respond to endogenous increases in Epo levels, is 
considered by many to be the primary cause of ACD (Means and 
Krantz, 1992) . 
The supply of Epo to the bone marrow may also be the rate-
limi ting factor in the impaired marrow response in ACD 
(Pavlovic-Kentera et al., 1979; Ward et al., 1969). When Epo 
levels in patients with ACD were compared with those in patients 
with iron deficiency anaemia, they were found to be 
i nappropriately low for the same degree of anaemia (Baer et al., 
1987; Spivak et al., 1989; Miller et al., 1990) . This suggested 
t hat Epo synthesis may have been inhibited by humoral factors 
e l aborated during the inflammatory process. Other investigators 
found Epo concentrations in the serum of patients with ACD to be 
normal (Douglas and Adamson, 1975; Birgegard et al., 1987). 
However, the observation that inflammatory cytokines can 
suppress Epo synthesis in vitro (Chapter 2) lends support to the 
occurrence of a blunted Epo response in ACD. This finding 
p r ompted the current investigation into the synthesis of Epo in 
a n animal model of chronic inflammation. Since the anaemia 
associated with RA often serves as a model for ACD, it was 
decided to study Epo production in a rat model of this chronic 
di sorder. 
5.2 DEVELOPMENT OF AN ANIMAL MODEL FOR THE AN~IA 
OF CHRONIC DISORDERS IN MAN. I. 
Adjuvant-induced arthritis (AIA) has been widely used as a model 
f or the study of human RA in view of their similar 
hi stopathological features. It is a chronic inflammatory 
polyarthritis that can be induced in rats by a single 
intradermal injection of an oil suspension of certain types of 
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heat-killed mycobacteria (Pearson, 1956; Pearson et al., 1961). 
This preparation is usually referred to as complete Freund's 
adjuvant (CFA). Adjuvant-induced arthritis usually appears 
within 10 to 14 days after injection and is most prominent in 
the small joints of the extremities. Histopathologically, like 
RA in humans, it is characterized by polymorphonuclear and 
mononuclear infiltration of the synovium, synovial hyperplasia, 
pannus formation, destruction of cartilage, and bone erosion, 
progressing to ankylosis and deformities of the paws (Pearson, 
1956; Pearson et al., 1961; Van Vollenhoven et al., 1988). Not 
all rat strains develop arthritis after inoculation with CFA 
(Battisto et al., 1982; Stuart et al., 1984). Several strains 
were, therefore, tested for susceptability to the disease. 
5.2.1 MATERIALS AND METHODS 
5.2.1.1 ANIMALS 
Groups of three to five rats (weighing between 220 and 270 g), 
of the following strains were used: GH (Genetic hypertensive), 
LE (Long-Evans), LOU/C, SD (Sprague-Dawley), and WAG rats. The 
animals were kept under the same conditions as described · in 
section 4.2.1. 
5.2.1.2 INDUCTION OF ARTHRITIS 
Each rat received a single intradermal injection (0.1 ml) in the 
footpad of the left hind paw of a preparation consisting of 
heat-killed Mycobacteria tuberculosis suspended in liquid 
paraffin (6 mg/ml). The suspension was sterilized by 
autoclaving ( 121 °C for 15 min) prior to administration. The 
magnitude of the inflammatory response was evaluated by 
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measuring the volume of the injected and uninjected 
(contralateral) hind paws to a level just above the insertion of 
t he Achilles tendon into the gastrocnemius muscle. Paw volumes 
were measured with a mercury displacement apparatus ( Figure 
5 .1 ) . A rat was considered arthritic if an increase was noted 
in the volume of its contralateral paw within 20 days subsequent 
to adjuvant administrat i on. An animal with swellings in its 












Figure 5.1. Mercury displacement apparatus used for 
measuring paw volumes. 
5.2.1.3 STATISTICS 
Da t a are expressed as means± SEM. The student t-test was used 
t o determine differences in volumes between the antigen-injected 




A single intradermal injection of CFA resulted in an acute 
inflammatory reaction in the injected paw of all rats within 12 
to 24 h (Figure 5.2). By day 5, the initial swelling had 
subsided in the WAG, LE, and GH strains, whereas in the LOU/C 
strain it was less by day 7, and in the SD rats, by day 9. In 
WAG rats (Figure 5.2e) the volume of the injected paw started to 
increase gradually from day 12 until day 19 when the experiment 
was terminated. In the other rat strains, the oedema started to 
plateau off by day 12. The volumes of the injected paws, 
however, remained significantly higher (p ~ 0.05) than those of 
the uninjected paws of all rats up to day 19. None of the rats 
developed inflammation in their contralateral hind paw, their 
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Figure 5.2. Volumes of the injected (•) and 
uninjected (0) hind paws of five different rat 
strains on several days following adjuvant 
administration. Paw volumes are expressed as the 
volume of mercury (Hg) displacement. a) GH rats, bl 
LE rats, c) LOU/C rats, d) SD rats, and e) WAG rats. 
5.2.3 DISCUSSION 
Five different rat strains were tested for susceptabili ty to 
adjuvant-induced arthritis. None of the animals, all males, 
developed a polyarthritis characteristic of the disease. An 
acute inflammation, which lasted for 5 to 7 days, was induced in 
the injected paws of all rats by the CFA. Although the initial 
inflammatory response subsided, significant (p s O. 5) oedema 
still remained in the injected paw of each animal. This 
subacute inflammation persisted until the experiment was 
stopped. WAG rats showed signs of a secondary inflammatory 
reaction since their paw volumes started to increase steadily 
from day 12 (Figure 5.2e). In spite of the active inflammation 
in the injected paw of the rats, none of them developed 
arthritic lesions in their contralateral paw, front paws, or 
tail. This suggested that the five rat strains were either not 
genetically susceptible to AIA, or that the CFA was not 
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effective in inducing the disease. 
Inoculating rats with CFA is not the only method for inducing 
arthritis. Another method is to immunize rats with collagen 
type I I ( Trentham et al., 1977) . Greater success has been 
achieved when rats were injected with a mixture of the two 
antigen preparations (Iisuka and Chong, 1982). The experiment 
was, thus, repeated but with a preparation consisting of both 
collagen type II and CFA. Only SD rats were used since CIA was 
successfully effected in this strain (Trentham et al., 1977). 
5.3 DEVELOPlv:IENT OF AN ANIMAL MODEL FOR THE ANAEMIA OF 
CHRONIC DISORDERS IN MAN. I I . 
As mentioned above, another experimental model of arthritis, 
developed by Trentham et al. (1977), is collagen type II 
autoimmunity. They found that immunizing rats with purified 
native type II collagen resulted in the development of 
polyarthritis. Immunization via an identical protocol but with 
types I and III collagens or denatured type II collagen was not 
effective. The arthritis became evident only after an interval 
of latency and was associated with high levels of both cellular 
and humoral immunity to collagen (Trentham et al., 1977; Stuart 
et al., 1984). Types I and III collagens are found in the skin 
and parenchyma of several organs, whereas type II collagen 
exists in cartilage (Trentham et al., 1977). 
It has been demonstrated that AIA by mycobacteria and CIA are 
mediated by different pathogenetic mechanisms (Stuart et al., 
1984; Phadke et al., 1984). It has also been reported that the 
pathogenetic mechanisms of AIA and CIA synergise to produce an 
extraordinary severe arthritic process (Iisuka and Chang, 1982). 
Since the incidence of both forms of experimental arthritis is 
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approximately 40 % (Taurog et al., 1985), it was decided to 
induce arthritis in rats with a preparation containing both 
collagen type II and Mycobacterium butyricum. Although AIA can 
be induced by several strains of mycobacteria, most studies 
were done with M. butyricum (Lukens et al., 1967; Battisto et 
al., 1982) 
Experimental arthritis, whether adjuvant- or collagen-induced, 
occurs only in genetically susceptible rat strains. Both 
responsiveness (the magnitude of the immune reaction) and 
susceptibility (to the development of arthritis) after 
immunization are controlled by genes within, or linked to, the 
major histocompatibility complex (Battisto et al., 1982; Stuart 
et al., 1984). Sprague-Dawley (SD) rats have been shown to be 
highly susceptible (Trentham et al., 1977; Ackerman et al., 
197 9) . 
5.3.1 MATERIALS AND METHODS 
5.3.1.1 ANIMALS 
Forty male and forty female SD rats, weighing between 180 to 
250 g, housed in pairs, were used. The animals were kept under 
the same conditions, and treated in the same manner, as 
described in section 4.2.1. 
5.3.1.2 INDUCTION OF ARTHRITIS 
Bovine type II collagen (Sigma, MO) was suspended in O .1 M 
acetic acid and solubilized by the addition of pepsin (Sigma) in 
a ratio of 1:10 of collagen. The mixture was stirred overnight 
at 4°C. One part of collagen solution was emulsified with one 
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part of eFA containing M. butyricum (20 mg/ml). Each rat was 
injected intradermally in the plantar region of the left hind 
foot with 100 µl of the antigen preparation which contained 80 
mg of collagen and 2 mg of M. butyricum. Fourteen days later 
the rats received a booster injection with an intradermal dose 
of 0.5 ml of the same preparation at four to five sites in the 
n ape of the neck. 
5.3.1.3 ASSESSMENT OF ARTHRITIS 
Rats were inspected daily for the presence of distal joint 
swelling and erythema. A rat was considered arthritic if 
swelling and erythema were observed either in the tail or in at 
l east one paw other than the injected foot. Arthritic lesions 
were photographed and radiographed. 
5.3.1.4 HAEMATOLOGIC AND BIOCHEMICAL MEASUREMENTS 
Haematological indices (Hct, Hb, RBe, wee, Mev, MeH, and MeHe) 
were determined as described before (section 4. 2. 3) . 
Erythropoietin concentrations in serum were assayed with a RIA 
kit (Incstar) described in section 4.2.7. 
Serum iron levels were quantified with a commercially available 
kit (Boehringer Mannheim) based on an automated micromethod 
(Siedel et al., 1984; Brozovic and Purcell, 1974). The method 
does not require deproteinization of the serum sample. In the 
t est, ferric ions (Fe3+) are separated from transferrin by means 
of guanidinium chloride, at a weakly acidic pH, and reduced to 
f errous ions (Fe 2+) with ascorbic acid. The Fe 2+ ions then form 
a coloured complex with FerroZine (a patented chromogen). The 
i ntensity of the coloured complex, which is a measure of the 
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a 
concentration of iron in serum, is read with an autoanalyzer 
(BM/Hitachi System 704). 
5.3.1.5 STATISTICAL ANALYSIS 
Data are expressed as means± SEM. One-way analysis of variance 
was used to determine (least) significant differences in 
laboratory measurements between normal control rats and those 
with experimental arthritis. A p value less or equal to 0.05 
was considered significant. 
5.3.2 RESULTS 
5.3.2.1 DEVELOPMENT OF ARTHRITIS 
The incidence of arthritis following immunization with the 
antigen preparation was very low. Only five, all females, out 
of a total of eighty rats developed the condition which appeared 
more than two months after the footpad inoculation. Arthritic 
lesions were observed in the joints of one or both front paws, 
in the untreated hind paw, and in some rats, even in the tail 
(Figures 5.3 and 5.4). Roentgenographs showed significant bone 






Figure 5 . 3 Jo i nt swelling in rats with antigen-
induced arthritis . a) Normal front paws. b) Front 
paw in rat with arthritis. c) Normal hind limbs. d) 
Hind limbs in arth r itic rat. 
b 
C 
Figure 5 . 4 Roentgenog r aphs of rats with arthritis. 
a ) Normal left front limb with arthritic joint in 
right limb. b) Both hind paws are inflamed . The one 
nearest to the tail was injected with the antigen 
preparation. c) Arthritic lesion in the tail . Note 
the normal appearanc e of the hind paw. 
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5.3.2.2 HAEMATOLOGY 
None of the animals with arthritis were found to be anaemic. 
Values for the different haematologic parameters were well 
within normal limits for female rats of this strain (Table 5.1). 
The wees in two rats were significantly higher than normal 
whilst the serum iron in one of these rats was well below that 
recorded for normal controls. 
inflammatory process . 
These are signs of the 
·NORMAL ... Bb Bet RCC wee MCV MCH MCHC SERUM Epo 
IRON 
CONTROLS g/dl % 1012 /1 10 9/1 fl pg g/dl µmol/1 
14.79 39.51 7.10 5.69 55.6 20.89 37.52 47.2 
(n=lO) ± ± ± ± ± ± ± ± 
0.115 0.355 0 . 052 0.42 0.265 0.175 0.346 3.454 
RATS 14.5 43.6 7.48 6.3 58.2 19.4 33.4 56.3 ... 
:: 13.3 39.1 7.01 12.1* 55.8 19.0 34.0 27. 4-P 
WITH 
15.4 44.1 8.02 9.4* 54.9 19.2 34.9 44.5 
ARTBRI- 14.2 40.3 7.13 2.9 56.5 19.9 35.1 ND 
.... 
TIS 14.2 42.0 7. 26 2.6 57.8 19.6 33.9 73.8 
ND=NOT DETERMINED 
TABLE 5.1 Haemopoietic indices, serum iron, and serum Epo levels 
in five female Sprague-Dawley rats with antigen-induced arthritis. 
The mean values with their SEM for each parameter found in ten 
normal rats are given in the top half of the table. The wees in two 
rats (*) were elevated above the normal value, indicating pronounced 
disease activity. One of these rats (-P) also had a reduced serum 












Adjuvant- or collagen-induced arthritis in rats are widely 
accepted models for the study of human rheumatoid arthritis 
(Pearson, 1956 ; Pearson et al., 1961; Van Vollenhoven et al., 
1988). Since the anaemia in RA patients has often served as a 
model for ACD, it was decided to use the arthritic rat model for 
investigating Epo biosynthesis during chronic inflammation . 
Arthritis was induced in SD rats with a water in oil emulsion 
containing heat-killed M. butyricum and solubilized bovine type 
II collagen. A booster injection was also administered in order 
to elicit an enhanced secondary immune response to the antigen 
preparation. In spite of this, the incidence of the condition 
was only 6 percent, with the disease appearing more than two 
months after the initial immunization. The rats which developed 
the condition were all females, suggesting that male SD rats may 
not be as susceptible to AIA. The affected animals presented 
with swellings in the joints of one or more limbs, and some even 
had lesions in the tail. Roentgenographs demonstrated 
significant bone destruction and new bone formation at the sites 
of inflammation . 
Al though the inflammatory lesions were severe, none of the 
animals presented with signs of anaemia (Table 5 .1) . The 
measured (Hct, Hb, and RCC) and calculated (MCV, MCH, and MCHC) 
haematological parameters for all diseased rats did not differ 
statistically from those of normal controls. These results 
suggest that anaemia does not always accompany experimentally 
induced arthritis in rats. This is not unusual, since not all 
patients with RA are anaemic (Birgegard et al., 1987; Reid et 
al., 1984). Antigen-induced arthritis in rats, although an 
excellent model for studying the pathology of RA in humans, is, 
therefore, not ideal as a model for ACD. A model for an 
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alternative chronic disorder 
anaemia was, thus, required. 
frequently anaemic, (Bentley, 
disease was used. 
which is also associated with 
Since cancer patients are also 
1982), an animal model for this 
5.4 ERYTHROPOIETIN SYNTHESIS IN A MURINE CANCER MODEL 
Anaemia in cancer patients, which is not due to marrow invasion 
by tumour or marrow suppression by chemotherapy, is also 
classified as ACD (Hansen, 1983). A number of animal cancer 
models are reported in the literature (Fidler, 1978; Hart, 1979; 
Zucker et al., 1979; MacManus et al., 1990). Cancer is usually 
induced by the transplantation of tumour tissue (Fidler, 1978), 
or by the injection of cancer cells (Hart, 1979; Zucker et al, 
1979), into a susceptible host. Solid tumours usually arise 
after seven days at the site of transplantation or injection. 
A profound anaemia is also in evidence at this stage (Zucker et 
al., 1979; MacManus et al., 1990). 
In this investigation, cancer was induced in C57BL/6J mice with 
a suspension of Bl6-Fl0-BL6 melanoma cells. The model was 
described by Fidler (1978) and Hart (1979) who characterized it 
in terms of the growth rate of the tumour, its dissemination and 
tissue invasiveness, as well as the inhibitory and enhancing 
responses of the host . 
5.4.1 MATERIALS AND METHODS 
5.4.1.1 ANIMALS 
The experiments were performed using inbred C57BL/6J mice which 
were originally obtained from Jackson Laboratories (Bar 
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Harbour, Maine, USA). A breeding colony was developed, and has 
since been maintained at the National Institute for Nutritional 
Diseases (Tygerberg, SA). 
Male mice, weighing between 20 to 25 g, were housed in groups of 
five to eight in polypropylene cages with metal rung tops, and 
kept in a well-ventilated room with a 12 h day/night cycle and 
ambient temperature of 23 ± 1°c. The animals had free access to 
clean water and rodent chow. 
5.4.1.2 CELLS 
B16-F10-BL6 mouse melanoma cells were provided by Dr C F 
Albrecht (Department of Pharmacology, Stellenbosch University, 
Tygerberg, SA). The cells were originally obtained from Dr I J 
Fidler of the Cancer Metastasis and Treatment Laboratory 
(National Cancer Institute, Frederick Cancer Research Facility, 
Frederick, Maryland, 21701). The cells were cultured in McCoy's 
SA medium supplemented with 10% heat-inactivated FCS, penicillin 
(100 units/ml), and streptomycin (100 µg/ml). Cells were 
c ultured at 37°C in a humidified atmosphere of 5 % CO2 and 95 % 
air. 
5.4.1.3 TUMOUR SYSTEM 
B16-F10-BL6 melanoma cells were harvested from nonconfluent 
monolayers by a 2 min incubation with a solution of O. 25 % 
t rypsin and O. 02 % EDTA. The cells were washed once and the 
suspension adjusted to 2 x 10 6 cells/ml of culture medium. 
Viability was assessed by trypan blue exclusion, and only 
suspensions containing ~95 % viable cells were used. Mice were 
i njected wi th 1 ml (i.p.) of the tumour cell suspension. 
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Control mice were injected with culture medium. All treatments 
were done under aseptic conditions. Starting from day ten after 
inoculation, blood was drawn via cardiac puncture from five to 
seven mice per day. The animals were anaesthetized with a 
solution containing 100 mg ketamine and 5 mg xylazine/ml. Each 
mouse received an i.p. dose of 5 µ1/g. After cardiac puncture, 
the mice were sacrificed by cervical dislocation. Blood was 
collected into microtainer tubes containing EDTA pellets (Radem 
l aboratories) . The following organs were collected from two 
cancer and two control mice for histological studies: Spleen, 
kidney, liver, testis, bladder, heart, lung, brain, intestine, 
and bone marrow. Organs were stored in 10 % formalin until such 
t ime that the histological studies could be carried out. 
5.4.1.4 EXPERIMENTAL ANAEMIA 
A second control group with experimental anaemia was required to 
compare their Epo response with that of mice with cancer. A 
group of twenty mice were injected (i.p.) with sterile 
phenylhydrazine hydrochloride ( 60 mg/kg) in isotonic saline. 
Blood was sampled via cardiac puncture from groups of five 
animals on subsequent days in order to obtain haematological 
parameters for mice ranging from very, to mildly anaemic. A 
second group of five mice received a dose of phenylhydrazine on 
t wo consecutive days. Blood was collected from this group, 
which had severe anaemia, on the day following administration of 
t he second dose. 
5.4.1.5 HAEMATOLOGIC AND BIOCHEMICAL DETERMINATIONS 
Haematological parameters (Hb, Hct, RBC, wee, MCV, MCH, and 
MCHC) were determined with a Coulter counter as before (section 
4.2.3). Serum was prepared from whole blood as described in 
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section 4.2.4. Serum Epo concentrations were measured with an 
RIA kit (Incstar) as outlined in section 4.2.7, and serum TNFa 
levels with an ELISA kit (Genzyme) described in section 4.2.8. 
5.4.1.6 STATISTICAL ANALYSIS 
Data are represented as means± SEM. Comparisons between control 
mice and those with cancer were carried out using ANOVA. A p 
value less or equal to 0.05 was considered significant. 
5.4.2 RESULTS 
5.4.2.1 TUMOUR DEVELOPMENT 
All mice injected with melanoma cells developed tumours in their 
peritoneal cavities. The tumours gradually increased in size 
until the animals died; usually after 15 to 17 days following 
inoculation. No tumours were observed in control mice. 
5.4.2.2 HISTOLOGY 
The histological appearance of the kidneys, liver, testis, 
bladder, heart, intestine, and brain in mice with cancer did not 
differ from those in control animals without the disease. 
Pulmonary metastases occurred in the mice with cancer. 
Metastatic epithelial melanomas were found in the peribronchial 
tissue, as well as in the alveolar walls of the lung. Tumour 
growth was also accompanied by massive splenomegaly. Pronounced 
extramedullary haemopoiesis could be observed in the spleen. 
Intense erythropoiesis and megakaryocytopoiesis could be 
detected in the red pulp. Total displacement of the normal red 
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pulp by cellular elements of the bone marrow was found. The 
white pulp of the spleen was morphologically normal. The bone 
marrow was also extremely active with haemopoiesis. There was 
no evidence of marrow infiltration by tumour cells. 
5.4.2.3 HAEMATOLOGICAL INDICES 
A steady decline in values of erythropoietic parameters (Hb, 
Hct, and RCC) accompanied tumour growth (Figure 5.5). The 
normal Hb range for ten C57BL/6J mice was found to be 12.62 ± 
2 .28 g/dl (2 SD). Mice that survived for 14 days after cancer 
cell inoculation had a mean value as low as 6.74 ± 2.69 g/dl 
(n=5}, indicating severe anaemia. A progressive leucocytosis 
was also present (Figure 5.5c). No changes occurred in the MCV, 
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Figure 5. 5 Haemopoietic parameters of mice with 
cancer at different stages of advancement. a) Hb, 
b) Hct, C) Ree and wee, d) MeV, e) MeH, and f) MeHe. 
5.4.2.4 SERUM ERYTHROPOIETIN 
~ 
50 a:: .... 
z 
w 












Figure 5.6 represents irnmunoreactive Epo concentrations in 
relation to Hb values for groups of mice with tumours at 
different stages. As the disease progressed and the animals 
became more anaemic, they responded by increasing their serum 
levels of the hormone. In Figure 5.7 serum Epo concentrations 
are plotted against Hct values for tumour-bearing mice and 
control mice with haemolytic anaemia. A negative correlation 
between the two parameters existed in both groups. The two 
correlation curves were not statistically different. When the 
mice were grouped according to their degree of anaemia, and 
their Epo levels compared, the most anaemic (Hct: 15 to 20 %) 
tumour-bearing group had Epo levels significantly lower (p ~ 
0.05) than the control group with the same degree of anaemia 
(Figure 5.8). In all the other groups, the Epo levels of 
anaemic controls and mice with cancer were essentially the same. 
This suggested that Epo production was inhibited only in mice 
which were severely anaemic. This group included mice with 
tumours older than 14 days, i.e., the animals with advanced 
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Figure 5.6 Serum Epo concentrations and Hb values 
of mice with cancer. Note how the Epo levels 
increased as the Hb concentrations declined with the 
progression of the disease. This relationship 
persisted until the fourteenth day. In mice with 17 
day-old tumours, the Epo concentrations decreased 
without an improvement in the anaemia. 
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Figure 5. 7 Regression lines between serum Epo 
concentrations and Hct values of mice with cancer 
and those with haemolytic anaemia. A negative 
correlation between the two parameters (which did 
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Figure 5.8 Serum Epo concentrations of tumour-
bearing mice and controls, grouped in terms of their 
degree of anaemia. Only the most anaemic cancer 
group(* ) had significantly lower levels of the 
hormone compared to controls. 
5.4.2.5 TUMOUR NECROSIS FACTOR-alpha 
Tumour necrosis factor-alpha levels did not correlate with the 
degree of anaemia (Figure 5.9). No correlation could be found 
between serum levels of this cytokine and any of the red cell 
indices. There was also no relationship between Epo 
concentrations in serum and that of TNFa. It is noteworthy, 
however, that the serum TNFa levels of mice with cancer exceeded 
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Figure 5. 9 Serum TNFCX levels versus Hct and Epo 
levels of mice with cancer. No correlation existed 
between TNFcx concentrations and the other two 
parameters, indicating that the cytokine was not a 
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Figure 5 .10 Serum TNFcx concentrations in LE rats 
(n=6) with acute inflammation and C57BL/6J mice 
(n=15) with cancer. Acute inflammation was induced 
with a subcutaneous injection of turpentine ( 0. 5 
ml/100 g). Mice with cancer had significantly higher 








In this investigation, erythropoiesis and erythropoietin 
biosynthesis were followed in mice with cancer of increasing 
severity, i.e., from the time they first showed signs of anaemia 
(tenth day) until they died (seventeenth day). The aim was to 
determine if Epo production was appropriate for the degree of 
the associated anaemia. This could be established by comparing 
the serum levels of the hormone in these animals with the levels 
measured in mice with a similar degree of haemolytic anaemia, 
in which the synthesis of the hormone was optimal. 
The anaemia was found to be progressive, becoming worse as the 
disease progressed. Serum Epo concentrations also increased as 
the anaemia developed, until the fourteenth day. Thereafter, 
the levels declined. When the Epo levels in diseased mice were 
compared to those of controls with the same degree of anaemia, 
no statistical difference could be demonstrated (Figure 5.7). 
This suggested that, in general, the Epo response in mice with 
cancer was appropriate for the associated anaemia. This is in 
contrast to what was found by MacManus et al. (1990), who 
reported the absence of a correlation between the Hct and serum 
Epo concentrations in mice with a transplantable murine mammary 
carcinoma. Miller et al. (1990), on the other hand, detected 
elevated serum levels of the hormone in patients with cancer, 
but found a lower incremental increase in their Epo response 
compared to patients with iron deficiency anaemia. 
When control and experimental mice were grouped in terms of the 
severity of their anaemia and their Epo concentrations compared 
(Figure 5.8), it was found that the most anaemic cancer group 
had significantly lower serum Epo concentrations than the 
corresponding control group. These mice were those with 
seventeen day-old tumours, i.e., the very sick animals. This 
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suggested that a blunted Epo response is dependent on disease 
activity. Whether the response was specific, however, seems 
questionable. It is more likely that the lower Epo response was 
representative of a generalized failure of the body's metabolism 
due to excessive disease activity. These animals suffered from 
cachexia and showed no interest in food or water. In fact, they 
did not have the strength to feed themselves. They were totally 
immobile and did not respond to physical stimuli. Under such 
conditions, the biosynthesis of any hormone would be negatively 
affected. 
How would one then explain the specific inhibition effected by 
the inflammatory cytokines on in vitro Epo synthesis (Chapter 
2)? The answer may lie with the cell line that was used. HepG2 
cells are transformed liver cells (Knowles et al., 1980). The 
liver, which is the site of acute phase protein synthesis 
(Kushner, 1982), appears to be extremely sensitive to cytokines. 
Moldawer et al., (1987) observed changes in acute phase 
reactants in the absence of detectable amounts of inflammatory 
cytokines. Rats with turpentine-induced acute inflammation had 
reduced albumin but optimal Epo concentrations at the time when 
TNFa levels could be demonstrated in their serum (Chapter 4). 
These observations suggest that the kidney cells which 
manufacture Epo in vivo are not as susceptible to cytokine-
mediated effects as normal hepatocytes or HepG2 cells. Whenever 
a cell-type becomes cancerous, it often reverts to the embryonic 
state. HepG2 cells, for example, secrete alpha-foetoprotein 
(Knowles et al., 1980), a protein normally expressed during 
foetal life (Crandall et al., 1989). Erythropoietin is 
synthesised by the liver in the foetus (Zanjani et al., 1977) 
and mainly by the kidney after birth (Jacobson et al., 1957; 
Adamson et al., 1968; Bondurant and Koury, 1986). The reason 
for this switch is still obscure. A possible explanation, based 
on the findings of this investigation, might be to protect the 
organism, once born, from succumbing to anaemia during 
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disturbances in its homeostasis that may precipitate acute phase 
responses. This hypothesis can only be tested by isolating the 
renal cells which synthesise Epo and characterizing their 
cytokine receptors. To date, the identity of the specific cell 




The primary objective of this investigation was to determine 
whether a blunted erythropoietin response, hypothesized to be 
mediated by inflammatory cytokines, contributed to the anaemia 
of chronic disorders. Epo synthesis during acute inflammation 
was also studied, since the cytokines implicated in the blunted 
Epo response, are also the regulators of acute phase protein 
synthesis. The results obtained in this investigation, enabled 
t he following conclusions to be made: 
1 . Macrophage-conditioned medium (MCM) and recombinant IL-lB, 
IL-6, and TNFa can effect dose-dependent reductions in in 
vitro Epo synthesis by the hepatoma cell line, HepG2. 
Interleukin-lB and TNFa appeared to mediate their effects 
by inhibiting transcription of the Epo gene, whereas IL-6 
seemed to exert its action by modulating a post-
transcriptional event in the Epo biosynthetic pathway. 
Interleukin-lB and TNFa potentiated each others effects on 
Epo production. Potentiation was, however, not observed 
between IL-6 and the other two cytokines. All three 
cytokines synergized with MCM in reducing HepG2 Epo output. 
2 . A mild anaemia developed in rats with turpentine-induced 
acute inflammation. The reduced erythropoiesis elicited 
an elevation in their serum Epo concentrations. Prior to 
the increase, the serum Epo levels fluctuated in accordance 
with a circadian rhythm similar to those of normal 
controls. With the drop in haemopoiesis, however, the 
rhythm was broken as the serum Epo concentrations 
increased. The reduction in haematological values 
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coincided with an increase in serum TNFa concentrations. 
A decrease was also noted in the serum levels of albumin, 
a negative acute phase reactant. Inflammatory cytokines, 
however, had no effect on in vivo Epo production. Serum 
concentrations of the hormone in rats with acute 
inflammation and phenylhydrazine-induced anaemia did not 
differ statistically from those of control rats with the 
same anaemic profile but without acute inflammation. The 
acute inflammatory reaction did, however, prolong the 
duration of the phenylhydrazine-induced anaemia which 
resulted in continued high serum levels of Epo. 
3. Adjuvant-induced arthritis in rats is a poor model for 
studying the anaemia of chronic disorders in man. The 
disease failed to develop in several rat strains, including 
GH, LE, LOU/C, and WAG . Even male Sprague-Dawley (SD) 
rats did not develop arthritis. Success was only achieved 
with female SD rats. The incidence was, however, very low 
( 12 % of all female rats) . Al though the affected rats 
developed several arthritic lesions, none of the animals 
became anaemic. Their serum Epo levels were within the 
normal range as well. 
The mouse cancer model that was selected proved more 
successful. The mice (C57BL/6J) became anaemic within ten 
days of inoculating them with Bl6-F10-BL6 melanoma cells. 
Histological examination ruled out tumour invasion of the 
bone marrow as the cause of the anaemia. In fact, the bone 
marrow was extremely active with erythropoiesis, as was the 
spleen. The anaemia became worse as the cancer progressed. 
Serum Epo concentrations, however, increased in response 
to the developing anaemia. This increase was found to be 
appropriate for most part of the disease process since the 
correlation curve between Hct values and Epo levels for 
mice with cancer, did not differ significantly from that 
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of control mice with phenylhydrazine-induced anaemia. 
However, when the animals were grouped in terms of their 
degree of anaemia and their Epo concentrations compared, 
it was found that the most anaemic cancer group had a 
significantly lower Epo level than the corresponding 
anaemic control group. These mice were those with the most 
advanced melanomas, suggesting that a blunted Epo response 
was dependent on disease activity. 
The data seem to suggest that a blunted Epo response does not 
contribute to anaemia of chronic disorders. It may become a 
contributing factor only in cases of severe cachexia, as in 
terminal cancer patients. Although cytokines like IL-lB, TNFa, 
and perhaps IL-6 have the ability to inhibit Epo synthesis, such 
inhibition does not occur readily in vivo. It may be that the 
renal cells which produce Epo, unlike hepatocytes, do not have 
receptors for these cytokines. The cytokines, especially IL-lB 
and TNFa, may nevertheless cause ACD, but by a mechanism of 
suppressed erythropoiesis in the bone marrow. They may act by 
antagonizing the action of Epo on Epo-sensitive erythropoietic 
precursors. Higher concentrations of Epo than that secreted by 
the kidney may, therefore, be required to overcome their 
inhibitory effects. It is postulated that renal Epo output is 
dependent on blood oxygen tension (Goldberg et al., 1988,1989) 
and, thus, not on bone marrow requirements. This may explain 
why exogenous Epo has been so successful in correcting the 
anaemia of patients with rheumatoid arthritis (Pinctus et al., 
1990), cancer (Abels, 1992), and even AIDS (Fischl, 1990). 
139 
BIBLIOGRAPHY 
Abels RI and Rudnick SA (1991). Erythropoietin: Evolving 
clinical applications. Exp. Hematol. 19:842-850. 
Abels R I (1992). Recombinant human erythropoietin in the 
treatment of the anaemia of cancer. Acta Haematol. 87(suppl 
1):4-11. 
Ackerman N R, Rooks W H, Shott L, Genant H, Maloney P, and West 
E (1979). Effects of naproxen on connective tissue changes in 
the adjuvant arthritic rat. Arthritis Rheum. 22(12) :1365-1374. 
Adamson J W, Eschbach J W, and Finch CA (1968). The kidney and 
erythropoiesis. Am. J. Med. 44:725-733. 
Adamson J Wand Eschbach J W (1989). Management of the anaemia 
of chronic renal failure with recombinant erythropoietin. 
Quart. J. Med. 73(272) :1093-1101. 
Adamson J Wand Finch CA (1975). Hemoglobin function, oxygen 
affinity, and erythropoietin. Annu. Rev. Physiol. 37:351-369. 
Al-Ismail S, Cavill I, Evans I H, Jacobs A, Ricketts C, Trevett 
D, and Whittaker J A (1979). Erythropoiesis and iron metabolism 
in Hodgkin's disease. Br. J. Cancer 40:365-370. 
Alippi R M, Barcelo A C, and Bozzini C E (1983a). 
Erythropoietic response to hypoxia in mice with polycythemia 
induced by hypoxia or transfusion. Exp. Hematol. 11(2) :122-128. 
Alippi RM, Barcelo AC, and Bozzini CE (1983b). Enhanced 
140 
erythropoiesis induced by hypoxia in hypertransfused, post -
hypoxic mice . Exp . Hematol . 11 (9) : 878-883 . 
Alvarez - Hernandez X, Liceaga J , McKay IC, and Brock J H (1989) . 
Induction of hypoferremia and modulation of macrophage iron 
metabolism by tumor necrosis factor. Lab . Invest . 61 (3) :319-
322. 
Andus T, Geiger T, Hirano T, Kishimoto T, Tran- Thi T-A, Decker 
K, and Heinrich P C (1988a). Regulation of synthesis and 
secretion of major rat acu te-phase p roteins by recombinant human 
interleukin- 6 ' (BSF- 2/IL-6) i n hepatocyte primary cultures . Eur . 
J. Biochem. 173: 287 - 293. 
Andus T, Geiger T, Hirano T, Kishimoto T, and Heinrich P C 
(1988b) . Action of recombinant human interleukin 6, interleukin 
1~ and tumor necrosis factor a on the mRNA induction of acute -
phase proteins . Eur . J . Imm unol . 18: 739 - 746 . 
Arai K, Lee F, Miyaji~a A, Miyatake S, Arai N, and Yokota T 
(1990) . Cytokines : coordinators of the immune and inflammatory 
responses . Annu . Rev. Bio~hem . 59: 783-836 . 
Ayehunie S, Sonnerborg A, Yemane- Berhan T, Zewdies D W, Britton 
S, and Strannegard O (1993) . Raised levels of tumour necrosis 
factor - alpha and neopterin , but not interferon-alpha , in serum 
of HIV-1 - infected patients from Ethiopia . Clin . Exp . Immunol . 
91 :37-42 . 
Bachmann S , Le Hir M, and Eckardt K- U (1993) . Co- localization 
of erythropoietin mRNA and Ecto-5 ' -nucleotidase immunoreactivity 
in peritubular cells of rat renal cortex indicates that 
f ibrblasts produce erythropoietin . J . Histochem . Cytochem . 
41 (3) : 335- 341 . 
Baer AN, Dessypris EN, Goldwasser E, and Krantz SB (1987). 
Blunted erythropoietin response to anaemia in rheumatoid 
arthritis . Br . J. Haematol . 66 :559-564. 
Balkwill F, Burke F, Talbot D, Tavernier J , Osborne R, Naylor 
141 
S, Durbin Hand Fiers W (1987). Evidence for tumour necrosis 
factor/cachectin production in cancer. Lancet 2: 1229-1232. 
Battisto JR, Smith RN, Beckman K, Sterlicht M, and Welles W 
L (1982). Susceptibility to adjuvant arthritis in DA and F344 
rats. Arthritis Rheum. 25(10) :1194-1200. 
Bauer C. Chemoreception 
erythropoietin production. 
of oxygen in the 
In: Rich IN, ed. 
kidney and 
Molecular and 
cellular aspects of erythropoietin and erythropoiesis. Berlin: 
Springer-Verlag, 1987:311-327. 
Baumann H, Onorato V, Gaul die J, and Jahreis G P ( 1987) . 
Distinct sets of acute phase plasma proteins are stimulated by 
separate human hepatocyte-stimulating factors and monokines in 
rat hepatoma cells. J. Biol. Chem. 262(20) :9756-9768. 
Beckman B s, Mason-Garcia M, Nystuen L, King L, and Fisher J 
W. ( 1987) . The action of erythropoietin is mediated by 
lipoxygenase metabolites in murine fetal liver cells. Biochem. 
Biophys. Res. Commun. 147(1) :392-398. 
Bentley DP (1982). Anaemia and chronic disease. 
Haematol. 11(2) :465-478 
Clinics in 
Beru N, Smith D, and Goldwasser E (1990). Evidence suggesting 
negative regulation of the erythropoietin gene by 
ribonucleoprotein. J. Biol. Chem. 265(24) :14100-14104. 
Besarab A, Caro J, Jarrell B E, Francos G, 
(1987). Dynamics of erythropoiesis 
transplantation. Kidney Int. 32:526-536. 
142 
and Erslev A J 
following renal 
Beutler B, Greenwald D, Hulmes JD, Chang M, Pan Y-C E, Mathison 
J, Ulevitch R, and Cerami A (1985). Identity of tumour necrosis 
factor and the macrophage-secreted factor cachectin. 
316:552-554. 
Nature 
Beutler B, Krochin N, Milsark I W, Luedke C, and Cerami A 
(1986). Control of cachectin (tumor necrosis factor) synthesis: 
mechanisms of endotoxin resistance. Science 232:977-980. 
Birgegard G, Hallgren R, and Caro J (1987). Serum 
erythropoietin in rheumatoid arthritis and other inflammatory 
arthritides: Relationship to anaemia and the effect of anti-
inflammatory treatment. Br. J. Haematol. 65:479-483. 
Birgegard G (1989). Erythropoiesis and inflammation. Contrib. 
Nephrol. 76:330-341. 
Blick M, Sherwin S A, Rosenblum M, and Gutterman J ( 1987) . 
Phase I Study of recombinant tumor necrosis factor in cancer 
patients. Cancer Res. 47:2986-2989. 
Boddyk K and Will G ( 1969) . Iron absorption in rheumatoid 
arthritis. Ann. Rheum. Dis. 28:537-540. 
Bondurant MC and Koury M J (1986). Anemia induces accumulation 
of erythropoietin mRNA in the kidney and liver. Mol. Cell. 
Biol. 6 (7) : 2731-2733. 
Broxmeyer HE, Williams DE, Lu L, Cooper S, Anderson SL, Beyer 
G S, Hoffman R, and Rubin B Y (1986). The suppressive 
influences of human tumor necrosis factors on bone marrow 
hematopoietic progenitor cells from normal donors and patients 
with leukemia: Synergism of tumor necrosis factor and 
interferon-y. J. Immunol. 136(12) :4487-4495. 
143 
Brozovic Band Purcell Y (1974) . An automated micromethod for 
measuring iron concentration in serum using thioglycollic acid 
and bathophenantrol i ne sulphonate. J . Clin . Pathol . 27: 222 - 225 . 
Bruneval P , Sassy C, Mayeux P , Belair M- F, Casadevall F-X R, 
Varet B, and Lacombe C ( 1993) . Erythropoietin synthesis by 
tumor ce l ls in a case of meningioma associated with 
erythrocytosis. Blood 81 (6) : 1593-1597 . 
Cairns J A, Guy G R, and Tan Y H (1992) . Inter leukin- 6 
regulates the cytotoxic effect of tumour necrosis factor on U93 7 
cells . Immunology 75 :669-673 . 
Caro J~ Schuster S, and Ramirez S (1989) . Regulating mechanisms 
involved in the expression of the erythropoietin gene . Contrib . 
Nephrol . 76: 7-13 
Caro J and Erslev A J (1988) . 
use in the study of anemias . 
Erythropoietin assays and the i r 
Contrib . Nephrol . 66: 54-62 . 
Carroll MP , Spivak J L, McMahon M, Weich N, Rapp UR , and May 
W S (1991) . Erythropoietin induces raf-1 activation and raf- 1 
is required for erythropoietin- mediated proliferation . J . Biol . 
Ch em . 2 6 6 ( 2 3 ) : 14 9 6 4 - 1 4 9 6 9 . 
Carswell E A, Old L J , Kassel R L, Green S , Fiore N , and 
Williamson B (1975). An endotoxin- induced serum factor that 
causes necrosis of tumours . Proc . Natl. Acad . Sci. 72 (9) :3666-
3670 . 
Cartwright G E and Lee G R (1971) . The anaemia of chronic 
disorders . Br. J . Haematol . 21: 147 - 152 . 
Casati S , Passerini P , Campise M R, Graziani G, Cesana B, 
Perisic M, and Ponticelli C ( 1987) . Benefits and risks of 
protracted treatment with human recombinant erythropoietin in 
patients having hemodialysis . Br. Med. J . 295: 1017 - 1020 . 
Cash J Mand Sears DA (1989) . The anemia o f chronic disease : 
144 
Spectrum of associated diseases in a series of unselected 
hospitalized patients. Am. J. Med. 87:638-644 
Cashman J, Benkelman D, Humphries K, Eaves C, and Eaves 
A. (1983). Individual BFU-E in polycythemia vera produce both 
erythropoietin dependent and independent progeny. Blood 61(5): 
876-884. 
Castell JV, Gomez-Leehan M J, David M, Hirano T, Kishimoto T, 
and Heinrich PC (1988). Recombinant human interleukin-6 (IL-
6/BSF/HSF) regulates the synthesis of acute phase proteins in 
human hepatocytes. Febs. Lett. 232(2) :347-350. 
Castell J V, Andus T, 
Interleukin-6: The major 
synthesis in man and rat. 
Kunz D, and Heinrich P C (1989). 
regulator of acute-phase protein 
Ann. NY Acad. Sci. 557:87-101. 
Cavill I, Ricketts C and Napier J AF (1977). Erythropoiesis 
in the anaemia of chronic disease. Scand. J. Haematol. 19:509-
512. 
Cavill I and Bentley DP (1982). Erythropoiesis in the anaemia 
of rheumatoid arthritis. Br. J. Haematol. 50:583-590. 
Chandra M, Clemons GK, and Mcvicar MI 
serum erythropoietin levels to renal 
(1988) Relation of 
excretory function: 
Evidence for lowered set point for erythropoietin production in 
chronic renal failure. J. Pediatr. 113(6) :1015-1021. 
Chiu C-P and Lee F (1989). IL-6 is a differential factor for 
Ml and WEHI-3B myeloid leukemic cells. 
1909-1915. 
J. Immunol. 142 ( 6) : 
Christensen RD, Liechty KW, Koenig J M, Schibler KR, and Ohls 
145 
R K (1991). Administration of erythropoietin to newborn rats 
results in diminished neutrophil production. Blood 78 (5) : 1241-
1246. 
Clibon U, Bonewald L, Caro J, and Roodrnan G D (1990) . 
Erythropoietin fails to reverse the anemia in mice continuously 
exposed to tumor necrosis factor-alpha in vivo. Exp . Hematol . 
18 :438-441. 
Corbett J A, Sweetland MA, Lancaster JR, and McDaniel ML 
(1993). A 1-hour pulse with IL-1~ induces formation of nitric 
oxide and inhibits insulin secretion by rat islets of 
Langerhans : evidence for a tyrosine signalling mechanism. Faseb 
J . 7:369- 374 . 
Costa-Giomi P, Caro J, and Weinmann R (1990) . Enhancement by 
hypoxia of human erythropoietin gene transcription in vitro . 
J. Biol . Chem . 265 (18) : 10185- 10188 . 
Crandall BF, Hanson F W, Tennant F, and Perdue ST (1989). a -
Fetoprotein levels in amniotic fluid between 11 and 15 weeks . 
Am. J. Obs . Gyn . 160 (5): 1204-1206. 
D'Andrea A D, Lodish H F, and Wong G G. (1989) Expression 
cloning of the murine erythropoietin receptor . Cell 57 (2) :277 -
285. 
Da Silva J - L, Lacombe C, Bruneval P, Casadevall N, Leporrier M, 
Camilleri J - P, Bariety J, Tanbqurin P, and Varet B (1990). 
Tumor cells are the site of erythropoietin synthesis in human 
renal cancers associated with polycythemia . Blood 75 (3) :577-
582. 
Dacie J V and Lewis S M. Practical Haematology . 5th ed . 
London : Churchill Livingston, 1975:42-43 . 
Dai CH, Krantz SB, Means RT , Horn ST , and Gilbert HS 
(1991) . Polycythemia vera blood burst-forming units-erythroid 
are hypersensitive to interleukin-3 . J . Clin . Invest . 87: 391 -
396. 
146 
Darnen J E, Mui A L-F, Puil L, Pawson T, and Krystal G (1993). 
Phosphatidylinositol 3-kinase associates, via its Src homology 
2 domains, with the activated erythropoietin receptor. Blood 
81(12) :3204-3210. 
Darlington G J, Wilson DR, and Lachrnan LB (1986). Monocyte-
conditioned medium, interleukin-1, and tumor necrosis factor 
stimulate the acute phase response in human hepatorna cells in 
vitro. J. Cell Biol. 103:787-793. 
Darnell J, Lodish H, and Baltimore D. Molecular cell biology. 
2nd ed. New York: Scientific American Books, 1990:391-445. 
Darnell J E, Kerr IM, and Stark GR (1994). Jak-STAT pathways 
and transcriptional activation in response to IFNs and other 
extracellular signalling proteins. Science 264:1415-1421. 
Davidson A, Van der Weyden MB, Fong H, Breidahl M J, and Ryan 
PF J (1984) Red cell ferritin content: A re-evaluation of 
indices for iron deficiency in the anaemia of rheumatoid 
arthritis. Br. Med. J. 289:648-650. 
Davis L G, Dibner M D, and Battey J F. Basic methods in 
molecular biology. New York: Elsevier Science Publishing Co., 
Inc., 1986. 
De Benedetti F, Massa M, Robbioni P, Ravelli A, Burgio GR, and 
Martini A (1991) . Correlation of serum interleukin- 6 levels 
with joint involvement and thrornbocytosis in systemic juvenile 
rheumatoid arthritis. Arthritis Rheum. 34(9) :1158-1163. 
De La Chapelle A, Traskelin A-L, and Juvonen E (1993). 
Truncated erythropoietin receptor causes dominantly inherited 
benign human erythrocytosis. Proc. Natl. Acad. Sci. USA, 
90:4495-4499. 
Dejana E, Breviario F, Erroi A, Bussilino F, Mussoni L, Grarnse 
M, Pintucci G, Casali B, Dinarello CA, Van Damme J, Mantovani 
147 
A ( 1987) . Modulation of endothelial cell functions by 
different molecular species of interleukin 1. Blood 69(2) :695-
699 . 
Dessypris E N and Krantz S B (1984) Effect of pure 
erythropoietin on DNA-synthesis by human marrow day 15 erythroid 
burst forming uni ts in short term liquid culture. Br. J. 
Haematol. 56:295-306. 
Dessypris EN, Graber SE, Krantz SB, and Stone W J (1988). 
Effect of recombinant erythropoietin on the concentration and 
cycling status of human marrrow hematopoietic progenitor cells 
in vivo. Blood 72(6) :2060-2062. 
Dinarello CA and Wolff SM (1993). Mechanism of disease. N. 
Engl. J. Med. 328(2) :106-113. 
Dinarello C A (1988) . 
2:108-115. 
Biology of interleukin 1. Faseb J. 
Dinarello C A (1991). Interleukin-1 and interleukin-1 
antagonism. Blood 77(8) :1627-1652. 
Dinarello CA, Goldin NP, and Wolff SM (1974). Demonstration 
and characterization of two distinct human leukocytic pyrogens. 
J. Exp. Med. 139:1369-1381. 
Douglas S W and Adamson J W (1975). The anemia of chronic 
disorder: studies of marrow regulation and iron metabolism. 
Blood 45( 1) :55-65. 
Dowton SB and Colten HR (1988). Acute phase reactants in 
inflammation and infection. Semin. Hematol. 25(2 ) :84-90 . 
148 
Dunn C D R and Lange R D (1980). Erythropoietin titres in 
normal human serum: An appraisal of assay techniques. Exp. 
Hematol. 8(3) :231-235. 
Eastgate J A, Wood NC, Di Giovine F S, Symons J A, Grinlinton 
FM, and Duff G W (1988). Correlation of plasma interleukin 1 
levels with disease activity in rheumatoid arthritis. 
2:706-709 
Lancet 
Eaves AC and Eaves CJ (1984). 
Clin. Haematol. 13(2) :371-391. 
Erythropoiesis in culture. 
Eckardt K-U, Kurtz A, and Bauer C (1989). 
erythropoietin production is related to 
function. Am. J. Physiol. 256:F942-F947. 
Regulation of 
proximal tubular 
Eckardt K-U and Bauer C (1989). Erythropoietin in health and 
d i sease. Eur. J. Clin. Invest. 19:117-127. 
Editorial, (1989). Polycythemia due to hypoxemia: advantages 
or disadvantages? Lancet 2:20-22. 
Ehrenman Kand St John T (1991). The erythropoietin receptor 
gene: Cloning and identification of multiple transcripts in an 
erythroid cell line OCIMl. Exp. Hematol. 19:973-977. 
Emerson S G, 
Nathan D G 
Sieff CA, Wang EA, Wong G G, Clark SC, and 
(1985). Purification of fetal hematopoietic 
progenitors and demonstration of recombinant mul tipotential 
colony-stimulating activity. J. Clin. Invest 76:1286-1290. 
Emerson S G, Yang Y-C, Clark SC, and Long MW (1988). Human 
recombinant granulocyte-macrophage colony stimulating factor and 
i nterleukin 3 have overlapping but distinct hematopoietic 
149 
activities. J. Clin. Invest. 82:1282-1287. 
Erslev A J (1990). Erythropoietin. Leuk. Res. 14(8) :683-688. 
Erslev A J (1974) In vitro production of erythropoietin by 
kidneys perfused with a serum-free solution. Blood 44(1) :77-85. 
Eschbach J W, Detter JC, and Adamson J W (1980). Physiologic 
studies in normal and uremic sheep. I I. Changes in 
erythropoiesis and oxygen transport. Kidney Int. 18:732-745. 
Eschbach J W, Mladenovic J, Garcia J F, Wahl PW, and Adamson 
J W (1984). The anemia of chronic renal failure in sheep. J. 
Clin. Invest. 74:434-441. 
Eschbach J W, Egrie JC, Downing MR, Browne J K, and Adamson 
J W. ( 1987) . Correction of the anemia of end-stage renal 
disease with recombinant human erythropoietin. N. Engl. J. 
Med. 316(2) :73-78. 
Faquin WC, Schneider T J, and Goldberg MA (1992). Effect of 
inflammatory cytokines on hypoxia-induced erythropoietin 
production. Blood 79(8) :1987-1994. 
Faquin WC, Schneider T J, and Goldberg MA (1993). Modulators 
of protein kinase C inhibit hypoxia-induced erythropoietin 
production. Exp. Hematol. 21:420-426. 
Fribbe WE and Williams R (1991). The role of interleukin-1 in 
haematopoiesis. Acta Haematol. 86:148-154. 
Fidler I J (1978). General considerations for studies of 
experimental cancer metastasis. Methods in Cancer 15:399-439. 
150 
Finch CA, Deubelbeiss K, Cook JD, Eschbach J W, Harker LA, 
Funk DD, Marsaglia G, Hillman RS, Slichter S, Adamson J W, 
Ganzoni A, and Giblett E R ( 1970) . Ferro kinetics in man. 
Medicine 49(1) :17-53. 
Fischl M, Galpin J E, Levine JD, Groopman J E, Henry DH, 
Kennedy P, Miles S, Robbins W, Starrett B, Zalusky R, Abels R 
I, Tsai H C, and Rudnick S A. (1990). Recombinant human 
erythropoietin for patients with AIDS treated with zidovudine. 
N. Engl. J. Med. 322(21) :1488-1493. 
Fisher J Wand Langston J W (1968). Effects of testosterone, 
cobalt and hypoxia on erythropoietin production in the isolated 
perfused dog kidney. Ann. NY Acad. Sci. 149(1) :75-87. 
Foa P ( 1991) . Erythropoietin: Clinical applications. 
Haematol. 86:162-168. 
Acta 
Fried W, Johnson C, and Heller P (1970) Observations on 
regulation of erythropoiesis during prolong periods of hypoxia. 
Blood 36(5) :607-616. 
Fried W(1972). The liver as a source of extrarenal 
erythropoietin production. Blood 40(5) :671-677. 
Fuchs D, Hausen A, Reibnegger G, Reissigl H, Schonitzer D, Spira 
T J and Wachter H (1984). Urinary neopterin in the diagnosis 
of acquired immune deficiency syndrome. Eur. J. Clin. 
Microbial. 3:70-71. 
Fuchs D, Hausen A, Reibnegger G, Werner G, Werner-Felmayer G, 
Dierich MP, and Wachter H (1991): Immune activation and the 
anaemia associated with chronic inflammatory disorders. Eur. 
151 
J. Haematol. 46:65-70. 
Fujiwara H, Kleinhenz ME, Wallis RS and Ellner J J (1986). 
Increased interleukin-1 production and monocyte suppressor cell 
activity associated with human tuberculosis. Am. Rev. Respir. 
Dis. 133:73-77. 
Fukamachi H, Saito T, Tojo A, Kitamura T, Urabe A, and Takaku 
F (1987). Binding of erythropoietin to CFU-E derived from fetal 
mouse liver cells. Exp. Hematol. 15:833-837. 
Furie B and Furie B C (1988). 
coagulation. Cell 53(4) :505-518. 
The molecular basis of blood 
Fyhrquist F, Karppinen K, Honkanen T, Saijon-Maa O, and Rosenlof 
K (1989). High serum erythropoietin levels are normalized 
during treatment of congestive heart failure with enalapril. 
J. Intern. Med. 226:257-260. 
Garcia J F, Ebbe SN, Hollander L, Cutting HO, Miller ME, and 
Cronkite E P ( 1982) . Radioimmunoassay of erythropoietin: 
circulating levels in normal and polycythemic human beings. J. 
Lab. Clin. Med. 99:624-635. 
Gauldie J, Richards C, Harnish D, Lansdorp P, and Baumann H 
(1987). Interferon 02 /B-cell stimulatory factor type 2 shares 
identity with monocyte-derived hepatocyte-stimulating factor and 
regulates the major acute phase protein response in liver cells. 
Proc. Natl. Acad. Sci. USA 84:7251-7255. 
Geiger T, Andus T, 
Heinrich PC (1988). 
Klapproth J, Hirano T, Kishimoto T, and 
Induction of rat acute-phase proteins by 
interleukin 6 in vivo. Eur. J. Immunol. 18:717-721. 
152 
Goldberg MA, Dunning SP, and Bunn HF (1988). Regulation of 
the erythropoietin gene: Evidence that the oxygen sensor is a 
heme protein. Science 242:1412-1415. 
Goldberg M A, Imagawa S, Dunning S P, and Bunn H F (1989). 
Oxygen sensing and erythropoietin gene regulation. Contrib. 
Nephrol. 76:39-56. 
Goldberg MA, Glass GA, Cunningham J M, and Bunn HF (1987). 
The regulated expression of erythropoietin by two human hepatoma 
cell lines. Proc. Natl. Acad. Sci. USA 84:7972-7976. 
Goldwasser E, Jacobson L O, 
Studies on erythropoiesis. 
production of erythropoietin. 
Fried W, and Plzak L F (1958). 
V. The effect of cobalt on the 
Blood 13:55-60. 
Goldwasser E, McDonald J and Beru N. The Molecular biology of 
erythropoietin and the expression of its gene In: Rich IN, ed. 
Molecular and cellular aspects of erythropoietin and 
erythropoiesis. Berlin: Springer-Verlag, 1987:11-21. 
Goldwasser E, Kung C K-H, and Eliason J (1974). On the 
mechanism of erythropoietin-induced differentiation. XIII. The 
role of sialic acid in erythropoietin action. J. Biol. Chem. 
249(13) :4202-4206. 
Goodnough LT, Rudnick S, Price TH, Ballas SK, Collins ML, 
Crowley JP, Kosmin M, Kruskall MS, Lenes BA, Menitove J E, 
Silberstein LE, Smith K J, Wallas CH, Abels R, and Von Tress 
M (1989). Increased preoperative collection of autologous blood 
with recombinant human erythropoietin therapy. N. Engl. J. Med. 
321 (17): 1163-1168. 
Gordon H (1976). The a macroglobulins of rat serum. Biochem. 
153 
J. 159:643-650. 
Grant G Hand Kachmar J F. The proteins of the body. In: Tietz 
NW, eds. Fundamentals of clinical chemistry. Philadelphia: 
W B Saunders, 1976:337-338. 
Gregory C J and Eaves A C (1978). Three stages of 
erythropoietic progenitor cell differentiation distinguished by 
a number of physical and biologic properties. Blood 51(3): 527-
537. 
Gross D M, Brookins J, Fink GD, and Fisher J W (1976). Effects 
of prostaglandins A2 , E2 and F2cx on erythropoietin production. J. 
Pharmacol. Exp. Ther. 198(2): 489-496. 
Gross M and Goldwasser E (1970). On the mechanism of 
erythropoietin differentiation. VII. The relationship between 
stimulated deoxyribonucleic acid synthesis and ribonucleic acid 
synthesis. J. Biol. Chem. 245(7) :1632-1636. 
Guidet B, Offenstadt G, Boffa G, Najman A, Bailleu C, Hatzfeld 
C, and Amstutz P (1987). Polycythemia in chronic obstructive 
pulmonary disease. A study of serum and urine erythropoietin 
and medullary erythroid progenitors. Chest 92:867-870. 
Halperin D S, Wacker P, Lacourt G, Felix M, Babel J-F, Aapro M, 
and Wyss M (1990). Effects of recombinant human erythropoietin 
in infants with the anaemia of prematurity: A pilot study. J. 
Pediatr. 116(5) :779-786. 
Hanazono Y, Chiba S, Sasaki K, Mano H, Yazaki Y, and Hirai H 
( 1993) . Erythropoietin induces tyrosine phosphorylation and 
kinase activity of the c-fps/fes proto-oncogene product in human 
erythropoietin-responsive cells. Blood 81(12) :3193-3196. 
154 
Hansen NE (1983). The anaemia of chronic disorders. A bag of 
unsolved problems. Scand. J. Haematol. 31:397-402. 
Hanspal M, Kalraiya R, Hanspal J, Sahr KE, and Pakek J (1991). 
Erythropoietin enhances the assembly of a,~ spectrin 
heterodimers on the murine erythroblast membranes by increasing 
~ spectrin synthesis. J. Biol. Chem. 266(24) :15626-15630. 
Hara Hand Ogawa M (1976). Erythropoietic precursors in mice 
with phenylhydrazine-induced anemia. Am. J. Hematol. 1:453-458. 
Hart I R (1979). The selection and characterization of an 
invasive variant of the B16 Melanoma. Am. J. Pathol. 97:587-
600. 
Helle M, Brakenhoff JP J, De Groot ER, and Aarden LA (1988). 
Interleukin 6 is involved in interleukin 1-induced activities. 
Eur. J. Immunol. 18:957-959. 
Helson L, Green S, Carswell E, and Old L J (1975). Effect of 
tumour necrosis factor on cultured human melanoma cells. Nature 
258:731-732. 
Hodgkin PD, Bond MW, O'Garra A, Frank G, Lee F, Coffman R L, 
Zlotnik A, and Howard M (1988). Identification of IL-6 as a T 
cell-derived factor that enhances the proliferative response of 
thymocytes to IL-4 and phorbol myristate acetate. J. Immunol. 
141 (1): 151-157. 
Huber C, Fuchs D, Hausen A, Margreiter R, Reibnegger G, 
Spielberger Mand Wachter H (1983). Pteridines as a new marker 
to detect human T cells activated by allogeneic or modified self 
major histocompatibility complex (MHC) determinants. J. 
Immunol. 130(3) :1047-1050. 
155 
Huber C, Batchelor JR, Fuchs D, Hausen A, Lang A, Niederwieser 
D, Reibnegger G, Swetley P, Troppmair J, and Wachter H (1984). 
Immune response-associated production of neopterin. Release 
from macrophages primarily under control of interferon-gamma. 
J . Exp. Med. 160:310-316. 
Iizuka Y and Chang Y-H (1982). Adjuvant polyarthritis. VII. 
The role of type II collagen in pathogenesis. Arthritis Rheum. 
25(11) :1325-1332. 
Imagawa S, Goldberg M A, Doweiko J, and Bunn H F (1989). 
Regulatory elements of the erythropoietin gene. Blood 
77 (2) :278-285. 
Jacobs K, Shoemaker C, Rudersdorf R, Neill SD, Kaufman R J, 
Mufson A, Seehra J, Jones S S, Hewick R, Fritsch E F, Kawakita 
M, Shimizu T, and Miyake T (1985). Isolation and 
characterization of genomic and cDNA clones of human 
erythropoietin. Nature 313:806-810. 
Jacobs P and Bird A. Basic haematology. 2nd ed. Cape Town: 
University of Cape Town, 1983:39-68. 
Jacobson LO, Goldwasser E, Fried W, and Plzak L (1957). Role 
of the kidney in erythropoiesis. Nature 179:633-634. 
Jelkmann W, Wolff M, and Fandrey J (1990). Modulators of the 
production of erythropoietin by cytokines: In vitro studies and 
their clinical implications. Contrib. Nephrol. 87:68-77. 
Jelkmann W, Pagel H, Wolff M, and Fandrey J (1992). Monokines 
i nhibiting erythropoietin production in human hepatoma cultures 
and in isolated perfused rat kidneys. Life Sci. 50:301-308. 
156 
Johnson RA, Waddelow TA, Caro J, Oliff A, and Roodman GD 
(1 989). Chronic exposure to tumor necrosis factor in vivo 
preferentially inhibits erythropoiesis in nude mice. Blood 
74 (1): 130-138. 
Johnson C S, Cook C A, and Furmanski P (1990). In vivo 
suppression of erythropoiesis by tumor necrosis factor-a (TNF-
a): Reversal with exogenous erythropoietin (Epo). Exp. Hematol. 
18:109-113. 
Jones S S, D'Andrea AD, Haines LL, and Wong G G (1990). Human 
erythropoietin receptor: Cloning, expression and biologic 
characterization. Blood 76(1) :31-35. 
Kaufmann S, Berlow S, Summer GK, Milstien S, Schulman JD, 
Orloff S, Spielberg S, and Pueschel S (1978). 
Hyperphenylalaninemia due to a deficiency of biopterin. A 
variant form of phenylketonuria. N. Engl. J. Med. 299(13): 673-
679. 
Kern P, Hemmer C J, Van Damme J, Gruss H-J and Dietrich M 
(1 989). Elevated tumor necrosis factor alpha and interleukin-6 
levels as markers for complicated Plasmodium falciparum malaria. 
Am. J. Med.87:139-143. 
Kew M C and Fisher J W 
concentrations in patients 
Cancer 58:2485-2488. 
(1986). Serum erythropoietin 
with hepatocellular carcinoma. 
Kickler TS and Spivak J L (1988). Effect of repeated whole 
blood donations on serum immunoreactive erythropoietin levels 
in autologous donors. J. Am. Med. Assoc. 260(1) :65-67. 
Klausner RD and Harford J B (1989). Cis-trans models for post-
157 
transcriptional gene regulation . Science 246:870- 872. 
Knowles B B, Howe C C, and Aden D P (1980) . Human 
hepatocellular carcinoma cell lines secrete the major plasma 
proteins and hepatitis B surface antigen. _ Science 2 09 :497-499 . 
Komatsu N, Adamson J W, Yamamoto K, Altschuler D, Torti M, 
Marzocchini R, and Lapetina E G (1992) . Erythropoietin rapidly 
induces tyrosine phosphorylation in the human erythropoietin-
dependent cell line, UT-7. Blood 80 (1) :53-59. 
Koury M J , Bondurant MC, Duncan D T, Krantz SB, and Hankins 
W D (1982). Specific differentiation events induced by 
erythropoietin in cells infected in vitro with the anemia strain 
of Friend virus . Proc. Natl. Acad . Sci . USA 79: 635-639 . 
Koury M J , Bondurant MC , Graber SE , and Sawyer ST (1988a) . 
Erythropoietin messenger RNA l~vels in developing mice and 
transfer of 125 I-erythropoietin by the placenta . 
Invest. 82: 154-159 . 
J . Cli n. 
Koury M J and Bondurant M .C (1990) . Erythropoietin retards DNA 
breakdown and prevents programmed death in erythroid progenitor 
cells . Science 248: 378-38 1. 
Koury ST , Bondurant MC , and Koury M J (1988b) . Localization 
of erythropoietin synthesizing cells in murine kidneys by in 
situ hybridization . Blood 71 (2) : 524-527 . 
Koury ST, Koury M J, Bondurant MC , Caro J, and Graber SE 
( 1989) . Quan ti tat ion of erythropoietin-producing cells in 
kidneys of mice by in situ hybridization : Correlation with 
hematocrit, renal erythropoietin mRNA, and serum erythropoietin 
concentration. Blood 74 (2) : 645-651 . 
Ko~ry ST , Bondurant MC, Koury M J , and Semenza G L (1991) . 
Localization of cells producing erythropoietin in murine liver 
by in situ hybridization . Blood 77 (11) : 2497-2503 . 
Krantz SB (1991) . Erythropoietin . Blood 77 (3) :419- 434 . 
Krantz S B and Goldwasser E ( 1984) . Specific binding of 
15 8 
erythropoietin to spleen cells infected with the anemia strain 
of Friend virus. Proc. Natl. Acad. Sci. USA 81:7574-7578. 
Kurtz A, Eckardt K-U, Tunnahill L, Bayer C (1988). Regulation 
o f erythropoietin production. Contrib. Nephrol. 66:1-16. 
Kushner I (1982). The phenomenon of the acute phase response. 
Ann. N. Y. Acad. Sci. 389:39-48. 
Lacombe C, Casadevall N, Choppin J, Muller O, Goldwasser E, 
Varet B, and Tambourin P. In: Rich IN, ed. Molecular and 
cellular aspects of erythropoietin and erythropoiesis. Berlin: 
Springer-Verlag, 1987:61-72. 
Lacombe C, Da Silva J-L, Bruneval P, Fournier J-G, Wendling F, 
Casadevall N, Camilleri J-P, Bariety J, Varet B, and Tambourin 
P (1988). Peri tubular cells are the site of erythropoietin 
s ynthesis in the murine hypoxic kidney. J. Clin. Invest. 
81:620-623. 
Lai P-H, Everett R, Wang F-F, Arakawa T, and Goldwasser E 
(1986). Structural characterization of human erythropoietin. 
J . Biol. Chem. 261(7) :3116-3121. 
Landschultz KT, Noyes AN, Rogers O, and Boyer SH (1989). 
Erythropoietin receptors on murine erythroid colony-forming 
units: Natural history. Blood 73(6) :1476-1486. 
Latchman D S (1993). Transcription factors: an overview. Int 
J . Exp. Path. 74:417-422. 
Law ML, Cai G-Y, Lin F-K, Wei Q, Huang S-Z, Hartz J H, Morse 
H, Lin C-H, Jones C, and Kao F-T (1986). Chromosomal assignment 
of the human erythropoietin gene and its DNA polymorphism. 
159 
Proc. Natl. Acad. Sci. USA 83:6920-6924. 
Lenfant C and Sullivan K (1971). Adaptation to high altitude 
N. Engl. J. Med. 284(23) :1298-1309. 
Lertora J J L, Dargon PA, Rege AB, and Fisher J W (1975). 
Studies on a radioirnmunoassay for human erythropoietin. J. Lab. 
Clin. Med. 86(1) :140-151. 
Leu R W, Leu N R, Shannon B J, and Fast D J (1991). IFN-y 
differentially modulates the susceptibility of L1210 and P815 
t umor targets for macrophage-mediated cytotoxicity. Role of 
macrophage-target interaction coupled to nitric oxide 
generation, but independent of tumor necrosis factor production. 
J . Immunol. 147(6) :1816-1822. 
Lewis S M and Porter I H (1960). Erythrocyte survival in 
rheumatoid arthritis. Ann. Rheum. Dis. 19:54-58. 
Lin F-K, Suggs S, Lin C-H, Browne J K, Smalling R, Egrie JC, 
Chen K K, Fox GM, Martin F, Stabinsky Z, Badrawi SM, Lai P-H, 
and Goldwasser E (1985). Cloning and expression of the human 
erythropoietin gene. Proc. Natl. Acad. Sci. USA 82:7580-7584. 
Lin F J, Lin CH, Lai PH, et al. (1986). Monkey erythropoietin 
gene: cloning, expression and comparison with the human 
erythropoietin gene. Gene 44:201-209. 
Linnekin D, Evans G A, D'Andrea A, and Farrar W L (1992). 
Association of the erythropoietin receptor with protein tyrosine 
kinase activity. Proc. Natl. Acad. Sci. USA 89:6237-6241. 
Lonberg-Holm K, Reed D L, Roberts RC, Hebert RR, Hillman MC, 
and Kutney RM (1987). Three high molecular weight protease 
160 
inhibitors of rat plasma . Isolation, characterization, and 
acute phase changes . J . Biol . Chem. 262: 438 - 442 
Lukens J N, Cartwright GE and Wintrobe MM (1967) 
adjuvant-induced inflammation in rats . Proc . Soc. 
Med. 126 :346- 349. 
Anemia of 
Exp . Biol . 
MacManus MP , Elder GE , Abram WP, Bridges J M (1990) . Effect 
of recombinant human erythropoietin on anemia caused by a murine 
mammary carcinoma . Exp . Hematol . 18: 848 - 852 . 
Mason- Garcia Mand Beckman BS (1991) . Signal transduction in 
erythropoiesis . Faseb J . 5: 2958-2964 . 
Maury C P J, Andersson LC , Teppo A- M, Partanen Sand Juvonen 
E (1988) . Mechanism of the anaemia in rheumatoid arthritis : 
Demonstration of raised interleukin lB concentrations in anaemic 
patients and of interleukin 1 mediated suppression of norma l 
erythropoiesis and proliferation of human erythroleukemia (HEL) 
cells in vitro . Ann. Rheum . Dis . . 47 :972-978 . 
Maxwell A P, Lappin T R, J , Johnston C F, Bridges J M, and 
McGeown MG (1990) . Erythropoietin production in kidney tubular 
cells . Br . J . Haematol . 75: 535- 539 . 
Maxwell PH, Ferguson DJ P, Osmond MK, Pugh CW, Heryet A, Doe 
BG, Johnson M H, and Ratcliffe P J (1994). Expression of a 
homologously recombined erythropoietin- SV40 T antigen fusion 
gene in mouse liver : Evidence for erythropoietin product i on by 
Ito cells . Blood 84 (6) :1823-1830 . 
Maxwell PH , Osmond MK , Pugh CW , Heryet A, Nicholls LG , Tan 
CC, Doe BG, Ferguson DJ P, Johnson M H, and Ratcliffe P J 
(1993) . Identification of the renal erythropoietin- producing 
cells using transgenic mice . Kidney Int . 44 :1149-1162 . 
McDonald J D, Lin F-K , and Goldwasser E ( 198 6) . Cloning, 
sequencing , and evolutionary analysis of the mouse erythropoietin 
gene . Mol . Cell. Biol. 6 :842-848 . 
McGonigle R JS, Brookins J, Pegram BL, and Fisher J W (1987). Enhanced 
erythropoietin production by calcium entry blockers in rats exposed to 
hypoxia . J. Pharmacol. Exptl . Ther . 241 (2) : 428-432 . 
161 
McKean J L, Saunders NA, Murree-Allen K, Olson LG, Gyulay S, 
Dickeson J, Houghton A, Wlodarczyk J, and Hensley M J. (1990). 
Urinary uric acid: creatinine ratio, serum erythropoietin, and 
blood 2,3-diposphoglycerate in patients with obstructive sleep 
apnea. Am. Rev. Respir. Dis. 142:8-13. 
Means RT and Krantz SB (1992). Progress in understanding the 
pathogenesis of the anemia of chronic disease. Blood 
80(7) :1639-1647. 
Means RT, Olsen NJ, Krantz SB, Dessypris EN, Graber SE, 
Stone W J, O'Neil V L, and Pincus T (1989). Treatment of the 
anemia of rheumatoid arthritis with recombinant human 
erythropoietin: clinical and in vitro studies. 
Rheum. 32(5) :638-642. 
Arthritis 
Miller BA, Scaduto RC, Tillotson D L, Botti J J, and Cheung 
J Y (1988). Erythropoietin stimulates a rise in intracellular 
free calcium concentration in single early human erythroid 
precursors. J. Clin. Invest. 82:309-315. 
Miller ME, Garcia J F, Cohen RA, Cronkite E P, Moccia G, and 
Acevedo (1981). Diurnal levels of immunoreactive erythropoietin 
in normal subjects and subjects with chronic lung disease. Br. 
J. Haematol. 49:189-200. 
Miller CB, Jones R J, Piantadosi S, Abeloff MD, and Spivak 
J L (1990). Decreased erythropoietin response in patients with 
the anemia of cancer. N. Engl. J. Med. 322:1689-1692. 
Milman N and Larsen L (1976). Iron absorption in patients with 
chronic uremia undergoing regular hemodialysis. Acta. Med. 
Scand. 199:113-119. 
162 
Mirand EA, Murphy GP, Steeves RA, Weber H Wand Retief F P. 
(1968). Extra-renal production of erythropoietin in man. Acta. 
Haematol. 39:359-365. 
Miyajima A, Kitamura T, Harada N, Yokota T, and Arai K-i (1992). 
Cytokine receptors and signal transduction. Annu. Rev. Immunol. 
10:295-331. 
Miyake T, Kung C K-H, Goldwasser E (1977). Purification of 
human erythropoietin. J. Biol. Chem. 252(15) :5558-5564. 
Moldawer LL, Gelin J, Schersten T, and Lundholm KG (1987). 
Circulating interleukin 1 and tumor necrosis factor during 
i nflammation. Am. J. Physiol. 253:R922-R928. 
Moldawer LL, Marano MA, Wei H, Fong Y, Silen ML, Kuo G, 
Manogue K R, Vlassara H, Cohen H, Cerami A, and Lowry S F 
(1989). Cachectin/tumor necrosis factor-a alters red blood cell 
kinetics and induces anemia in vivo. Faseb J. 3:1637-1643. 
Morell AG, Irvine RA, Sternlieb I, and Scheinberg I H (1968). 
Physical and chemical studies on ceruloplasmin. V. Metabolic 
s tudies on sialic acid-free ceruloplasmin in vivo. J. Biol. 
Chem. 243(1 ) :155-159. 
Morgan E S and Jacox R F (1964). Erythrocyte survival in 
r heumatoid arthritis. Arthritis Rheum. 7(5) :481-489. 
Morrone G, Ciliberto G, Oliviero S, Arcane R, Dente L, Content 
J , and Cortese R (1988). Recombinant interleukin 6 regulates 
t he transcriptional activation of a set of human acute phase 
genes. J. Biol. Chem. 263(25) :12554-12558. 
Mortensin RF, Shapiro J, Lin B-F, Douches S, and Neta R (1988). 
163 
Interaction of recombinant IL-1 and recombinant tumor necrosis 
factor in the induction of mouse acute phase proteins. J. 
Immunol. 140(7) :2260-2266. 
Mufson RA and Gesner T G (1987). Binding and internalization 
of recombinant human erythropoietin in murine erythroid 
precursor cells. Blood 69(5) :1485-1490. 
Mujovic V Mand Fisher J W (1975). The role of prostaglandins 
in the production of erythropoietin (ESF) by the kidney. II 
Effects of indomethacin on erythropoietin production following 
hypoxia in dogs. Life Sci. 16:463-473. 
Murphy GP, Mirand EA, Staubitz W J (1976). The value of 
erythropoietin assay in the follow-up of Wilms' tumor patients. 
Oncology 33:154-156. 
Muto S, Asano Y, Hosoda S, Shionoya S, Miuray Y, Urabe A, Takaku 
F ( 1987) . Polycythemia of end-stage renal failure: No 
inhibition of erythropoiesis by uremic serum and markedly 
increased serum erythropoietin level. Nephron 46:34-36. 
Naets JP and Wittek M (1968). Presence of erythropoietin in 
the plasma of one anephric patient. Blood 31(2) :249-251. 
Naughton BA, Kaplan SM, Ror M, Burdowski A J, and Gordon A 
S (1977). Hepatic regeneration and erythropoietin production 
in the rat. Science 196:301-302. 
Nielsen o J (1988). Determination of human erythropoietin by 
radioimmunoassay. Method and clinical data. Clin. Chim. Acta 
176:303-314. 
Nielsen OJ, Egfjord M, and Hirth P (1989). Erythropoietin 
164 
metabolism in the isolated perfused rat liver. 
Nephrol. 76:90-97. 
Contrib. 
Nijhof w, Wierenga PK, Sahr K, Beru N, and Goldwasser E (1987). 
Induction of globin mRNA transcription by erythropoietin in 
differentiating erythroid precursor cells Exp. Hematol. 15: 
779-784. 
Nijhof Wand Wierenga PK. The purification of spleen CFU-E 
and its application in the study of in vitro erythropoiesis. 
In: Rich I N, ed. Molecular and cellular aspects of 
erythropoietin and erythropoiesis. Berlin: Springer-Verlag, 
1987:73-88. 
Noe G, Riedel W, Kubanek B, and Rich IN (1992). A sensitive 
sandwich ELISA for measuring erythropoietin in human serum. Br. 
J. Haematol. 80:285-292. 
Northemann W, Andus T, Gross V, Nagashima M, Schreiber G, and 
Heinrich PC (1983). Messenger RNA activities of four acute 
phase proteins during inflammation. Febs. Lett. 161(2) :319-322. 
Offner F, Philippe J, Vogelaers D, Colardyn F, Baele G, 
Baudrihaye M, Vermeulen A, and Leroux-Roels G (1990). Serum 
tumor necrosis factor levels in patients with infectious disease 
and septic shock. J. Lab. Clin. Med. 116:100-105. 
Ogawa M, MacEachern M D, and Avila L (1977). Human marrow 
erythropoiesis in culture: II. Heterogeneity in the 
morphology, time course of colony formation, and sedimentation 
velocities of the colony-forming cells. Am. J. Hematol. 3:29-
36. 
Okusawa S, Gelfand J A, Ikejima T, Connolly R J, Dinarello CA 
165 
(1988). Interleukin 1 induces a shock-like state in rabbits. 
Synergism with tumour necrosis factor and the effect of 
cyclooxygenase inhibition. J. Clin. Invest. 81:1162-1172. 
Paul P, Rothmann SA, and Meagher RC (1988). Modulation of 
erythropoietin production by adenosine. J. Lab. Clin. Med. 
112:168-173 
Pavlovic-Kentera V, Ruvidic R, Milenkovic P, and Marinkovic D 
(1 979). Erythropoietin in patients with anaemia in rheumatoid 
arthritis. Scand. J. Haematol. 23:141-145. 
Pearson CM (1956). Development of arthritis, periarthritis and 
periostitis in rats given adjuvants. Proc. Soc. Exp. Biol. Med. 
91:95-101. 
Pearson CM, Waksman B H, and Sharp J T (1961). Studies of 
arthritis and other lesions induced in rats by injection of 
mycobacterial adjuvant. V. Changes affecting the skin and mucous 
membranes. Comparison of the experimental process with human 
disease. J. Exp. Med. 113:485-510. 
Peled T, Rigel M, Peritt D, Fibach E, Treves A J, and Barak V 
(1 992). Effect of M20 interleukin-1-inhibitor on normal and 
leukemic human myeloid progenitors. Blood 79(5) :1172-1177. 
Pepys M B and Baltz M L (1983). Acute phase proteins with 
special reference to C-reactive protein and related proteins 
(pentraxins) and serum amyloid A protein. Adv. Immunol. 34:141-
212. 
Perlmutter D H, Dinarello C A, Punsal P I, and Col ten H R 
(1 986). Cachectin/tumor necrosis factor regulates hepatic acute-
phase gene expression. J. Clin. Invest. 78:1349-1354. 
166 
Phadke K, Fouts R, and Parrish J E (1984). Collagen-induced and 
adjuvant-induced arthritis in rats. Post-immunization treatment 
with collagen to suppress or abrogate the arthritic response. 
Arthritis Rheum. 27(7) :797-806. 
Phibbs RH, Shannon KM, and Mentzer WC (1992). Potential for 
t reatment of anaemia of prematurity with recombinant human 
erythropoietin: Preliminary results. Acta Haematol. 87(suppl 
1) :28-33. 
Philip R and Epstein L B (1986). Tumour necrosis factor as 
i rnmunomodulator and mediator of monocyte cytotoxicity induced 
b y itself, y-interferon and interleukin-1. Nature 323:86-89. 
Pincus T, Olsen NJ, Russell I J, Wolfe F, Harris ER, Schnitzer 
T J, Boccagno J A, Krantz SB (1990). Multicenter study of 
r ecombinant human erythropoietin in correction of anemia in 
rheumatoid arthritis. Am. J. Med. 89:161-168. 
Porter D L and Goldberg M A (1993). Regulation of 
e rythropoietin production. Exp. Hematol. 21:399-404. 
Powell JS, Berkner KL, Lebo RV, and Adamson J W (1986). 
Human erythropoietin gene: High level expression i n stably 
t ransfected mammalian cells and chromosome localization. Proc. 
Natl. Acad. Sci USA 83:6465-6469. 
Raine A E G (1988). Hypertension, blood 
c ardiovascular morbidity in renal failure: 





Ramadori G, Sipe JD, Dinarello CA, Mizel SB, and Colten HR 
( 1985) . Pretranslational modulation of acute phase hepatic 
protein synthesis by murine recombinant interleukin-1 (IL-1) and 
167 
purified human IL-1. J. Exp. Med. 162:930-942. 
Ratcliffe P J, Jones R W, Phillips RE, Nicholls LG, and Bell 
JI (1990). Oxygen-dependent modulation of erythropoietin mRNA 
levels in isolated rat kidneys studied by RNase protection. J. 
Exp. Med. 172:657-660. 
Reibnegger G, Egg D, Fuchs D, Gunther R, Hausen A, Werner ER, 
and Wachter H ( 198 6) . Urinary neopterin reflects clinical 
activity in patients with rheumatoid arthritis. Arthritis 
Rheum. 29(9) :1063-1070. 
Reid CD L, Prouse P J, Baptista LC, Gumpel J M, and Chanarin 
I (1984). The mechanism of the anaemia in rheumatoid arthritis: 
effects of bone marrow adherent cells and of serum on in-vitro 
erythropoiesis. Br. J. Haematol. 58:607-615. 
Reismann KR (1950). Studies on the mechanism of erythropoietic 
stimulation in parabiotic rats during hypoxia. Blood 5(4) :372-
380. 
Rencricca NJ, Rizzoli V, Howard D, Duffy P, and Stahlman F 
(1970). Stem cell migration and proliferation during severe 
anemia. Blood 36(6) :764-771. 
Rennick D, Jackson J, Yang G, Wideman J, Lee F, and Hudak S 
(1989). Interleukin-6 interacts with interleukin-4 and-other 
hematopoietic growth factors to selectively enhance the growth 
of megakaryocytic, erythroid, myeloid, and multipotential 
progenitor cells. Blood 73(7) :1828-1835. 
Rich I N and Kubanek B ( 1982) . Extrarenal erythropoietin 
production by macrophages. Blood 60(4) :1007-1018. 
168 
Rocha e Silva Mand Leme JG. Chemical mediators of the acute 
inflammatory reaction. In: Alexander P and Bacq Z M, eds. 
Modern trends in physiological sciences. Oxford: Pergamon Press, 
1972, vol. 37. 
Rodgers GM, Fisher J W, and George W J (1975). Increase in 
hematocrit, hemaglobin and red cell mass in normal mice after 
treatment with cyclic AMP. Proc. Soc. Exp. Biol. Med. 
148:380-382. 
Rodgers GM, Fisher J W, and George W J (1975). 
renal adenosine 3', 5' -monophosphate in the 
erythropoietin production. Am. J. Med. 58:31-38. 
The role of 
control of 
Rondon I J, MacMillan LA, Beckman BS, Goldberg MA, Schneider 
T, Bunn HF, and Malter JS (1991). Hypoxia up-regulates the 
activity of a novel erythropoietin mRNA binding protein. J. 
Biol. Chem. 266(25) :16594-16598. 
Roodman GD, Bird A, Hutzler D, and Montgomery W (1987). Tumor 
necrosis factor-alpha and hematopoietic progenitors: Effects of 
tumor necrosis factor on the growth of erythroid progenitors 
CFU-E and BFU-E and the hematopoietic cell lines K562, HL60, and 
HEL cells. Exp. Hematol. 15:928-935. 
Ross R (1993). The pathogenesis of atherosclerosis: a 
perspective for the 1990s. Nature 362:801-809. 
Sakata S, Enoki Y, Nakatani A, Kohzuki H, Ohga Y, and Shimizu 
S (1987). Plasma erythropoietin assay by a fetal mouse liver 
cell culture method with special reference to effective 
elimination of erythroid colony inhibitor(s) in plasma. Exp. 
Hematol. 15:226-233. 
169 
Sambrook J, Fritsch E F, and Maniatis T. Molecular cloning . A 
laboratory manual. 2nd ed . New York: Cold Spring Harbor Laboratory 
Press, 1989. 
Sawada K, Krantz SB, Dessypris EN, Koury ST , and Sawyer ST 
( 1989) . Human colony-forming uni ts-erythroid do not require 
accessory cells , but do require direct interaction with insulin-
like growth factor I and/or insulin for erythroid development. 
J. Clin . Invest. 83 :1701-1709 . 
Sawyer ST, Krantz SB, and Goldwasser E (1987) . Binding and 
receptor - mediated endocytosis of erythropoietin in Friend virus-
infected erythroid cells . J. Biol. Chem . 262 (12) : 5554-5562. 
Sawyer S T (1989) . The two proteins of the erythropoietin 
receptor are structurally similar . J . Biol . Chem . 264 (22) :13343-
13347 . 
Sawyer S T and Koury M J (1987) . Erythropoietin requirements 
during terminal erythroid differentiation: The role of surface 
receptors for erythropoietin . J . Cell . Biol . 105: 191a ( abs tr, 
suppl . ) . 
Sawyer S T and Krantz S B (1984). Erythropoietin stimulates 45Ca2+ 
uptake in Friend virus-infected erythroid cells. J. Biol . Chem. 
259 (5) : 2769-2774 . 
Schall T J, Lewis M, Koller K J , Lee A, Rice G C, Wong G H W, 
Gatanaga T, Granger GA, Lentz R, Raab H, Kohr W J , and Goeddel 
D V, (1990). Molecular cloning and expression of a receptor for 
human tumor necrosis factor. Cell 61 (2) :361-370. 
Schooley JC , Kullgren B, and Allison AC (1987) . Inhibition by 
interleukin- 1 of the action of erythropoietin on erythroid 
precursors and its possible role in the pathogenesis of 
hypoplastic anaemias . Br. J . Haematol. 67: 11-17. 
Schooley JC and Mahlman L J (1972) . Evidence for the de novo 
synthesis of erythropoietin in hypoxic rats. Blood 40 (5) : 662 -
670. 
170 
Schreiber G, Howlett G, Nagashima M, Millership A, Martin H, 
Urban J, and Kotler L (1982) . The acute phase response of 
plasma protein synthesis during experimental inflammation. J . 
Biol. Chem . 257 (17) : 10271-10277 . 
Schreiber G, Tsykin A, Aldred AR, Thomas T, Fung W-P, Dickson 
P w, Cole T, Birch H, De Jong FA, and Milland J (1989) . The 
acute phase response in the rodent . 
557 :61-86 . 
Ann . N . Y. Acad . Sci. 
Schuster s J, Wilson J H, Erslev A J, and Caro J (1987). 
Physiologic regulation and tissue localization of renal 
erythropoietin messenger RNA . Blood 70 (1) :316-318. 
Schuster s J, Badiavas EV, Costa-Giomi P, Weinmann R, Erslev 
A J, and Caro J ( 198 9) . Stimulation of erythropoietin gene 
transcription during hypoxia and cobalt exposure. Blood 
73 (1) : 13-16 . 
Schuster SJ, Koury ST, Bohrer M, Salceda S, and Caro J (1992) . 
Cellular sites of extrarenal and renal erythropoietin productioo 
' 
in anaemic rats. Br. J. Haematol . 81: 153-159 . 
Semenza G L, Traystman M D, Gearhart J D, Antonarakis S E 
(1989) . Polycythemia in transgenic mice expressing the human 
erythropoietin gene. Proc . Natl . Acad . Sci. USA 86: 2301-2305 . 
Semenza G L, Nejfelt MK , Chi SM, and Antonarakis SE (1991) . 
Hypoxia-inducible nuclear factors bind to an enhancer element 
located 3' to the human erythropoietin gene. Proc . Natl. Acad. 
Sci. USA 88: 5680-5684. 
Semenza G Land Wang G L (1992) . A nuclear factor induced by 
hypoxia via de novo protein synthesis binds to the human 
erythropoietin gene enhancer at a site required for 
transcriptional activation . Moll . Cell . Biol . 12 (12) :5447-5454. 
Shacter E, Arzadon GK, and William J (1992) . Elevation of 
interleukin-6 in response to a chronic inflammatory stimulus in 
171 
mice: Inhibition by indomethacin. Blood 80(1) :194-202. 
Sherwood J B (1984). The chemistry and physiology of 
erythropoietin. Vitam. Horm. 41:161-211. 
Shoemaker CB and Mitsock L D (1986). Murine erythropoietin 
gene: cloning, expressing and human gene homology. Mol. Cell. 
Biol. 6:849-859. 
Siedel J, Wahlefeld AW, and Ziegenhorn J (1984). Improved 
FerroZine-based reagent for the determination of serum iron 
(transferrin iron) without deproteinization. Clin. Chem. 
30:975. 
Sims J E, March C J, Cosman D, Widmer M B, MacDonald H R, 
McMahan CJ, Grubin CE, Wignall J M, Jackson J L, Call SM, 
Friend D, Alpert AR, Gillis S, Urdal D Land Dower SK (1988). 
cDNA expression cloning of the IL-1 receptor, a member of the 
immunoglobulin superfamily. Science 241:585-589. 
Smith GK and Nichol CA (1986). Synthesis, utilization, and 
structure of the tetrahydropterin intermediates in the bovine 
adrenal medullary de novo biosynthesis of tetrahydrobiopterin. 
J. Biol. Chem. 261(6) :2725-2737. 
Spivak J L, Barnes DC, Fuchs E, and Quinn TC (1989). Serum 
immunoreactive erythropoietin in HIV-infected patients. JAMA 
261(21) :3104-3107. 
Stephenson JR, Axelrad A A, McLeod D L, and Shreeve MM (1971). 
Induction of colonies of hemoglobin synthesizing cells by 
erythropoietin in vitro. Proc. Natl. Acad. Sci. USA 68: 1542-
1546. 
172 
Stohlman F, Rath CE, and Rose JC (1954). Evidence for a 
humeral regulation of erythropoiesis. Studies on a patient with 
polycythemia secondary to regional hypoxia. Blood 9:721-733. 
Stuart J M, Townes A S, and Kang A H (1984). Collagen 
autoimmune arthritis. Annu. Rev. Immunol. 2:199-218. 
Takeuchi M, Inoue N, Strickland T W, Kubota M, Wada M, Shimizu 
R, Hoshi S, Kozutsumi H, Takasaki S, and Kobata A (1989). 
Relationship between sugar chain structure and biological 
activity of recombinant human erythropoietin produced in chinese 
hamster ovary cells. Proc. Natl. Acad. Sci. USA 86:7819-7822. 
Tan C H, Eckardt K-U, and Ratcliffe P J (1991). Organ 
distribution of erythropoietin messenger RNA in normal and 
uremic rats. Kidney Int. 40:69-76. 
Taurog JD, Kerwar S S, McReynolds RA, Sandberg GP, Leary S 
L, and Mahowald ML (1985). Synergy between adjuvant arthritis 
and collagen-induced arthritis in rats. J. Exp. Med. 162:962-
978. 
Tepperman A D, Curtis J E, and McCulloch E A (1974). 
Erythropoietic colonies in cultures of human marrow. Blood 
44 (5): 659-669. 
Teppo A-Mand Maury C P J (1987). Radioimmunoassay of tumor 
necrosis factor in serum. Clin. Chem. 33:2024-2027. 
Thorling E B (1972). Paraneoplastic erythrocytosis and 
inappropriate erythropoietin production. 
17:1-166(Suppl.). 
Scand. J. Haematol. 
Tobler A, Meier R, Seitz M, Dewald B, Baggiolini M, and Fey M 
173 
F (1992). Glucocorticoids downregulate gene expression of GM-
CSF, NAP-l/IL-8, and IL-6, but not of M-CSF in human fibroblast. 
Blood 79(1 ) :45-51. 
Tosato G, Seamon K B, Goldman N D, Sehgal P B, May L T, 
Washington G C, Jones K D., and Pike S E (1988) . Monocyte-
derived human B-cell growth factor identified as interferon-~ 2 
(BSF-2, IL-6). Science 239:502-504. 
Tracey K J, Beutler B, Lowry S F, Merryweather J, Wolpe S, 
Milsark I W, Hariri R J, Fahey T J, Zentella A, Albert JD, 
Shires G T, and Cerami A ( 198 6) . Shock and tissue injury 
induced by recombinant human cachectin. Science 234: 470-474. 
Tracey K J, Wei H, Manogue KR, Fong Y, Hesse D G, Nguyen HT, 
Kuo G C, Beutler B, Cotran RS, Cerami A, and Lowry SF (1988). 
Cachectin/tumor necrosis factor induces cachexia, anemia, and 
inflammation. J. Exp. Med. 167:1211-1227 . 
• 
Trentham DE, Townes AS, ~nd Kang AH (1977). Autoimmunity to 
type II collagen: An experimental model of arthritis. J. Exp. 
Med. 146:857-868 . 
Trimble M, Caro CJ, Talalla A, and Brain M (1991). Secondary 
erythrocytosis due to a cerebellar hemangioblastoma: 
Demonstration of erythropoietin mRNA in the tumor. Blood 78 
( 3 ) : 599-601 
Tsuda H, Sawada T, Kawakita M, and Takatsuki K (1989). Mode of 
action of erythropoietin (Epo) in an Epo-dependent murine cell 
line. II. Cell cycle dependency of Epo Action. Exp. Hematol. 
17: 218-222. 
Tsukada J, Misago M, Kikuchi M, Sato T, Ogawa R, Ota T, Oda S, 
Morimoto I, Chiba S, and Eto S ( 1992) . Interaction between 
recombinant human erythropoietin and serum factor(s) on murine 
megakaryocyte colony formation. Blood 80(1) :37-45. 
Ueno M, Seferynska I, Beckman B, Brookins J, Nakashima J, and 
174 
Fisher J W (1989). Enhanced erythropoietin secretion in 
hepatoblastoma cells in response to hypoxia. Am. J. Physiol. 
257:C743-C749. 
Utsunomiya I, Nagai S, and Oh-Ishi (1991). Sequential 
appearance of IL-1 and IL-6 activities in rat carrageenin-
induced pleurisy. J. Immunol. 147(6) :1803-1809. 
Van de Loosdrecht A A, Beelen R H J, Ossenkoppele G J, 
Broekhoven MG, and Langenhuijsen MM AC (1993). Cellular and 
cytokine dependent monocyte-mediated leukemic cell death: 
modulation by interferon-y and tumor necrosis factor-a. Exp. 
Hematol. 21:461-468. 
Van Vollenhoven RF, Soriano A, McCarthy PE, Schwartz R L, 
Garbrecht F C, Thorbecke G J, and Siskind G W (1988). The role 
of immunity to cartilage proteoglycan in adjuvant arthritis. 
I ntravenous injection of bovine proteoglycan enhances adjuvant 
arthritis. J. Immunol. 141(4) :1168-1173. 
Vassalli P ( 1992) . The pa thophysiology of tumor necrosis 
factors. Annu Rev. Immunol. 10:411-452. 
Vreugdenhil G, Wognum AW, Van Eijk HG, and Swaak A J G(1990). 
Anemia in rheumatoid arthritis: the role of iron, vitamin B12 , 
and folic acid deficiency, and erythropoietin responsiveness. 
Ann. Rheum. Dis. 49:93-98. 
Waage A, Halstensen A, and Espevik T (1987). Association 
between tumour necrosis factor in serum and fatal outcome in 
patients with meningococcal disease. Lancet 1: 355-357. 
Wang FF, Kung C K-H, and Goldwasser E (1985). Some chemical 
properties of human erythropoietin. Endocrinology 116(6) :2286-
175 
2292. 
Ward HP, Gordon Band Pickett JC (1969). Serum levels of 
erythropoietin in rheumatoid arthritis. J. Lab. Clin. Med. 
74(1) :93-97. 
Weber J, Werre J M, Julius H W, and Marx J J M (1988). 
Decreased iron absorption in patients with active rheumatoid 
arthritis, with and without iron deficiency. Ann. Rheum. Dis. 
47:404-409. 
White LE and George W J (1981). Increased concentrations of 
cyclic GMP in fetal liver cells stimulated by erythropoietin. 
Proc. Soc. Exp. Biol. Med. 166:186-193. 
Wide L, Bengtsson C, and Birgegard G (1989). Circadian rhythm 
of erythropoietin in human serum. Br. J. Haematol. 72:85-90. 
Williams D Mand Johnson NW (1976). Alterations in peripheral 
blood leucocyte distribution in response to local inflammatory 
stimuli in the rat. J. Path. 118:129-141. 
Williams RA, Samson D, Tikerpae J, Crowne H, and Gumpel J M 
(1982). In-vitro studies of ineffective erythropoiesis in 
rheumatoid arthritis. Ann. Rheum. Dis. 41:502-507. 
Winearls CG, Pippard M J, Downing MR, Oliver D 0, Reid C, and 
Cotes PM (1986). Effect of human erythropoietin derived from 
recombinant DNA on the anaemia of patients maintained by chronic 
haemodialysis. Lancet 2:1175-1178, 
Witthuhn BA, Quelle F W, Silvennoinen 0, Yi T, Tang B, Miura 0, and 
Ihle J N (1993). JAK2 associates with the erythropoietin receptor and 
is tyrosine phosphorylated and activated following stimulation with 
erythropoietin. Cell 74:227-236. 
Wong G G, Witek-Giannotti JS, Temple PA, Kriz R, Ferenz C, Hewick 
RM, Clark SC, Ikebuchi K, and Ogawa M (1988). Stimulation 
of murine hemopoietic colony formation by human IL -
176 
6. J. Immunol. 140:3040-3044. 
Wood N C, Symons J A, Dickens E, Duff G W ( 1992) . In situ 
hybridization of IL-6 in rheumatoid arthritis. Clin. Exp. 
Immunol. 87:183-189. 
Yamasaki K, Taga T, Hirata Y, Yawata H, Kawanishi Y, Seed B, 
Taniguchi T, Hirano T, and Kishimoto T (1988). Cloning and 
expression of the human interleukin-6 (BSF-2/IFNG 2) receptor. 
Science 241:825-828. 
Zanjani ED, Poster J, Burlington H, Mann LI, and Wasserman L 
R (1977). Liver as the primary site of erythropoietin formation 
in the fetus. J. Lab. Clin. Med. 89:640-644. 
Zappacosta AR, Caro J, and Erslev A (1982). Normalization of 
hematocrit in patients with end-stage renal disease on 
continuous ambulatory peritoneal dialysis. Am. J. Med. 72:53-
57. 
Zucker S, Michael MS, Lysik RM, Glucksman M J, Reese J, Rudin 
A, and Distefano J(1979). Lipoprotein inhibitor of bone marrow 
cells in tumor-bearing rats. Cell Tissue Kinet. 12:393-404. 
177 
APPENDIX 
















Bromocresol Green Stock Solution (0.6 mmol/1) 
Bromocresol green 
Sodium azide 
NaOH (0.1 M) 














Bromocresol green working solution was prepared by mixing one 
volume of stock solution with three volumes of succinate buffer 
(0.1 M) and adjusting the pH to 4. 2. 
Chromic Acid Solution 
Chromium (VI) oxide 84 g 
H20 700 ml 
Sulphuric acid 400 ml 
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Column Loading Buffer (2X)* 
Tris. Cl (pH 7.6) 
NaCl 
EDTA 





* lX column loading buffer was prepared by diluting 1 part of 
t he 2X buffer with 1 part DEPC-treated sterile water. 
Column Buffer (RNase protection) 
NaCl 
Tris (pH 7.5) 
EDTA 
SDS 
Denhart's Solution (lOOX) 
Polyvinylpyrolidine 
Bovi ne serum albumin 
Ficoll 400 
H20 
Digestion Buffer (RNase protection) 
NaCl 
LiCl 
Tris (pH 7.5) 
EDTA 
Elution Buffer 
Tris. Cl (pH 7.6) 
EDTA (pH 8. 0) 
SDS 





















Formalin (40 %) 
Distilled H20, up to 
Formamide Loading Dye (RNase protection) 
Formamide 





Tris-HCl (pH 8.0) 
EDTA 





bis [2-ethanesulfonic acid]) 




















Added water to 950 ml and adjusted the pH to 7.4. Made up to 
1 l with water and autoclaved at 15 p.s.i for 20 min. 














Hepes (pH 7.6) 
2-mercoptoethanol 






Polyacrylamide (6%)/Urea (7 M) Gel Mixture 
Acrylamide/urea solution 
TEMED 
Ammonium persulfate (50 %) 
Potassium Acetate Solution 
Potassium acetate (SM) 







Tris (2 M, pH 7.4) 
Denhart's solution (100x) 



















1. 6 g 






Tris.Cl (pH 8. 0) 
EDTA (pH 8. 0) 
NaCl 
SDS 
RNA Dye Mixture 
Formamide 
MOPS buffer (lOX) 
Formaldehyde 
H20 
Glycerol (100 %) 
Bromophenol blue 
RNA Extraction Buffer 
NaCl 
MgC1 2 
Tris. Cl (pH 8.6) 
Nonidet P-40 
Dithiothreitol 





Succinate Buffer (0.1 M) 
Succinic acid 
Sodium azide 
Water, up to 
pH 
TBE Buffer (lOX) 

























Boric acid 0.5 M 
EDTA (pH 8. 0) 20 mM 
TE Buffer 
Tris. Cl (pH 7. 4) 10 mM 
EDTA (pH 8. 0) 1 mM 
pH 7.4 
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